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ABSTRACT 
 
 
 
The management of Colorectal Cancer has evolved, and in many parts of the world is provided by 
multidisciplinary teams (MDTs). In the UK all patients with colorectal cancer have their 
management discussed at MDTs. This thesis presents a series of mixed method studies aimed at 
developing and utilising methods to evaluate and assess the functioning of Colorectal Cancer 
MDTs. 
 
The introduction presents an overview of Colorectal Cancer and the role of MDTs. 
Chapter 2 presents a systematic review and meta-analysis of studies on Colorectal Cancer MDTs. 
Chapter 3 explores the views of core members of Colorectal Cancer MDTs on potential 
assessment tools. Chapter 4 concludes this section with an analysis of the costs involved with these 
teams. 
 
In Chapter 5 I describe the development and validation of an observational tool for evaluation of 
Colorectal Cancer MDTs, followed by an evaluation of the relationships between decision making 
within the team and the various aspects of the tool described in Chapter 6. Chapter 7 presents the 
feasibility of reliably using this tool for video based assessments of Colorectal Cancer MDTs. 
 
I conclude this thesis with a general discussion – focussing on relevant findings, clinical 
implications of my work and directions for future research. 
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CHAPTER 1: INTRODUCTION 
 
 
 
1.1 Introduction 
As the National Health Service (NHS) approaches the end of its seventh decade in existence, there 
are numerous challenges facing this established body. One of the central principles on which the 
NHS was founded was to provide healthcare to all, with financing coming from the public purse (1). 
 
With increasingly limited resources and a rising population (2) – both in number and in age - there is 
immeasurable pressure on a system that many speculate is close to breaking point. Nowhere is this 
truer than with cancer services in the NHS. Whilst the overall provision of cancer services has 
changed drastically, the pressures remain similar – and, with an aging population, are projected to 
intensify. 
 
In this chapter I will outline the origins and the current state of cancer services in England. I will then 
summarise the evidence for the use of multidisciplinary teams and their origins. I will then focus 
specifically on colorectal cancer, highlighting the reasons for this. Finally, I will outline the aims and 
objectives of this thesis. 
 
 
1.2 Cancer care in England 
The provision of care for patients with cancer has undergone significant changes since the inception 
of the National Health Service. Perhaps the most significant event in recent history was the 
publication in 1995 of the Calman-Hine report – formally known as the “Policy framework for 
commissioning cancer services – a report by the Expert Advisory Group to the chief medical officers 
of England and Wales” (3). This landmark report led to a significant reconfiguration of 
infrastructure and personnel with the aim of delivering improved cancer care. The sections that 
follow outline the key elements of the report, as well as the changes made to the structure of 
healthcare as a result of this report. 
19  
1.2.1 Cancer services: pre-1995 
Cancer services in England have evolved. Prior to the mid-1990s, much of the care was provided by 
individual clinicians, with the onus on the individual clinician to arrange appropriate treatment – 
with or without involving clinicians from other related specialties. Whilst the overall organisation of 
the NHS meant that the responsibility for commissioning and provision of services was held locally, 
there were concerns regarding the uniformity of care. To many, this meant that access to specific 
treatments and medications were ‘rationed’ by the physical location of patients. However, a more 
subtle effect of this was the variation in access to specialist care for specific diseases. These two 
factors meant that patients were referred to individual clinicians locally, and received treatments 
depending on the available expertise, often without referral or discussion with other, related 
specialties; with the possibility that they were not receiving the best, most appropriate care for their 
conditions (4). 
 
If local services were matched however, this may not have been seen as such an issue – as patients 
preferred to be treated locally if they were receiving appropriate treatments (4). However, statistics 
showed that there was significant variability in the types and volumes of specific treatments available 
between clinicians (5) and between hospitals (6). Furthermore, there was evidence of variations in 
clinical outcomes across England (7, 8). Although not available at the time, more recent evidence has 
highlighted the relationship between hospital volume and clinical outcomes (9, 10). The evidence 
provided by the European cancer registry based study of survival and care of cancer patients (11) 
showed that generally, outcomes were worse in the United Kingdom for most types of cancers 
compared with those countries that had a more centralized, specialized approach to cancer 
treatments. 
 
Within cancer services in England, the changes in breast cancer care provided further evidence of the 
possible benefits specialisation could bring (12). The contrast between the improvements seen in the 
organisation and delivery of services for patients diagnosed through the screening programme – 
established in 1987 – and those diagnosed following symptoms was evident to those in the specialty, 
and brought to the attention of specialists in cancer care in all areas by the British Breast Group in 
1994 (13). 
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1.2.2 The Calman-Hine report: 1995 
At the time of the developments described above, the Chief Medical Officers of England and Wales 
were Professor Sir Kenneth Calman and Dame Deirdre Hine respectively. In developing their cancer 
policy, they established the expert advisory group on cancer with the aim of reviewing and assessing 
current evidence on best practice for cancer care. 
 
Following the reports of the group, the landmark government document, ‘A policy framework for 
commissioning cancer services – a report by the Expert Advisory Group to the chief medical officers 
of England and Wales’ (3) was produced in 1995. The detailed report identified seven key principles 
to govern the provision of cancer care: 
 
• Access to uniform high-quality care in the community or hospital 
• Early identification of cancer and availability of national screening programmes 
• Patients to be given clear information at all stages 
• Services to be patient centred 
• Centrality of primary care and effective communications 
• Psychosocial aspects of care are important 
• Cancer registration and monitoring of treatment and outcomes are essential 
 
 
Whilst the recommendations of the report were many and far-reaching, the overall message was one 
of changes in structures and processes to ensure the effective delivery of cancer services to all 
patients. The policy proposed a change in model from one of generalists treating patients, to the 
development of a specialist cancer service for the treatment of all patients. 
 
The policy set out the importance of specialist clinicians in cancer care leading the management of 
cancer patients, with close working between related specialties in the form of multidisciplinary 
teams. The organisational arrangements proposed the development of cancer units, cancer centres 
and cancer networks (3). 
 
Cancer units were local hospitals with speciality-specific departments to provide the surrounding 
population with all aspects of cancer care for those cancers and specialties that were common, and 
had sufficient numbers. More complex cases, rarer cancers or those with poor outcomes would be 
referred by local cancer units to regional (or in some cases national) cancer centres – usually within 
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the same cancer network. This would allow for specialist treatments by a team of clinicians that had 
sufficient exposure to the cancer type to make and carry out appropriate care recommendations. 
 
1.2.3 After The Calman-Hine report: 1995 onwards 
Whilst the Calman-Hine report set out general recommendations on the delivery of cancer services in 
England, the policy was light on detail (3). The aim was to set out a framework, upon which future 
cancer services would be based. The policy was followed a year later by a more detailed circular 
(14). Following this, the publication of a series of reports, beginning with breast cancer outlined 
more detailed aspects of the proposed development of cancer services. These ‘Improving Outcomes 
Guidance’ documents were produced for different tumour types (15-18) and had a significant impact 
on the layout of cancer services. Further Government policy, in the form of the first National Cancer 
Plan (19) in 2000 built on previous work and set out clearer objectives, with specific numbers and 
financial costs attached to it. In 2000, cancer networks were introduced to provide comprehensive 
cancer services for a specific geographical area. Their remit was far reaching, but involved provision, 
co-ordination and support for cancer services for the members of the network. 
 
Whilst overall outcomes in cancer services have improved since the Calman-Hine report (1995) and 
the National Cancer plan (2000), there have been further Government policy documents aimed at 
improving cancer services. I will not go into further details of all these separately, but I conclude this 
section by highlighting the importance of multidisciplinary teams in cancer are - an underlying theme 
in all these documents was the key role that the multidisciplinary team played in cancer care. 
 
1.3 Multidisciplinary teams in cancer care 
A multidisciplinary team has been defined as a group of people of different healthcare disciplines, 
who meet together at a given time (whether physically in one place, or by video or teleconferencing) 
to discuss a particular patient and who are each able to contribute independently to the diagnostic and 
treatment decisions about the patient (20). 
 
The idea behind multidisciplinary teams is perhaps best summarised by the following quote by Atul 
Gawande in The New Yorker: 
 
“But you can’t hold all the information in your head any longer, and you can’t master all the skills. 
No one person can work up a patient’s back pain, run the immunoassay, do the physical therapy, 
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protocol the MRI, and direct the treatment of the unexpected cancer found growing in the spine. I 
don’t even know what it means to “protocol” the MRI” (21). 
 
Although referring to healthcare in general, this notion epitomises the rationale behind 
multidisciplinary care for cancer patients, and highlights the importance of a team of specialists 
treating cancer patients. Differences in tumour types and tumour stages affect the types of treatments 
offered to patients. As cancer treatments become more complex, there has been a decline in the 
number of cases that are treated by a sole general clinician – indeed a number of different clinicians, 
from various specialties, provide care to cancer patients. 
 
1.3.1 Multidisciplinary teams in England 
One of the key recommendations of the Calman-Hine report was the introduction of 
multidisciplinary teams into cancer care (3). However, whilst the Calman-Hine report proposed the 
implementation of multidisciplinary teams in the management of cancer, it is important to note that 
evidence of the benefits of multidisciplinary teams in cancer care had already begun to appear in the 
literature (4, 22); indeed some of this evidence formed part of the reasoning behind the report. 
 
Multidisciplinary care in cancer services is now a mandatory aspect of service delivery, and all 
hospitals in England delivering cancer care have specific multidisciplinary teams. Indeed, 
multidisciplinary teams form a core part of the service for specialties outside of cancer management 
(23, 24). In the United Kingdom, a cancer multidisciplinary team is made up of surgeons, physicians, 
clinical and medical oncologists, radiologists, pathologists, specialist nurses, and palliative care 
specialists and may also include researchers, dieticians, radiographers, social workers and other 
allied healthcare professionals. 
 
Most teams meet on a weekly basis at a set venue, and patients with cancer are discussed at the 
meeting at various stages of their management, and recommendations made regarding ongoing care. 
All patients with cancer must have their care led by a multidisciplinary team. Guidance on the 
structure, organisation and functioning of multidisciplinary teams in the UK was provided by the 
National Cancer Action Team (NCAT) (25), with a regular evaluation of the Cancer pathway, 
including the MDT being undertaken in the form of Peer Review (26). 
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1.3.2 Multidisciplinary teams around the world 
Globally, multidisciplinary teams are increasingly becoming the model of care for patients with 
cancer (27-30), with varying levels of integration into the national policies of different countries (31- 
33). 
 
The emergence of cancer multidisciplinary teams (or tumour boards as they are known in some 
settings) as a forum for patient management discussions allows individual clinicians from different 
specialties to come together and discuss the diagnosis, staging and treatment plans of patients with 
cancer. In the United States, The National Cancer Institute defines a tumor board review as “a 
treatment planning approach in which a number of doctors who are experts in different specialties 
(disciplines) review and discuss the medical condition and treatment options of a patient” (34). They 
go on further to propose the members of a cancer tumor board to include a medical oncologist (who 
provides cancer treatment with drugs), a surgical oncologist (who provides cancer treatment with 
surgery), and a radiation oncologist (who provides cancer treatment with radiation). 
 
The principle behind tumor boards is that combined decision making, with the presence of different 
clinicians, ensures that patients receive the most appropriate care for their disease and stage. Whilst 
tumour boards have been an integral part of surgical care in various hospitals, particularly in the 
USA, their structure and purpose have changed with time. Table 1.1 summarises the key differences 
between traditional tumor boards (predominantly in the USA) and more modern multidisciplinary 
teams, based on the principles of multidisciplinary care from around the world. 
 
Whilst the idea of multidisciplinary team working has now been endorsed in cancer care systems 
throughout much of Europe, their prevalence is much lower in the USA and Australasia. In Europe, 
multidisciplinary care forms a core component of clinical guidelines in all cancer care services, and 
is pivotal to many of the National Cancer Plans in Europe (33). In USA, despite being a requirement 
for accreditation by the American College of Surgeons’ Cancer Program Standards (35), they are not 
always present in hospitals that treat cancer patients. 
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Table 1.1: Differences between tumour boards and multidisciplinary 
treatment care teams 
 
 
Dimension Tumour boards Multidisciplinary treatment care teams 
Stage of cases 
Newly diagnosed; complex 
cases 
Newly diagnosed, complex cases, plus 
“repeat” cases at later stages 
Approach 
Consultative; advice provided to 
lead MD 
Collaborative, consultation between all 
members of team 
 
Focus 
 
Treatment only 
Treatment and patient’s quality of life 
(rehabilitation; psychosocial needs; long- 
term care) 
Primary purpose Education and training Planning treatment and care management 
 
Participants 
 
Open to any practitioner 
Focused on care team responsible for 
managing patient care for specific disease 
site 
Timing At one point in time Multiple points along treatment pathway 
Case review 
Retrospective; prospective 
planning potential more recently 
Prospective 
Treatment decision 
process 
Physician in charge Consensus 
 
 
 
 
 
1.3.3 Multidisciplinary teams – what does the evidence say? 
The use of multidisciplinary teams in the management of cancer patients provides an interesting 
insight into the world of modern medicine. In a field where up to date evidence is essential before 
tests, treatments and pathways are used in clinical practice, multidisciplinary teams seem to have 
‘snuck in under the radar’ There is almost universal approval for this strategy, which indeed some 
consider critical for ensuring all the involved disciplines are included in patient care, yet there was 
little evidence that suggested that this form of multidisciplinary care actually improved outcomes for 
patients (28). The ideal standard would therefore be to run a suitably powered randomized control 
trial to compare a matched cohort of patients managed either by individual clinicians or by a 
multidisciplinary team. However, in most healthcare systems, where multidisciplinary team working 
is now established, this would be a nearly impossible task. 
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Across tumour types, there are a number of recent studies, the majority longitudinal, that have looked 
at the impact of the introduction of multidisciplinary teams on patient care as well as on service 
delivery. 
 
Studies on multidisciplinary teams have explored the impact that multidisciplinary teams have had 
on clinical outcomes as a means of evaluating the effectiveness and success of MDTs. There have 
been studies in different cancer types, including lung, colorectal and breast, looking at the impact of 
MDTs on clinical outcomes such as recurrence rates, disease free survival and overall survival. 
Whilst a number of these studies have shown an improvement in clinical outcomes in different 
specialties (36, 37), a recent large study from the USA (38) has not shown similar improvements in 
the majority of specialty multidisciplinary teams. Furthermore, a major limitation of all these studies 
is the inability to distinguish the introduction of multidisciplinary care from the overall 
improvements made in the fields of cancer care, ranging from improved diagnostics, screening, and a 
wider range of treatment modalities and types. Attributing the improvement in clinical outcomes 
solely to the introduction of tumor boards ignores the improvements made in cancer care over the 
same time periods. The difficulties in setting up randomized controlled trials as described above, as 
well as the ethical questions related to setting up such a study mean that there is unlikely to be a 
definitive answer available. 
 
A further group of studies on multidisciplinary team processes have highlighted the significant 
resource and manpower that is associated with these meetings, however there have been few 
attempts to quantify this. Chinai and colleagues (39) provide a robust evaluation of the costs 
associated with MDT meetings at a single centre, however, acknowledge the fact that these results 
may not be transferrable due to the significant variations in practice reported anecdotally. Indeed, a 
review by Taylor and colleagues (28) highlighted the vast differences between hospitals as well as 
between departments within the same hospital as an example of how little guidance is available on 
the implementation and running of MDTs. Without appropriate guidance against which to 
benchmark performance, it is difficult to evaluate the success of multidisciplinary teams. 
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1.4 Colorectal cancer 
Colorectal disease is an area of healthcare that holds a special interest for me. In particular, as a 
trainee surgeon, the management of colorectal cancer (also known as bowel, colon or rectal cancer) 
has a certain appeal due to the mix of technical skills required and the mental challenge it provides. 
Figure 1.1 shows the different areas in the colon and rectum that can be affected by cancer. 
 
 
 
Figure 1.1: Large bowel – colon and rectum – potential sites of cancer 
 
 
 
 
1.4.1 Importance of Colorectal Cancer 
 
Colorectal cancer is becoming increasingly common, and continues to form a large part of the cancer 
burden globally (40). Colorectal cancer affects the lower part of the digestive system; approximately 
two-thirds of these tumours develop in the colon or large bowel and about one third are in the rectum 
or anus. The most common type of bowel cancer is adenocarcinoma (41). 
 
The latest statistics available from the Office of National Statistics (2012) identify Colorectal cancer 
as having the 4th highest incidence amongst cancers in the United Kingdom (42). In 2010, colorectal 
cancer accounted for the second highest cancer mortality in the UK (43). Furthermore, the statistics 
show that it is on the increase - Cases of bowel cancer for men have increased from 45 per 100,000 
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in 1975-77 to 58 per 100,000 in 2008-10 (a rise of 29%) and for women have increased from 35 per 
100,000 to 37 per 100,000 in the same timescale (a rise of 6%). 
 
Globally, the incidence and mortality of colorectal cancer is amongst the highest of all cancers. The 
GLOBOCAN report of 2008 (40) estimated that there were 1.2 million new cases of colorectal 
cancer diagnosed globally (3rd most common incidence) and 610,000 deaths attributed to colorectal 
cancer (4th most common mortality). 
 
1.4.2 Differences in presentation 
 
Whilst definitive diagnosis of colorectal cancer is made following an endoscopic examination of the 
large bowel (either a flexible sigmoidoscopy or a colonoscopy) with biopsy of the suspect lesion, 
colorectal cancer presents in one of two main ways: 
 
• Symptoms – these include blood or mucus in the stools, changes in bowel habit, abdominal 
pain, rectal pain, weight loss or symptoms of anaemia (such as tiredness) 
 
• Screening – these are often asymptomatic individuals, but have had abnormalities identified 
on screening programmes. In the UK, the NHS Bowel Cancer Screening Programme (44) 
offers screening in the form of Faecal Occult Blood tests to all individuals aged between 60 
and 69, every 2 years. More recently, a pilot programme has been initiated using flexible 
sigmoidoscopy between the ages of 55 and 60. Additionally there are specific screening 
programmes for those individuals with diseases that are thought to pre-dispose to Bowel 
Cancer (such as Peutz-Jeghers Syndrome). 
 
These two groups of patients may present at various stages of disease progression, with evidence 
suggesting that cancers or pre-cancerous lesions are picked up earlier through screening 
asymptomatic individuals (45). This is likely to increase the number of patients discussed at 
multidisciplinary team meetings, placing increasing pressure on services. Furthermore the exact 
management and follow-up of patients with early cancers or pre-cancerous lesions is yet to be agreed 
upon, and there are likely to be differing strategies for this. 
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1.4.3 Differences in diagnostics 
Once the diagnosis of colorectal cancer has been made (or in some cases suspected), a number of 
investigations are undertaken to accurately stage the disease prior to planning further management. 
Traditionally, in England, local staging has been carried out with CT scans (colon) and MRI scans 
(rectal) (46) and distant staging with CT scans. Guidelines from the UK National Institute for Health 
and Clinical Excellence (NICE) released in 2011 (31) concur with this and advise that the above is 
all that is necessary – recommendations similar to that of the previous version of the guidelines. 
 
However, since the introduction of the initial, evidence-based guideline, several improvements have 
been made in imaging such as the wide-spread use of multi-spiral CT, new available MRI-contrast 
liver agents and the more widespread use of FDG-PET and the introduction of FDG-PET/CT. 
Additionally, there has been an increase in the use of trans-rectal and endo-anal ultrasound for 
specific local staging of low rectal cancers. 
 
Given these advances, there are now many more options for optimal staging, which will be affected 
by local availability and local expertise, making appropriate decision making important. The best 
treatment plans depend on the most accurate information regarding the disease being available, and 
the choice of staging techniques is an important determinant of this. 
 
1.4.4 Differences in management 
 
Treatments for colorectal cancer are determined by the stage of the disease. Specific staged disease 
can be treated with fixed treatment plans based on sound clinical evidence. However there remain a 
number of areas where there is still debate regarding optimal management. A specific example is the 
treatment of localized T2 stage rectal cancer. There is now a growing body of proponents for the use 
of local techniques such as trans-anal endoscopic microsurgery (TEMS). However, there remain 
concerns regarding the adequacy of resection and the ongoing risk of local recurrence or distant 
spread. Furthermore, the delivery of such techniques is limited by the expertise of local personnel 
and the availability of specific equipment (47). Another example of treatment debates relate to the 
use of radiotherapy (either none, short course or long course) in the management of rectal cancer 
(48). 
 
These management debates emphasise the fact that there remains a role for constructive discussion of 
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management strategies for patients with colorectal cancer. The multidisciplinary team meeting 
provides an avenue for such debate to take place. 
 
1.4.5 Clinical guidelines 
Previous sections have highlighted that advances in diagnostics and management strategies have 
challenged clinicians to keep up to date and query the recommendations from guidelines such as 
those from UK NICE (31). However the presence of relevant, up to date guidelines for colorectal 
cancer means that a standard protocol for diagnostics and management does exist. In cases where 
there is little debate (such as, for example, the management of T2 colon cancer with no nodal or 
metastatic disease) there is an argument to state that these cases do not all need to be discussed at a 
multidisciplinary meeting. Similar strategies exist in parts of Europe with considerable success, but it 
is important to note that this relies heavily on the presence of up to date guidelines that are based on 
sound clinical evidence. 
 
1.4.6 Clinical trials 
The previous sections have identified some of the potential diagnostic and management dilemmas 
clinicians’ face in the management of colorectal cancer. Currently, there are numerous trials running 
(200 as of 25/10/15 according to the Cancer Research UK website) (41) looking at various aspects of 
colorectal cancer management with a view to answering some of these dilemmas. The high number 
of trials means that patients that present with colorectal cancer may fit the criteria for enrolment into 
trials; indeed, some estimates state that approximately a quarter of patients with colorectal cancer are 
eligible for trials. 
 
The multidisciplinary team meeting provides an open forum for discussion of enrolment into various 
trials, often led by different specialties. 
 
1.4.7 Section summary 
This section discusses some of the aspects of colorectal cancer that make the use of multidisciplinary 
care particularly important. As pressure on services increases with greater numbers, the specialty 
provides an area to examine the need for discussing all patients in multidisciplinary teams, whilst 
emphasizing the need for a multi-specialty approach due to the variations in diagnostic techniques 
and management strategies. 
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Thesis Aims 
This MD(Res) Thesis aims to evaluate and assess the functioning of Colorectal MDTs and their 
decision making. The specific objectives are: 
 
1. To review the evidence base on Colorectal Cancer MDTs. 
 
 
2. To identify key aspects that could be utilised in evaluating Colorectal Cancer MDTs. 
 
 
3. To develop an objective evaluation tool for Colorectal Cancer MDTs which can be used in 
different formats. 
 
4. To  identify  key  elements  that  predict  decision  making  in  Colorectal  Cancer  MDTs. 
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1.5 Chapter summary and thesis outline 
This chapter gives a brief description of cancer services in England leading up to the introduction of 
multidisciplinary teams. It goes on to outline the reasons why I have focused on colorectal cancer 
multidisciplinary teams for this thesis. 
 
In this thesis, I report a variety of qualitative and quantitative studies that will attempt to explore 
multidisciplinary care in colorectal cancer. 
 
The thesis is split into 3 distinct sections. Section 1 includes the introduction, and the background 
behind the thesis. Section 2 is made up of Chapters 2, 3 and 4. Section 4 consists of Chapters 5, 6 and 
7. The discussion in Chapter 8 completes the thesis. 
 
Following the introductory section, in section 2, I present information regarding colorectal cancer 
multidisciplinary teams. Chapter 2 describes a systematic review of the available literature on 
colorectal cancer multidisciplinary teams. In chapter 3, I explore the views of core members of 
colorectal cancer multidisciplinary teams on proposed assessment tools. In Chapter 4, I report 
financial data on the cost of colorectal cancer multidisciplinary teams. I complete this section with a 
summary of the previous three chapters, and I go on to identify and expand on specific areas for 
assessment. 
 
In section 3, I focus on some of the specific findings from the previous section: the ability of 
multidisciplinary teams to make decisions and the assessment of teamwork in multidisciplinary team 
meetings. In Chapter 5, I describe the development and validation of an objective assessment tool for 
evaluation of colorectal cancer multidisciplinary teams, and, in Chapter 6 I use the tool to evaluate 
the relationships between decision making and various aspects of the multidisciplinary meeting. 
Finally, in Chapter 7, I evaluate the feasibility of reliably using the tool for video based assessments 
of multidisciplinary teams. 
 
In Chapter 8, I complete this thesis with a detailed discussion of my findings and their implications, 
and outline areas for future work. 
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CHAPTER 2: COLORECTAL CANCER MULTIDISCIPLINARY 
TEAMS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF 
THE LITERATURE 
 
 
 
 
 
2.1 Chapter overview 
In this Chapter, I present a systematic review and meta-analysis of the available literature on 
Colorectal Cancer Multidisciplinary teams. 
 
 
2.2 Introduction 
The previous chapter outlined the development of cancer care in England over the past few decades. 
It highlighted some of the available literature on multidisciplinary teams by discussing a combination 
of narrative and systematic reviews on the topic. There is large body of research looking at various 
aspects of multidisciplinary teams. The introductory chapter further outlined the specific challenges 
faced in the management of colorectal cancer – a specialty where the disease burden continues to 
increase, whilst the options for investigation and management are wide reaching. 
 
This chapter sets the scene for the rest of the thesis, by focusing specifically on colorectal cancer 
multidisciplinary teams. I undertook a systematic review of the literature on colorectal cancer, 
specifically looking at three aspects of the meetings. Following this, I undertook a meta-analysis of 
selective, appropriate data – further details are found in the sections that follow. The final section 
discusses proposed methods of assessment of Colorectal Cancer MDTs, based on the information 
available from the systematic review. 
 
2.3 Aims 
The aims of the systematic review in this chapter are to identify the available literature on Colorectal 
Cancer Multidisciplinary teams. My analysis specifically aims to identify studies that look at MDT 
processes and implementation, the impact of MDTs on pre-treatment decisions and the impact of 
MDTs on outcomes. Where there are multiple studies that examine a specific factor related to the 
MDT, I have combined this data and assessed its suitability for further analysis, undertaking a meta- 
analysis in three different areas. 
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2.4 Methods 
 
2.4.1 Search strategy and selection criteria 
 
I undertook systematic literature searches of Embase, Medline, PsycINFO (using Ovid SP) and the 
Cochrane Library. The free text search terms used were ‘colorectal’, ‘cancer’, ‘multidisciplinary’ and 
relevant derivatives (for a detailed search strategy please see Table 2.1). MeSH terms were identified 
for each database separately and incorporated into the search. Results were limited to humans, 
English Language and dates from 1980 to 15th October 2015. Additionally, I hand-searched the 
reference lists of all articles that fitted the inclusion criteria to identify any other articles for 
inclusion. 
 
Articles were included in the review if they presented empirical data on management of Colorectal 
Cancer by a Multidisciplinary team. A distinction was made between articles relating simply to 
multimodality treatment of Colorectal Cancer, or those looking at a specific treatment, and these 
articles were excluded. 
 
I reviewed all titles and those that did not meet the inclusion criteria were excluded. To ensure 
adequate article retrieval, any titles that were unclear were included for review of the abstracts. I then 
reviewed the remaining abstracts (n= 834) for relevance and excluded those that did not meet the 
inclusion criteria. A second reviewer (Sevdalis) independently reviewed the abstracts for relevance 
to ensure adequate retrieval. Concordance between reviewers was very good, with a Cohen’s Kappa 
coefficient of 0.80. Discordant decisions were arbitrated by a third reviewer (Arora), and an 
agreement reached between all of us. I then reviewed all full text articles (n=172) and included them 
if they met all the inclusion criteria. Where I had any doubts about inclusion, full text articles were 
reviewed by Arora and following discussion a final decision regarding inclusion was made. A final 
number of 42 articles were included in the review. Figure 2.1 outlines the study selection process. 
  
Table 2.1: Search strategy 
 
1 colo$.mp 
2 rect$.mp 
3 anus.mp 
4 anal.mp 
5 anorect$.mp 
6 caec$.mp 
7 colon/ 
8 rectum/ 
9 anus/ 
10 colorectal surgery/ 
11 cancer$.mp 
12 neoplas$.mp 
13 tumo?r$.mp 
14 onco$.mp 
15 carcinoma$.mp 
16 carcinoma/ 
17 neoplasms/ 
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18 MDT$.mp 
19 multidisciplinary.mp 
20 multiprofessional.mp 
21 interdisciplinary.mp 
22 interprofessional.mp 
23 tumo$r board$.mp 
24 tumo$r conference.mp 
25 case conference.mp 
26 interdisciplinary communication/ 
27 patient care team/ 
28 interdisciplinary treatment approach/ 
29 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 
30 11 or 12 or 13 or 14 or 15 or 16 or 17 
31 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 
32 29 and 30 and 31 
33 limit 32 to human 
34 limit 33 to English language 
35 limit 34 to year = “1980 - Current” 
36 remove duplicates from 35 
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Figure 2.1: Study selection flow diagram 
 
 
 
36  
 
2.4.2 Data extraction and quality assessment 
 
Data I extracted by myself from the 42 included papers for: country in which the study was 
undertaken, population size, patient characteristics, health-care professional characteristics, setting of 
the MDT, study design, study objectives and study findings. I divided the studies into three groups – 
the first included studies that presented data on MDT running and implementation, the second on the 
impact of MDT on pre-treatment decisions, and the third on the impact of MDT on outcomes. Some 
studies were included in more than one group. 
 
Within each group, I placed studies that identified specific pre-treatment decisions or outcomes into 
different sub-groups, and those sub-groups that included three or more studies were included in a 
meta-analysis. 
 
I undertook meta-analysis of three separate sub-groups that fulfilled the above criteria – use of MRI 
or TRUS for staging in rectal cancer, positive resection margins and 3 year overall survival rates. 
This was performed on advice from a meta-analysis expert (Athanasiou) and in line with 
recommendations from Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) (49), and the Meta-analysis of Observational Studies in Epidemiology (MOOSE) (50). A 
random-effects model was used which assumes that there is variation among studies because this 
model better accounts for heterogeneity between studies, and the odds ratio (OR) was the summary 
statistic used. 
 
As there was considerable variation among studies identified for meta-analysis in terms of the 
homogeneity of study populations pre and post the MDTs, I thought that performing a further sub- 
group analysis may provide more meaningful results. In order to categorize studies into those that 
were homogenous, and therefore, a more reliable comparison, and those that were less so, I identified 
five specific criteria (Table 2.2 below) and compared these in the pre and post MDT groups. I 
attributed one point to each criterion that was matched or zero points to each criterion that was 
unmatched or unspecified. 
 
However, within each sub-group, no two studies scored more than three out of five, and therefore 
further sub-group analysis was not carried out. I refer to this in more detail in the discussion. 
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Table 2.2: Quality scoring: criteria for comparison 
 
 
 
 
Criterion 
Patient factors 
Age 
Co-morbidity 
Tumour factors 
Tumour stage 
Tumour location 
Operative factors 
Type of surgery (including open or laparoscopic) 
 
 
 
 
2.5 Results 
 
2.5.1 Study Characteristics 
 
A total of 5753 articles were retrieved by the search criteria above. Application of the inclusion 
criteria excluded 5713 articles. 6 further articles were identified from hand-searching, and of these 
2 fitted the inclusion criteria. A final list of 42
1 
included articles was completed, and is presented in 
Table 2.3. 
 
The 42 included studies included articles published in peer reviewed journals between 2003 and 
2015 inclusive. Papers were from 10 countries: UK (n= 14), USA (n= 7), France (n= 4), Sweden 
(n=3), China (n=2),Australia (n=2), Canada (n=2), Italy (n=2), Netherlands (n=2) Denmark (n=1), 
Iran (n=1) and two multi-centre, international studies (principal authors from USA). 
 
 
 
 
 
 
 
 
 
 
 
 
1 The updated systematic review carried out on 15/10/2015 also identified Shah et al - Decision- 
making in Colorectal Cancer Tumor Board meetings: results of a prospective observational 
assessment (Surg End). This has been excluded from this analysis as it was developed based on the 
initial review, and forms part of the content of further chapters in this thesis 
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Table 2.3: Characteristics of included studies 
 
 
 
 
Author / Year / Country Study design, methodology Main Study Themes 
Abraham, N. S., J. T. Gossey, et al 
(2006), USA (51) 
Cross-sectional study Effect of MDT on receipt of recommended therapy 
 
Aissaoui S, Aissaoui H, et al (2014), 
France (52) 
Questionnaire MDT implementation, structure and process 
 
Augestad K, Lindsetmo R, et al (2010), 
North America, Europe, Asia (53) 
Questionnaire Effect of MDT on pre-operative decision making 
 
Augestad K, Lindsetmo R, et al (2012), 
North America, Europe, Asia (54) 
Survey Effect of MDT (and other organisational factors) on decision making for rectal 
cancer surgery 
 
Bouvier A, Bauvin E, et al (2007), France 
(55) 
1. Cross-sectional study 
2. Survey 
What factors influence whether or not an MDT is held for patients? 
 
Brannstrom F, Bjerregaard J et al (2015), 
Sweden (56) 
Retrospective review of registry data Predictors of discussion at MDTs 
Effect of MDT on treatment decision making 
 
Burton S, Brown G, et al (2006), UK (57) Audit Effect of MDT on overall CRM positivity 
 
Catt S, Fallowfield L et al (2005), UK 
(58) 
Chang-Zheng D, Jie L et al (2011), China 
(59) 
Questionnaire  Individual roles within MDTs 
Psychological impact of MDT work 
Longitudinal study Effect of MDTs on overall management of Colorectal Cancer 
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Chinai N, Bintcliffe F et al (2013), UK 
(39) 
Longitudinal study Concordance of MDT recommendations 
 
Derwinger K, Carlsson G, et al (2007); 
Sweden (60) 
Longitudinal study Effect of MDT on pathology reporting 
 
Feroci F, Lenzi E et al (2012), Italy (61) Questionnaire MDT implementation, structure and process 
 
Gagliardi A, Smith A et al (2003), 
Canada (62) 
Scenario based discussion 
Questionnaire 
Video-conferencing in MDTs 
 
Genovesi D, Mazzilli L et al (2014), 
Italy (63) 
Audit Adherence to guidelines 
 
Haddad P, Mir M.-R. et al (2013), 
Iran (64) 
Longitudinal study MDT implementation, structure and process 
 
Hamaker M, van Rixtel B et al (2015), 
Netherlands (65) 
 
Jones R, Vauthey J et al (2012), UK (66) 
Retrospective review of management 
 
 
Retrospective review of management 
Effect of patient age on MDT decisions 
 
 
Effect of specialist input on MDT decisions 
 
Keating N, Landrum M et al (2012), USA 
(38) 
Survey and retrospective review of 
registry data 
Effect of MDT on overall management of and outcomes from Colorectal 
Cancer 
 
Kehl K, Landrum M et al (2015), USA 
(67) 
Survey and retrospective review of 
registry data 
Effect of MDT on overall management of and outcomes from Colorectal 
Cancer 
 
Kurtz J, Heitz D et al (2010), France (68) Longitudinal study Effect of MDT on adherence to guidelines 
MDTs in elderly patients 
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Lamb B, Sevdalis N et al (2012), UK (69) Analysis of survey data Comparison of survey responses for Colorectal Cancer and other cancer types 
 
Levine R, Chawla B et al (2012), USA 
(70) 
Lordan J, Karanjia N et al (2008), UK 
(71) 
MacDermid E, Hooton G et al (2008), 
UK (72) 
Longitudinal study Effect of MDTs on overall management of Colorectal Cancer 
 
Longitudinal study Effect of team composition on referrals to MDT 
 
Longitudinal study Effects of MDT on overall outcomes in Colorectal Cancer 
 
Marshall C, Balentine C et al (2011), 
USA (73) Longitudinal study Effects of MDT on overall outcomes in Colorectal Cancer 
 
Mathoulin-Pélissier S, Bécouarn Y et al 
(2012), France (74) 
Longitudinal study MDT implementation 
 
Rogers S, Ayanian J et al (2009), USA 
(75) 
Survey Effects of surgical volume on attendance at MDTs 
 
Ryan J, Faragher I (2014), Australia (76) Prospective study Concordance of MDT recommendations 
 
Segelman J, Singomklao T et al (2008), 
Sweden (77) 
Longitudinal study Effect of MDTs on overall management of Colorectal Cancer 
 
Sharma A, Sharp D et al (2008), UK (78) Questionnaire MDT implementation, structure and process 
 
Snelgrove R, Subendran J et al (2015), 
Canada (79) 
 
Soukop M, Robinson A et al (2006), 
UK (80) 
Longitudinal study 
 
 
Questionnaire 
MDT implementation, structure and process 
Concordance of MDT recommendations 
 
MDT implementation, structure and process 
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Swellengrebel H, Peters E et al (2011), 
Netherlands (81) 
Longitudinal study Effect of MDT on overall pre-operative evaluation, management and CRM 
positivity 
 
Taylor A, Sheridan M et al (2004), UK 
(82) 
Questionnaire Effect of MDT on pre-operative staging techniques 
 
Taylor C, Sippitt J et al (2010), UK (83) Questionnaire MDT implementation, structure and process 
Effect of development programme on MDT members 
Vasudevan S, Cresswell A, et al (2013), 
UK (84) 
Prospective study Ability of colorectal MDT to make specialist hepatobiliary decisions 
 
Vaughan-Shaw P, Wheeler J et al 
(2015), UK (85) 
 
Wilcoxon H, Luxford K et al (2011), 
Australia (86) 
 
Longitudinal study 
 
 
Survey 
 
Effect of MDTs on overall management of early Rectal Cancer 
 
 
MDT implementation, structure and process 
 
Wilks J, Liebig C et al (2009), USA 
(87) 
Longitudinal study Effect of MDTs on overall management of Colorectal Cancer 
 
Wille-Jørgensen P, Sparre P et al 
(2013), Denmark (88) 
Longitudinal study Effect of MDTs on overall management of Colorectal Cancer 
 
Wood J, Metcalfe C et al (2008), UK 
(89) 
Longitudinal study Implementation of decisions made at MDT 
Ye Y, Shen Z et al (2012), China (90) Longitudinal study Effect of MDTs on overall management of Colorectal Cancer 
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2.5.2 MDT Running and implementation 
 
2.5.2.1 Organisation 
 
Kelly et al’s questionnaire study in 2003 of colorectal cancer MDTs in the UK showed that not all 
colorectal cancer MDTs were fully functioning (90% up and running, 9% partially running), and 
only 51% met weekly. In comparison, an Australian study by Wilcoxon et al from 2011 identified 
only a third of hospitals had an MDT. There were no similar studies from Europe or the USA. 
 
Significantly, approximately 62% of MDTs surveyed by Kelly et al had problems with organization 
of the meeting, with 32% of these not having a MDT co-ordinator. Soukop et al sent a questionnaire 
to all MDT co-ordinators in the UK, and identified that only 70% of respondents had a dedicated 
CRC MDT co-ordinator. Within this group, only 26% had the role of communicating decisions with 
primary care. 
 
2.5.2.2 Team members 
 
The attendance of core team members was variable, with surgeons and CNSs attending the most 
according to Kelly et al, whilst Wilcoxon et al reported that less than 1% of MDTs had core team 
members attending regularly. Rogers et al reported that surgeons that regularly attended MDTs were 
more likely to be high volume surgeons, and were more likely to collaborate with other specialties in 
decision making processes. 
 
Catt et al showed that there was good role clarity amongst surgeons, oncologists, radiologists and 
CNSs. This study also examined overall psychiatric morbidity related to MDTs, and overall rates 
were lower than previously reported – however, there was considerable variation between results for 
the colorectal cancer teams involved – ranging between 7% and 25%. Taylor et al’s study from 2010 
reported that although surgeons reported highest total job stress, they also reported highest job 
satisfaction. 
 
This study also reported that all members of the MDT felt that “providing better care from working 
in a MDT” were predominant sources of job satisfaction – a finding echoed by the Gagliardi et al. 
Respondents in this study also stated that attendance at MDTs provided useful tips for practice (61%) 
and changed current practice (30%). Results of the study by Sharma et al showed that clinicians felt 
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that CRC MDTs improved quality of care, whilst having a positive impact on training and team 
morale. 
 
2.5.2.3 Case selection 
 
Three European studies which reported data on which patients were discussed at MDT all reported 
a less than a 100% rate. The reasons for this varied: Bouvier et al reported that those over the age 
of 75, those with colon cancer (as opposed to rectal cancer) and those with early disease were less 
likely to be discussed, whilst treatment in a university hospital meant that case were more likely to 
be discussed. Segelman et al similarly reported that patients over the age of 72 were less likely to 
be discussed at MDT. Swellengrebel et al reported that patients with distal tumours were more 
likely to be discussed at MDT than those with proximal tumours.  Taylor et al’s study from 2004 
reported that 95% of UK departments discussed all cases at MDT, although Chinai et al’s study 
proposed that even in the UK setting, not all cases needed to be discussed. 
 
2.5.2.4 Decisions made – concordance and implementation 
 
Both Ryan et al and Chinai et al compared the decisions made by MDTs with those made by 
individual clinicians blindly. Both these studies showed that within a subset of cases discussed, 
there was no deviation from the MDT decision, and proposed that certain cases did not need to go 
through the MDT. One study reported that not all decisions made at MDT are implemented (Wood 
et al), with 10% not implemented – 9 due to co-morbidity, 7 due to patient choice and 2 due to 
further clinical information at time of surgery. 
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Table 2.4: MDT running and implementation 
 
 
 
Reference Outcomes Aspects of MDTs investigated Relevant results 
 
Structure Members Patient 
selection 
 
 
Bouvier A, 
Bauvin E, et al 
(2007); France 
1. Whether or not 
MDT was held for 
patients 
2. Specific features 
influencing this 
✓ 32.3% (Range 6.4%-76.9%) discussed at MDT 
MDT use in: 
1. >75 years less likely OR 0.71, 0.64-0.79, p<0.001 than in >75 
2. Public non-university hospital (OR 0.36, 0.26-0.5, P<0.001) and private 
hospital (OR 0.40, 0.31-0.54, p<0.001) less likely than in public university 
hospital 
3. rectum more often (OR1.83, 1.48-2.25, p<0.001) than in colon 
4. advanced disease (37.1%) than in early disease (27.5%) (p<0.001) 
Patients discussed at MDT were more likely to be included in therapeutic 
trials (OR 1.99, 1.23-3.21, p=0.005) 
 
 
Catt S, 
Fallowfield L et 
al (2005), UK 
 
1. Awareness of roles 
(IRQ) 
2. GHQ-12 scores 
 
✓ 1. Good role clarity amongst surgeons, oncologists, radiologists and CNSs 
2. Percentage of GHQ-12>4 in CRC teams - 7, 22, 25% 
 
Chinai N, 
Bintcliffe F et al 
(2013), UK 
1. Cost of MDT 
2. Concurrence 
✓ 1.  Total cost of 1 colorectal MDT meeting - £162,734 
2.  94% concurrence between management plan documented by each 
consultant prior to MDT meeting and recorded outcomes 
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Feroci F, Lenzi Questionnaire       1. Only 28.5% of Community hospital and 15.1% of teaching hospital 
E et al (2012), responses from     surgeons attended MDTs once a week, with the highest being 
Italy surgeons     pathologists and oncologists in both 
 2. Significant differences between how decisions were recorded between 
 community and teaching hospitals 
3. Not all hospitals discussed all cases at MDTs – 67.4% of community 
 hospitals and only 15.1% of teaching hospitals 
4. Surgeons felt that there were numerous perceived benefits of MDTs 
 
Gagliardi A, 
Smith A et al 
(2003), Canada 
Completed evaluation 
forms after each 
session 
✓ 1. CRC (2 teams) - 10/22 (45.5%) and 13/25 (52%) individual response rate 
(total number = 23) 
2. 73.9% were, "overall, satisfied with event" 
3. 30.4% said, "information revealed, not accessible elsewhere" 
4. 60.8% felt discussion provided useful tips for practice 
5. 69.5% felt discussion caused reflection on practice 
6. 30.4% stated that current practice would change 
 
Kelly M, Lloyd 
T et al (2003), 
UK 
Questionnaire 
responses - Yes / No 
responses and free 
text 
✓ 1. 90% had MDT up and running fully, further 9% partially. 
2. 51% meet weekly, approx a third fortnightly 
3. "Core team" attendance variable - "most of the time" attendance - surgeon 
98%, CNS 97%, Pathologist 82%, Radiologist 85%, Oncologist 82%, MDT 
Clerk 46%, Physician 43%, Palliative care 42% 
4. 102 (62%) had problems with organization of meeting - 32% of these did 
not have a MDT clerk 
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Lamb B, 
Sevdalis N et al 
(2011), UK 
Survey responses  1.  116/136 statements were similar across tumour types 
2. Significant differences in opinions between colorectal cancer MDT 
members (percentage in brackets) and other MDT members were: 
 Good MDTs save time in periods between meetings (88%) 
 All MDT core members need to do some preparation before meeting 
(77%) 
 Case summaries should be circulated before meeting (50%) 
 Late additions should not be allowed unless clinically urgent (61%) 
 Patient’s case should not be discussed unless someone who has been 
involved in assess patient is present (68%) 
 Aspects of clinical decision making process 
 
Mathoulin- 
Pélissier S, 
Bécouarn Y et 
al (2012), 
France 
Proportion of patients 
discussed at MDT 
✓ Multidisciplinary approach was taken: 
1. 86/625 (14%) of colon cancer patients before surgery 
2. 175/327 (54%) of rectal patients before surgery 
3. 128/190 (67%) of rectal cancer patients before a pre-surgical treatment 
performed 
4. 685/767 (89%) of colon cancer patients after surgery 
5. 273/340 (80%) of rectal cancer patients after surgery 
 
Rogers S, 
Ayanian J et al 
(2009) USA 
Survey responses   Compared to surgeons that attended MDTs quarterly or less frequent, 
surgeons that attended MDTs weekly were more likely to: 
  
1. Be high volume surgeons (OR 1.62, CI 0.93-2.82, p = 0.09) 
2. Collaborate with other specialties for decisions regarding chemotherapy 
(OR 1.66, CI 1.06-2.60, p = 0.02) 
3. Collaborate with other specialties for decisions regarding radiotherapy 
(OR 1.82, CI 1.17-2.82, p = 0.008) 
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Segelman J, 
Singomklao T 
et al (2008), 
Sweden 
1. Assessment by 
MDT 
2. Overall survival 
    1. Patients under 72 were more likely to be discussed at MDT then those 
over 72 (OR 7.88, CI 5.88-10.57, p<0.001) 
2. Surgery for metastases more common among patients discussed at MDT 
than those who were not (72/1041 vs 5/409, p<0.001) 
Sharma A, 
Sharp D et al 
(2006), UK 
Questionnaire 
responses - from 
Colorectal Surgeons 
(CRS) and Colorectal 
Nurse Specialists 
(CNS) 
    
 
1. CRC MDTs improve quality of care - 95.6% agree 
2. CRC MDTs have positive impact on training - 80% agree 
3. CRC MDTs have positive impact on morale - 78.6% agree 
4. CRC MDTs are cost effective - 73% agree 
5. CRC MDTs not a passing fad - 89% agree 
6. 50.4% of CRSs and 35.2% of CNSs stated that job plan did not have 
enough time for CRC MDTs 
7. Overall CNSs responses had more positive views than CRSs 
8. CNSs significantly improve care of CRC patients - 98.9% of CRSs and 
95% of CNSs agree 
Soukop M, 
Robinson A et 
al (2006), UK 
Questionnaire 
responses - from 
MDT co-ordinator 
    
 
1.70% of responders had a dedicated MDT co-ordinator 
2. Presence of CRCMDTC correlated in use of pro forma for recording 
patient details 83% vs 44% (p<0.001) 
3. CRCMDTC responsible for communicating decisions in 26% 
Swellengrebel 
H, Peters E et al 
(2011) 
Netherlands 
1. Staging methods 
2. Treatments 
3. Positive CRM 
  
  1. Patients with distal tumours more likely to be discussed at MDT than 
those with proximal (69% vs 47%, p=0.002) 
Taylor A, 
Sheridan M et al 
(2004), UK 
Questionnaire 
responses - from 
radiologists 
      1. 138/142 (95%) - all cases discussed at MDT, 1 (1%) not always, 3 (2%) 
not discussed and 3 (2%) not stated 
2. 126/142 (89%) - nominated radiologist regularly participates in MDT 
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Taylor C, 
Sippitt J et al 
(2010), UK 
Questionnaire 
responses: 
1. Changes in self- 
reported job stress 
2. Changes in self- 
reported job 
satisfaction 
3.Changes in team 
performance 
✓ 1. 90% of MDT co-ordinators and CNSs were female, 90% of surgeons and 
79% of radiologists were male 
2. Surgeons reported highest total job stress 
3. Surgeons and CNSs reported highest job satisfaction 
4. Across all members - "working in MDT" and "providing better care from 
working in a MDT" were predominant sources of job satisfaction 
 
Wilcoxon H, 
Luxford K et al 
(2011), 
Australia 
 
 
Wood J, 
Metcalfe C et al 
(2008), UK 
Questionnaire 
responses 
 
 
 
 
Implementation 
of decisions 
✓ 1. 1/3 of hospitals surveyed reported having an MDT 
2. Of those with MDT, 2/3 informed patient of MDT discussion 
3. Of those with MDT, under half reported that patient consent not sought 
for discussing their case 
4. only 2/299 had core team members regularly attending MDT meetings 
✓ 1. 20/201 (10% (CI 6.3-15.2%) decisions not implemented. 
2. All these patients had more conservative treatment then original. 
 
3. Of these, 16 due to patient factors (9 co-morbidity, 7 patient choice), 1 
due to irresectable tumour at laparotomy, 1 due to unsuitability for 
colonoscopic local excision, 1 due to doctor changing decision as did not 
feel adjuvant therapy would be beneficial, and 1 with no apparent reason 
4. Decisions more likely to change for colon cancers than for rectal cancers 
(OR 4.34, CI 0.97-15.06, p=0.024) 
 
 
 
 
 2.5.3 The impact of MDTs on pre-treatment decisions 
 
The study by Kurtz et al showed that presentation at MDT resulted in good compliance with local 
guidelines in patients with colorectal cancer – 91% and 83% in different groups. Although this study 
did not compare these to a control group prior to the introduction of the MDT, the findings were 
echoed by Abraham et al who showed that presentation at MDT resulted in improved adherence to 
recommended therapy in patients with colon cancer and rectal cancer, although the findings were not 
significant in colon cancer. 
 
A number of studies showed that presentation at MDT improved both local and distant staging – both 
in their use as well as in the accuracy of reporting. Metaanalysis of studies reporting use of MRI or 
TRUS for local staging of rectal cancer patients showed that patients in the MDT group were more 
likely to have MRI / TRUS than those not discussed at MDT (OR 6.97, 2.92, 16.64). The proportion 
of patients referred for and receiving neoadjuvant oncological treatment was also greater in patients 
discussed at MDT – statistically significant findings reported by Levine et al, Marshall et al, 
Swellengrebel et al and Wilks et al. 
 
Figure 2.2: The impact of MDTs on the use of MRI / TRUS for 
staging in rectal cancer 
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Table 2.5: The impact of MDT on pre-treatment decisions 
 
 
 
Reference Outcomes Aspects of MDTs investigated Relevant results 
 
Guidelines Oncology Staging Treatment 
choice 
 
 
Abraham, N. S., J. T. 
Gossey, et al. (2006); 
USA 
Receipt of 
recommended treatment 
✓ 1. Colon cancer - no statistically significant 
difference in receipt of recommended 
treatment between groups presented or not 
presented at MDT 
2. Rectal cancer - presentation at MDT more 
likely to result in appropriate use of 
recommended treatment (strict definition) 
(OR 3.62; CI: 1.18-11.17). This was true for 
both intention to treat (broad) and actual 
(strict) treatment 
 
Augestad K, 
Lindsetmo R, et al 
(2010); North America, 
Europe, Asia 
Questionnaire responses   MDTs influence preoperative factors: 
1. choice of staging modality - MRI used 
more (RR 3.62, CI 0.93-14.03, p=0.06) 
2. CRM as indication for neoadjuvant 
treatment increased (RR 5.67, CI 1.8-17.89, 
p=0.003) 
3. Quality of pathology report improved (RR 
4.85, CI 1.34-17.46, p=0.01) 
4. Use of new chemotherapy regimen if liver 
mets present improved (RR 6.41, CI 1.34- 
30.64, p=0.02) 
5. 1 stage surgery when liver mets present - 
reduced (RR 0.25, CI 0.08-0.8, p=0.02) 
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Augestad K, 
Lindsetmo R, et al 
(2012); North America, 
Europe, Asia 
Survey responses  1. Decision for one stage surgery was less 
likely in departments with MDTs (OR 0.24) 
 
Burton S, Brown G, et 
al (2006); UK 
 
 
 
 
Chang-Zheng D, Jie L 
et al (2011), China 
 
 
 
 
 
 
 
Jones R, Vauthey J et 
al (2012), UK 
Percentage of patients 
with preoperative MDT 
discussion of MRI and 
associated CRM 
positivity 
 
1. Pre-operative 
evaluation 
2. Sphincter 
preservation surgery 
3. Local recurrence 
4. Distant metastases 
5. 5 year disease free 
and overall survival 
1. Agreement between 
specialists 
2. Concordance 
between original 
decision and specialist 
decision 
✓ 1. 62/259 (24%) proceeded to surgery 
without pre-op MDT discussion of MRI (no 
neoadjuvant therapy) 
2. no MDT group - 20/62 had MRI, but not 
discussed 
3. All patients in MDT group had MRI 
✓ 1. All complicated patients (n=516) discussed 
at MDT 2. Rectal 
cancer: MDT group - 61/101 (60.4%) had 
MRI vs non-MDT - 66/162 (40.7%) - 
p<0.001 
 
 
 
✓ 1. High degree of agreement between 
reviewers classing decision to treat 
palliatively as correct (K statistic 0.577) 
2. Overall, in only 5/52 patients were all 
6 reviewers in agreement that decision to 
treat palliatively was correct 
3. Differences in individual management 
strategies 
 
Keating N, Landrum M 
et al (2012), USA 
1. Adjuvant 
chemotherapy for stage 
III colon cancer 
2. Adjuvant chemo- 
radiotherapy for stage 
✓ 1.  Colon cancer: 68.7% (no MDT) vs 69.3% 
(General MDT) vs 70.4% (CRC specific 
MDT) – p=0.83 
2.  Rectal cancer: 74.6% (no MDT) vs 73.9% 
(General MDT) vs 74.6% (CRC specific 
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Kurtz J, Heitz D et al 
II/III rectal cancer 
 
1. MDT cases: what 
 
 
  
 
 
  
 MDT) – p=0.97 
 
1. 65 patients advocated adjuvant 
(2010), France percentage patients > 70 
years had treatment 
according to guidelines. 
2. Percentage of these 
that actually had 
recommended treatment 
   chemotherapy, 128 advocated follow-up. 
2. 91% in chemo group were in accordance 
with guidelines, 83% in follow-up group - of 
those not according to guidelines (22) - 7 due 
to comorbidities, 11 due to old age, 4 - no 
reason. 
Levine R, Chawla B et 
al (2012), USA 
1. Pre-operative 
evaluation 
2. Access to multimodal 
therapy 
 
    As compared to those not discussed at MDT, 
patients discussed at MDT had: 
1. CT: abdomen - 97.5% vs 83.1% (p=0.03); 
chest- 95% vs 37.1% (p<0.0001) 
2. CEA - 100% vs 63.8% (p<0.0001) 
3. TRUS (rectal pts) - 88% vs 37.7% 
(p<0.0001) 
4. Overall complete work-up - 85% vs 23% 
(p<0.0001) 
5. Oncology consultation - 98.9% vs 25.4% 
(p<0.0001) & treatment – 62.5% vs 41.5% 
(p=0.02) 
6. Advanced pathology testing - 29.6% vs 
10.6% (p=0.0001) 
7. Neoadjuvant therapy rate - 76% vs 20% 
(p<0.0001) 
Marshall C, Balentine 
C et al (2011), USA 
1. Overall & disease 
free survival 
2. R0 resections 
3. Recurrence rate 
4. No. of lymph nodes 
found 
 
  
 
1.Neoadjuvant therapy (rectal) - 35% to 91% 
(p<0.01) 
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5. No. of patients 
receiving neoadjuvant 
therapy 
 
 
Palmer G, Martling A 
et al (2010), Sweden 
 
1. Pre-operative staging 
techniques / 
completeness 
2. Type of surgery 
3. R0 Resection 
4. Residual tumour / 
recurrence 
 
✓ 1. 65/65 in group 1 had local staging, compared to 44/139 in group 
3 (p<0.001) 
2. 65/65 in group 1 had distant staging, 
compared to 53/139 in group 3 (p<0.001) 
3. 51/65 in group 1 had pre-op treatment, 
compared to 48/139 in group 3 (p<0.001) 
 
Swellengrebel H, 
Peters E et al (2011) 
Netherlands 
1. Pre-operative staging 
techniques / 
completeness 
2. Treatments 
3. Positive CRM 
✓ 1. More complete staging in MDT+ group - 94% vs 73%, p<0.001) 
2. Patients undergoing pre-op therapy 
discussed more often at MDT then those 
straight to TME (63% VS 19%, p<0.001) 
 
Taylor A, Sheridan M 
et al (2004), UK 
Questionnaire responses  1. 138/142 (95%) - all cases discussed at 
MDT, 1 (1%) not always, and 3 (2%) not 
discussed. 3 (2%) not stated 
2. 126/142 (89%) - nominated radiologist 
regularly participates in MDT 
3. 79/142 (56%) - more than 75% of patients 
have pre-operative MRI 
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Wilks J, Liebig C et al 
(2009), USA 
1. No. of lymph nodes 
resected 2. % of 
patients undergoing R0 
resection 
3. No. of patients 
receiving neoadjuvant 
therapy 
✓ 1. Number of patients receiving neoadjuvant 
therapy inreased from 32% pre to 74% post 
(p<0.0001) 
 
 
Wille-Jørgensen P, 
Sparre P et al (2012), 
Denmark 
1. Preoperative staging 
done 
2. MRI performed 
✓ 1.  Full preoperative staging done – 240/467 
(pre) and 300/344 (post) (p<0.001) 
2.   MRI performed – 100/467 (pre) and 
249/344 (post) p=0.007 
 
 
Ye Y, Shen Z et al 
(2012), China 
1. Number of lymph 
nodes examined 
2. Pre-operative staging 
techniques / 
completeness 
3. Rate of tumour 
recurrence 
  1. CT done in 90/297 (30.3%) in pre, vs 
185/298 (55.7%) post - p<0.001 
2. CT TNM staging done in 37/90 (41.1%) in 
pre, vs 150/185 (81.3%) post - p<0.001 
3. Accurate CT TNM staging done in 17/37 
(45.9%) in pre, vs 96/150 (64.0%) post - 
p=0.044 
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2.5.4 The impact of MDTs on outcomes 
 
Two studies (Burton et al and Swellengrebel et al) reported reductions in the rates of CRM positive 
resections; however these findings were only statistically significant in the former study. Overall, the 
number of Lymph Nodes found improved in data from three studies (Derwinger et al, Marshall et al 
and Ye et al). Additionally, Derwinger et al demonstrated a significant increase from 27% to 67% in 
the number of patients who had the minimum number of 12 Lymph nodes identified. Despite 
differences in reporting survival – Lordan et al, Segelman et al and Ye et al reported overall survival, 
MacDermid et al reported 3 year survival and Chang-Zheng et al reported 5 year survival – there was 
an overall improvement shown following the introduction of MDTs. Metaanalysis of overall survival 
at 3 years showed an improvement following the introduction of MDTs – OR 1.51 (0.91, 2.52). 
Overall positive margins following surgery improved following introduction of MDTs, as reported 
by Marshall et al, Palmer et al, Wilks et al and Wille Jorgensen et al – metaanalysis showed a 
reduction in these rates – OR 0.35 (0.24, 0.52). 
 
Figure 2.3: The impact of MDTs on 3 year overall survival 
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Figure 2.4: The impact of MDTs on reducing positive resection 
margins 
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Table 2.6: The impact of MDT on outcomes 
 
 
Reference Outcomes Aspects of MDTs investigated Relevant results 
 
Surgical Resection 
Margins 
Recurrence 
/ Survival 
 
 
Burton S, 
Brown G, et 
al (2006); UK 
Percentage of 
patients with 
preoperative MDT 
discussion of MRI 
and associated 
CRM positivity 
✓ 1. Histologial CRM+ve rate 16/62 - 26% (CI 16.6-39.7%) vs Histological 
CRM+ve rate 1/116 - 1% in group who proceeded to surgery alone after MDT 
discussion of MRI 
2. Overall Histological CRM+ve rate in patients discussed at MDT (all groups) 
- 16/197 - 8% 
 
3. Patients discussed at MDT - MRI CRM+ve of 60/197 - 30%, however actual 
histological CRM+ve 
4 - 2% - significant downstaging (all groups) - additionally further 15 patients 
(12 unresectable, 3 refused surgery) - 8% unresected 
 
Chang-Zheng 
D, Jie L et al 
(2011), China 
1. Pre-operative 
evaluation 
2. Sphincter 
preservation surgery 
3. Local recurrence 
4. Distant metastases 
5. 5 year disease free 
and overall survival 
✓ 1. MDT group - 13/35 (37.14%) had sphincter preservation surgery for tumours 
<5cm vs non-MDT - 5/37 (13.51%) - p=0.041 
2. MDT group - 4/101 (3.96%) had local recurrence vs non-MDT - 18/162 
(11.11%) - p=0.042 
3. MDT group - 22/101 (21.78%) had distant mets vs non-MDT - 36/162 
(22.22%) - p=0.933 (not significant) 
4. MDT group - 77/101 (76.24%) 5yr disease free survival vs non-MDT - 
109/162 (67.28%) - p=0.039 
5. MDT group - 78/101 (77.23%) 5yr overall survival vs non-MDT - 113/162 
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Derwinger K, 
 
1. Number of lymph 
 
  
   (69.75%) - p=0.049 
1. Increase in number of nodes from mean of 9 (median 7, range 1-33) to mean 
Carlsson G, et 
al (2007); 
Sweden 
 
Keating N, 
Landrum M et 
al (2012), 
USA 
nodes found 
2.Positive nodes 
 
 
3 year all cause 
survival 
   
 
 
 
  
 17 (median 16, range 5-36) - p<0.05 
2. Increase in positive nodes from mean of 1.7 to 2.4 
3. Improvement in requirement of 12 nodes to be examined - from 27% to 67% 
(p<0.05) 
1. Colon cancer: 57.5% (no MDT) vs 58.2% (General MDT) vs 60.2% (CRC 
specific MDT) – p=0.24 
2. Rectal cancer: 52.5% (no MDT) vs 56.2% (General MDT) vs 54.6% (CRC 
specific MDT) – p=0.37 
Lordan J, 
Karanjia N et 
al (2008), UK 
(Study 
comparing 
referrals to 
specialist 
HPB MDT) 
1. Intra-operative 
parameters 
2. Disease free 
survival 
3. Overall survival 
  
  
  1. Less operative blood loss in Group A (200mls, 0-1500) than Group B 
(387.5mls, 0-2500), p=0.03 
2. Higher overall survival in Group A (3..6years, 0.08-7.8) vs Group B 
(2.61years, 0-9.6), p=0.0001 
3. Smaller tumour size in Group A (30mm, 3-130), vs Group B (35mm, 5-150), 
p=0.05 
MacDermid 
E, Hooton G 
et al (2008), 
UK 
1. 3 year survival 
2. Prescription and 
completion of 
adjuvant 
chemotherapy. 
   
  1. Dukes C 3 year survival - 58% post vs 66% pre (p=0.023) 
2. No statistically significant difference in Dukes B 
3. Overall more patients prescribed chemo post MDT (31.3%) vs pre (13%) - 
p=0.0002. 
Marshall C, 1. Overall survival     
 
  1. Positive margins - 20% to 6.5% (p<0.03) 
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Balentine C et 
al (2011), 
USA 
2. Disease free 
survival 
3. Proportion of R0 
resections 
4. Recurrence rates 
5. Number of lymph 
nodes found 
    2. Number lymph nodes - 9 to 17 (p<0.01) 
3. Adjuvant therapy (rectal) - 53% to 74% (p<0.04) 
4. Laparoscopic procedures - 0% to 34.7% 
5. Unadjusted 3 year overall survival - 65% to 82% (p=0.03) - Hazard ratio 
0.42 (0.19-0.92) p<0.03 
Palmer G, 
Martling A et 
al (2010), 
Sweden 
1. Pre-operative 
staging techniques / 
completeness 
2. Type of surgery 
3. R0 Resection 
4. Residual tumour / 
recurrence 
 
    
 
1. R0 resection - 52% in group 1, 43% in 2, 21% in 3 (p<0.001) (assessed in 
patients without metastases at time of surgery) 
2. Percentage with no sign of pelvic tumour at end of follow-up- 57% in group 
1, 36% in 2, 19% in 3 (p<0.001) 
Segelman J, 
Singomklao T 
et al (2008), 
Sweden 
1. Assessment by 
MDT 
2. Overall survival 
   
  1.Patients not assessed by MDT had significantly higher risk of dying than 
those who were assessed by MDT(HR 2.52, CI 2.20-2.90, p<0.001) 
Swellengrebel 
H, Peters E et 
al (2011) 
Netherlands 
1. Staging methods 
2. Treatments 
3. Positive CRM 
 
  
  
1. Overall CRM +ve rate not significantly different between both groups 
Wilks J, 
Liebig C et al 
1. Number of lymph 
nodes resected 
2. % of patients 
    
  
1. Number of lymph nodes resected - 9.3+/-0.9 (pre) to 16.1+/-1.1 (post) 
2. % of patients undergoing R0 resection 78% pre and 95% post (p<0.05) 
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(2009), USA undergoing R0 
resection 
3. Number of 
patients receiving 
neoadjuvant therapy 
 
Wille- 
Jørgensen P, 
Sparre P et al 
(2012), 
Denmark 
1. Tumour resection 
2. R0 resection 
3. >12 lymph nodes 
4. Curative surgery 
5. Postoperative 
mortality <30 
      1. >12 Lymph nodes resected – 119/368 (pre) and 119/261 (post) (p<0.001) 
2. Postoperative mortality <30 days – 41/467 (pre) and 17/344 (post) p=0.007 
 
 
 
 
Ye Y, Shen Z 
et al (2012), 
China 
days 
6. Local recurrence 
7. Distant 
metastases 
1. Number of lymph 
nodes examined 
2. Accuracy of 
TNM staging 
3. Rate of tumour 
recurrence 
 
 
 
 
✓ 1. Mean number of lymph nodes resected 8.5+/-5.9 (pre) to 13.7+/-4.1 (post) (p<0.001), 
but no statistically significant difference between number of positive nodes
 2. 
Overall 
survival - patients in pre-MDT survived for significantly shorter time than 
those post-MDT (log-rank test, p=0.015). 
3. Rate of tumour recurrence in MDT group lower than pre-MDT group (log 
rank test, p<0.001) 
4. Mean time to recurrence: 11.0 months in pre-MDT group, 14.1 months in 
MDT group (p<0.01) 
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2.6 Discussion 
 
2.6.1 Summary of results 
 
The aim of this review was not to question whether or not multidisciplinary team management in 
colorectal cancer care should continue, but simply to identify a body of evidence to validate its use. 
Furthermore I aimed to review the current literature on functioning and quality. This is the first 
review that systematically evaluates multidisciplinary care in colorectal cancer, and provides an 
overview of current practice, and a broad outline of the impact of multidisciplinary teams on 
management strategies and outcomes. 
 
Multidisciplinary teams are now established in colorectal cancer care in the UK, with increasing 
acceptance globally. However it is clear that the direct impact of their introduction is difficult to 
measure, given the numerous changes in overall care for colorectal cancers over the same period. 
Similar results have been found in previous studies in obstetrics and cardiology. 
 
The primary aim of this review was to identify the available literature on Colorectal Cancer. We 
identified 42 empirical studies on colorectal cancer MDTs. Given the widespread use in clinical 
practice, it is perhaps surprising that there are so few studies available. Within the UK, where MDTs 
are a mandatory part of cancer care, there were 13 studies, with only a few studies in recent years. 
Indeed, despite the recommendations made by Fleissig et al in 2006 (27), there have been few studies 
that have addressed the issues raised. 
 
The secondary aims of the review were to identify studies in three distinct categories. We were able 
to classify the studies in this way, and separated them further into sub-themes, based on particular 
factors. In doing this, it was clear that there was wide variation in the studies, and differing methods 
of assessment. There were very few studies (those selected for meta-analysis) where similar 
measures were used. However, one could argue that the studies included in the meta-analysis are 
mismatched and therefore that the results not valid. However they do provide a broad picture of 
benefit from MDT introduction. Leading on from this, there was considerable variation in study 
methodology, and some of the studies report responses to surveys or questionnaires regarding current 
practice – and therefore may not be a true reflection of actual processes in place. However such 
studies are clearly identified, and do not form the basis for any of the meta-analysis. 
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What this review highlights is that MDTs in colorectal cancer care are still a “work in progress”, and 
there are considerable differences in how Colorectal cancer MDT meetings are run, and how 
individual clinicians and teams choose to assess their effectiveness. 
 
There are variations in the frequency and organization of meetings, and significant issues in ensuring 
a full complement of core team members are present. Additionally, the increased volume of cases 
that come through meetings, with increased awareness, screening and diagnosis mean that the time 
pressures for clinicians and meetings are ever increasing. This raises the somewhat controversial 
suggestion that not all cases should be discussed at MDT, with the MDT lead reviewing cases 
beforehand, and highlighting complex cases for discussion, whilst making decisions on simpler cases 
with the aid of a pre-agreed protocol. 
 
Cancer care clinicians do feel the benefit of attending meetings, describing them as valuable 
opportunities for learning and improving practice, whilst enhancing job satisfaction. Notably, 
however, there is little mention of the value of MDTs as teaching aids – this may be influenced by 
the limited time available. 
 
2.6.2 Limitations 
 
The results of both the systematic review and the meta-analysis are limited by the quality of the 
studies included. There is significant variation in the studies in terms of study type, methodology, 
numbers and types of participants. Furthermore, with the studies looking at improvements in 
practice, there was considerable variation in the measured outcomes. Additionally, all of these 
studies were before and after studies, with the majority being retrospective. 
 
Whilst we have undertaken a meta-analysis of a subset of the studies, it must be noted that there was 
variation between these studies as well. We attempted to categorise these studies based on the 
similarities between the MDT groups and the pre-MDT groups, but found that there were significant 
differences in all these studies. 
 
The lack of standardized studies presents a challenge, in an area where it is no longer feasible to 
conduct prospective, double blinded randomised clinical trials. However, it does highlight the 
significant task set in identifying assessment measures for colorectal cancer MDTs. 
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The types of studies presented and their study location and participants may introduce bias. There are 
a number of survey and questionnaire studies, which, by their nature, introduce bias from the 
participants. Additionally some of the studies have low response rates. The majority of studies 
emerge from large centres, where multidisciplinary team working may be established, and therefore 
the results may not reflect practice or results elsewhere. 
 
2.7 Conclusion 
 
This review highlights that despite the high prevalence of MDTs in colorectal cancer care, there are 
no standardised methods of measuring how well they work, or whether they improve outcome. 
Specific outcome measures have been quoted, however it is important to appreciate that these are 
often more specific measures of particular aspects of care within the process, or global measures of 
the overall cancer care pathway. With this in mind, the review highlights the difference between 
measuring how well the MDT works – something which is inherently measurable; to how MDTs 
impact on clinical outcomes – more difficult as there are numerous factors that may affect this – and 
outcomes therefore measure a series of events in the cancer care pathway. 
 
The next chapter outlines an interview study with core clinical members of the colorectal 
multidisciplinary team, aimed at identifying specific measures that could be used to assess colorectal 
cancer multidisciplinary teams. 
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CHAPTER 3: USER DEFINED OPINIONS ON COLORECTAL 
CANCER MULTIDISCIPLINARY TEAMS: AN INTERVIEW 
STUDY 
 
 
 
3.1 Chapter overview 
Chapter 2 identified the key aspects of colorectal cancer multidisciplinary care. It highlighted that there 
are variations in structure and implementation of Colorectal Cancer MDTs and established that there are 
no specific measures of effectiveness and performance of a multidisciplinary team. It showed different 
clinical outcomes used to illustrate improvements in care following the introduction of multidisciplinary 
teams – however, again, there is variation in what measures are used. 
 
In order to explore in detail some of the issues raised in Chapter 2, in this chapter I report the results of a 
qualitative interview study aimed at exploring the views of core members of the colorectal cancer MDT 
on assessment in colorectal cancer MDTs. 
 
3.2 Introduction 
Whilst the previous chapter has gone some way to identifying specific areas that could be utilised to 
evaluate how a colorectal cancer multidisciplinary teams works, the results show that there is huge 
variation in how this is done. Furthermore, the studies included are over a long period of time, 
meaning that some of the measures raised may no longer be suitable, particularly as the management 
of colorectal cancer is constantly evolving. 
 
To obtain a current, diverse view of what assessment measures could be used, I conducted an 
interview study involving all the core clinical members of a colorectal cancer MDTM. I deliberately 
chose this qualitative approach as it offers detailed information from individual participants and is 
well-suited to explore complex matters with clinical experts, from which hypotheses can be 
generated and tested further (91). 
 
3.3 Aims 
 
The aims of the study were to: 
1. Explore individuals’ perceptions of their roles within colorectal cancer MDTMs, and particular 
individual and team characteristics they consider important to effective colorectal cancer MDTM 
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working; 
2. Investigate awareness of any assessment tools, both for individuals as well as for the colorectal 
cancer MDTM as a whole; 
3. Define what measures may be suitable for assessing colorectal cancer MDTMs, taking into 
account the characteristics mentioned above. 
 
3.4 Methods 
 
3.4.1 Protocol development 
 
This was a qualitative, semi-structured interview study. In the first instance, I developed a semi- 
structured interview topic guide based upon the aims of this study and piloted it in iterative phases to 
ensure feasibility and adequate content. In addition to the findings from the Chapter 2, I utilised the 
expertise of our research team, who have published similar studies on surgical teams’ views on their 
communication problems, stressors in the operating theatre, and views of urology MDT members on 
their team working (92, 93) to refine the interview protocol. An overview of the final version (Figure 
3.1) consisted of key questions which explored participants’ opinions on the following issues in 
colorectal cancer MDTs: Individual roles and responsibilities, evaluation of performance, current 
methods of assessment and options for further measures of assessment. A complete version of this is 
presented in Appendix 2. 
 
3.4.2 Participants 
 
I recruited 20 MDT members from three different hospitals (District General Hospital, tertiary 
referral and university teaching) using purposive sampling techniques. For each of these three 
settings, participants included all core clinical MDT members who make clinical decisions and have 
contact with patients. MDT members recruited were colorectal surgeons (a proportion of whom had 
acted as MDT chair), oncologists, radiologists, pathologists and clinical nurse specialists. As per 
standardized qualitative methodological techniques (91), recruitment of MDT members continued 
until ‘saturation’ of the themes that emerged from participants’ interviews was reached (i.e. no new 
themes were arising from successive interviews). Participation in the study was voluntary and 
informed consent was obtained. Anonymity was ensured throughout the study. 
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3.4.3 Procedure 
 
I undertook individual interviews face to face at a pre-arranged venue between March and August 
2012. All the interviews were audio-taped and transcribed verbatim. Transcripts were cross-checked 
with the original recordings to ensure accuracy and anonymised. A sample transcript is shown in 
Appendix 3. 
 
3.4.4 Data analysis 
 
I used emergent theme analysis for qualitative data that emerged from the study (91). Transcripts 
were cross-checked with the original recordings to ensure accuracy. I then read the transcripts 
multiple times to ensure full immersion in the data. I subsequently analysed each transcript for 
content to identify emergent themes. A random sample of interview transcripts (25%) was selected 
using a free online random number generator (www.random.org). These were then coded 
independently by another member of the research team, with qualitative methodology expertise 
(Wheelock) to ensure reliability of theme extraction. Finally, I reviewed all the emergent themes 
together with another researcher (Arora), who was blind to the theme extraction process, and key 
themes were tabulated. 
 
 
I evaluated the level of coding agreement between researchers (i.e., reliability) both qualitatively 
and quantitatively. First, I discussed emergent themes with the other coder (Wheelock) and we 
obtained consensus on theme content to include (qualitative evaluation). Second, the overall number 
of themes identified from each interview by myself and the second coder (Wheelock) was submitted 
to a correlational analysis (Pearson’s r correlation coefficients) to ensure that similar numbers of 
themes were extracted (quantitative evaluation). Where quantitative analysis was appropriate, 
analyses were performed using SPSS version 20.0 (SPSS Inc., Chicago, IL, USA). Significance was 
set at the 0.05 level. 
 Figure 3.1: Interview protocol 
 
 
  INTRODUCTION  
 Establish ID of who I’m speaking to – name, job title 
 Introduce myself 
 Introduce project – State aim of the interview: To identify outcomes that can be used to evaluate Colorectal 
Cancer MDTs. 
 Ask permission to tape interview, assure anonymity 
 Confirm that the information provided will be treated confidentially 
  RESPONSIBILITIES  
2.1.1 1. Can you please describe your role in the Colorectal Cancer MDT? 
-+ What strengths do you bring to the MDT 
-+ Do you think your role is limited to the meeting? 
-+ Do you have time to prepare for the MDT beforehand? How much time is typically required? 
-+ Is there anything that limits your ability to perform your role? If yes, what is it? 
2.1.2 2. How do you know that you are performing your role satisfactorily? 
-+ Do you ever self-evaluate your contribution? 
-+ How is your performance measured and reviewed? 
-+ Have you received any detailed feedback (verbal or written)? 
-+ Are such performance assessments / reviews regular / formal or ad hoc? 
CURRENT METHODS OFASSESSING COLORECTAL CANCER MDTs 
3. Do you know of any tools or methods available to assess how well Colorectal Cancer   MDTs work? 
-+ Do these assess individual members? 
-+ Do these assess the overall process of the MDT? 
-+ Do these assess the outcomes from MDTs? 
-+ If there are such tools, how are they applied (ie how frequently, in what form?) 
1.  Do you think these tools are suitable? 
-+ How could they be improved? 
YOUR OPINIONS 
2.  What measures of performance would you recommend for assessing how well Colorectal Cancer MDTs work? 
-+ What aspect of the MDT would these measures assess? 
-+ Rather than focusing on the process, are there measures that could assess the outcome? 
-+ If you were designing a tool, what outcome measures would you include? – Do you think these assess the MDT 
decision individually, or do they assess the whole process, from initial referral to final treatment? 
  EXPERT OPINION  
6.  Who would you consider to be experts who could provide a consensus on outcome measures for Colorectal Cancer 
MDTs? 
-+ Do you think that these should be specialty specific, or that an overall consensus for all MDTs would be suitable? 
-+ Are there any particular organisations? 
-+ What do you think is the best way to collect this consensus – ie are there particular groups / conferences that could be 
contacted to facilitate this? 
  RESPONSIBILITY  
7.   In the event of any complaints / proceedings, who do you think is responsible for the recommendations of 
multidisciplinary team meetings? 
-+Do individual clinicians have responsibility / liability, even if they have not been actively involved in the discussion? 
-+What would you do in the event that you did not agree with the final recommendation given by the MDT? 
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3.5 Results 
Twenty colorectal cancer MDT members participated in the study – all at expert Consultant level. 
There were six colorectal surgeons (S1-6), five radiologists (R1-5), three pathologists (P1-3), three 
oncologists (O1-3) and three colorectal clinical nurse specialists (CN1-3). Four of the colorectal 
surgeons had previous or current experience as the MDTM chair. All twenty interviews took place 
face-to-face at a pre-arranged venue at the participants’ place of work between March and August 
2012, lasting a median 22 minutes (range 12 – 35 minutes). 
 
3.5.1 Intercoder agreement (reliability) 
 
Following blind coding, the second coder (Wheelock) and I discussed the content of themes 
identified in the interview transcript. Only one disagreement arose at this stage due to a 
misunderstanding on specific medical terminology by my colleague, a non-medical coder and once 
clarified, consensus was reached. Moreover, a correlation was carried out between the number of 
themes that we identified per interview: this was very good (r=0.73, p<0.01) indicating that both of 
us extracted similar number of themes. Taken together, these findings indicate reliability of theme 
extraction. 
3.5.2 Roles, responsibilities and characteristics of MDTM 
members 
3.5.2.1 Awareness of Roles 
 
Of the 20 participants, 19 were able to clearly define their role within the MDTM. 19 individuals felt 
that their role extended beyond the domain of the meeting, whilst only one felt that their role was 
limited solely to the meeting. As one radiologist put it, “the meeting is just one facet of the colorectal 
multidisciplinary team…. so no, I don’t think the MDT stops when the meeting finishes” (R4). 
 
Importantly, there was no consensus amongst the participants as to who assumed overall 
responsibility for the decisions made at the MDTM. Ten participants stated that it was individual 
clinicians. Six participants stated that it was the team’s responsibility, and the remainder stating that 
it was a combination of the two. The group that felt it was individual clinician’s responsibility 
included all of the oncologists and five out of the six surgeons – suggesting that those clinicians that 
come into direct contact with patients had a greater sense of ownership. One oncologist stated that 
“it’s ultimately the decision of the Consultant that’s looking after the patient, and the MDT is a 
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guide” (O2) – a view echoed by other clinicians who felt that the ultimate decision and responsibility 
lay with the treating clinician – taking into account the d i scuss ion  f rom  the MDT. The 
opposing group, which included all three pathologists, felt that once patients were discussed at 
meetings,, the responsibility was collective – a view emphasized by a pathologist: “I think it’s a 
collective responsibility at the end because of all the different elements are brought together and then 
a final decision is taken”(P3). 
 
3.5.2.2 Barriers to performing roles 
 
The most common barriers quoted by the participants to adequately performing their role were 
insufficient time and inadequate information about the patient. Only half of the individuals felt that 
they always had sufficient preparation time before the meeting. Interestingly, eight of the ten 
participants who stated lack of sufficient time, did not feel that dedicated preparation time was 
necessary prior to the meeting. Although there was no apparent difference between specialties 
regarding these barriers, it was interesting to note that all those individuals who felt that inadequate 
patient information was an issue were from the District General hospital. As one radiologist put it, 
“getting a feel for the actual clinical background, how does the patient present, what other relevant 
clinical laboratory findings were there, is important obviously in the whole process of reaching an 
opinion and a conclusion”(R3). 
 
3.5.2.3 Important characteristics of the team and its 
members 
 
Characteristics identified by participants were split into two groups: those specific to individuals, and 
those related to the team. 
 
Key characteristics that were highlighted for individuals were individual specialist knowledge / skills 
(11 participants), experience (nine participants), and ability and readiness to offer different opinions 
(three participants). Surprisingly, only two participants mentioned the importance of acting as the 
patient’s advocate, although both highlighted the importance of this role, as highlighted by a clinical 
nurse specialist: "I get an idea of other psychosocial issues with the patient, and a holistic view of the 
patient, their social support, things about them that may be affected by treatment decisions that we 
make…so it’s important for the other members of the team to actually have access to that 
information, and what the patients are worried about, and things that may have implications on 
treatment decisions" (CN1). 
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Characteristics related to the team were focused around the team’s ability to include all parties in the 
discussion (six participants), establishing and maintaining good relationships with colleagues and 
educating trainees: “inform the trainees or the juniors that are at the MDT because I think the MDT 
if it works well can be a very educational meeting and it’s crucial in understanding the complexities 
regarding patients, and I think hopefully offer knowledge and experience of oncology and managing 
colorectal patients.” (O2). 
 
 
The MDTM chair was identified as a key individual within the team, and in addition to the above 
characteristics, nine individuals highlighted the importance of their effectiveness at controlling the 
discussion – “it would be a poor chairman who perhaps interferes with the flow of discussion too 
early... Important to recognize when the discussion has run its natural course" (S1). 
 
 
3.5.3 Current methods of assessment of the Colorectal Cancer 
MDTM 
3.5.3.1 Self-assessment 
Six of the participants in the study regularly carried out self-assessments, whilst a further five did so 
occasionally (radiologists did this most frequently). This self-assessment was undertaken in various 
forms: audit of MRI staging versus pathological staging adherence to guidelines were the most 
common. 
 
3.5.3.2 Formal assessment methods 
None of the individuals interviewed were able to identify any formal methods of assessment of the 
colorectal cancer MDT or the MDTM. Five individuals went on to discuss formal assessments of 
performance that they undertook as part of their wider clinical roles, however, they all acknowledged 
that none of these methods were specific to MDTMs. These included patient satisfaction surveys and 
360 degree / multi-source feedback tools. When the subject of ‘peer review’ in MDTs was raised in 
the interviews (i.e., the annual mandatory procedure of assessing how MDTs are faring across all 
cancer types in England), this was not seen as an assessment method, but as a quality improvement 
tool. Not all clinicians interviewed had been part of a peer review process. 
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3.5.3.3 Informal assessment methods 
 
Informal methods identified included verbal feedback from colleagues; approximately half of the 
individuals interviewed received informal feedback from colleagues, and felt it was useful: "it would 
all be completely informal, people coming down and telling me they didn’t like this or they didn’t like 
that" (R1). Three of the participants also stated that they actively asked their colleagues for informal 
feedback. Non-verbal feedback was less obvious, but two participants felt that whether or not others 
listened to them attentively during the meeting was indicative of their performance. 
 
3.5.4 Proposed methods of assessment of the Colorectal Cancer 
MDTM 
Participants were asked to identify what methods they thought would be useful in assessing 
colorectal cancer MDTMs. They identified two broad categories of elements which could form the 
basis of assessing MDTM performance: how the MDTM worked (i.e., process measures; Table 3.1) 
and clinical outcomes associated with the decisions made at the MDTM (i.e., outcome measures; 
Table 3.2). 
 
Overall, there was awareness that whilst no specific assessment measures were used in the MDTMs 
regular practice, there were specific measures that existed elsewhere, and could be used to good 
effect. As an oncologist participant stated, “I think it would be good to evaluate whether there could 
have been stronger oncological input, whether there could have been stronger histological input; I 
think that would be useful to be able to identify weak areas that you can develop” (O3). In discussing 
the different process measures, participants were aware that a lot of this information was likely to be 
readily available (including, for example, attendance, length of meeting), and specific assessment 
tools would need to combine these data and standardize them as a first step. Interestingly, process 
measures like those mentioned above were more readily reported by participants who did not have 
direct contact with patients – mainly radiologists and pathologists. 
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Table 3.1: Process measures for application to Colorectal MDTMs 
 
 
 
 
 
Measure 
N of participants 
mentioning 
Attendance and 
contributions, 
particularly core 
members 
 
 
7 
O2: “Making sure you have all the core members for the very least the minimum amount of 
MDTs and ideally much closer to 100% of MDTs” 
 
Length of meeting 
4 P1: “Just the length of the meeting – I mean, that’s a basic one” 
Creation and completion 
of standardised proforma 4 
R1: “Probably ought to report on a standardized proforma ..(so you can ask).. Are you doing 
it?.. Are you doing it accurately?” 
No of times a case is 
(re)discussed 3 R2: “The ones that keep coming back, maybe five or six times.  Why?” 
 
Ability of chair to co- 
ordinate meeting 3 
S1: “I think it’s important to recognise when the discussion has run its natural course and so 
that we can move on in an expeditious manner” 
 
 
 
Peer review 
R4: Informally, “you rely on your peers to tell you you’re doing a good job or you’re doing a 
2 bad job” AND formally, “our formal peer review process, and that covers a lot of the 
effectiveness of the MDT.” 
 
 
Recording time spent 
discussing cases 
R2: “Record how much time we spend discussing certain cases, and having a feel whether, as 
2 individuals, we feel that was appropriate for that case, if there are any cases we feel, at the 
end of a session, were rushed through because of time issues” 
 
 
Illustrative quote 
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Table 3.2: Outcomes measures for application to Colorectal MDTMs 
 
 
 
 
Measure 
N of participants 
mentioning 
 
Correlating radiological staging 
and pathology 5 
R3: “Looking at pathological staging, and comparing this with the pre-treatment 
radiological staging gives you two figures you can easily compare” 
Long term survival rates 
4 We can measure surgical outcomes - …, survival,…” 
CRM positivity 
4 We have these indirect measures – CRM positivity...” 
30 day mortality 
3 We have these indirect measures – …, 30 day mortality..” 
Recurrence 
3 We can measure surgical outcomes- cancer recurrence,…” 
Decision reached or not, and 
clearly documented 3 
You’ve got to look at decision making and whether a decision is formulated, and that’s 
correctly recorded” 
Percentage of decisions not 
carried through 2  
: “Looking at percentage of decisions that aren’t carried through, and looking at what reason 
they’re not necessarily carried through” 
 
 
 
Illustrative quote 
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Conversely, surgeons and oncologists spoke more readily about outcome measures. However, the 
suitability of these measures was questioned by the same participants, as they realized that the 
majority of these measures were not specific to the MDTM but covered wider aspects of colorectal 
cancer care. These measures included evaluating the post-operative resection margins and comparing 
these with pre-operative staging, to identify any discrepancies. Three participants felt that it would be 
appropriate and useful to measure the specific processes that individual team members carried out – 
an example being the lymph node yield as a means of assessing how thorough the pathologist was in 
examining the specimen. How different MDTs managed specific case vignettes was also a popular 
idea on assessment, particularly from surgeons - “a theoretical example that you can give out to 
various different groups and just see how they’re behaving”(S6). One radiologist (R2) also 
mentioned global targets, such as the proportion of cancer patients who were treated within the 
required time-frame, and argued that failure to progress smoothly through the MDTM would result 
in delays and inability to achieve set targets. Therefore such measures could measure the efficiency 
of the MDTM process. 
 
 
3.6 Discussion 
3.6.1 Summary of results 
The first aim was to explore individuals’ perceptions of their roles within colorectal cancer MDTMs, 
and characteristics they felt were important. This study established that individuals were clear about 
their roles, and were able to identify key characteristics that they felt were important for all team 
members. Particular importance was placed by all team members on the MDT chair – they 
were thought to be critical in ensuring the smooth, efficient running of MDT meetings. 
Additionally, the medical members of the team valued the role of the CNS – particularly 
due to their significant role in approaching the patient in a holistic manner. Th e role of the 
MDT co-ordinator, whilst understood, was not mentioned frequently, as much of their 
work was done between meetings, and there may be a degree of under -appreciation of their 
importance. 
 
The second aim was to investigate cancer experts’ awareness of any assessment tools that could be 
used for colorectal cancer MDTs. It was clear that there are currently no methods specific to the 
colorectal cancer MDT that individuals were able to identify. Finally, therefore, we set out to 
define what performance measures may be suitable for assessing colorectal cancer MDTMs from the 
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clinicians that made up the teams. This aim produced a number of different points, which we then 
organized into a structured set of suggested measurements – including measures of MDTM processes 
and also outcomes. 
 
Previous studies on MDTs in other specialties have also highlighted the absence of specific tools to 
assess how MDTMs work. Various methods have been used, and include implementation of MDTM 
decisions (94), evaluation of resection margins (57, 73, 95) and overall survival (71, 77). Recent 
work in urological cancer MDTMs has seen the development of an observational tool for the 
assessment of decision making in meeting (96). In their review, Fleissig et al (27) highlighted the 
variability in cancer services in the UK, and in highlighting barriers to successful implementation of 
MDTMs, they have identified the areas where assessment tools should focus. It is these similar areas 
that I have identified in this study. 
 
One additional area of interest that was raised in these interviews was that of patient ownership. It was 
interesting to note that the members of the MDT that had direct clinical contact with patients felt 
personally responsible for the care of these patients, whilst those that did not felt it was a team 
responsibility. Sidhom and colleagues (111) discuss the potential legal aspects of this, but there are no 
clear-cut legal cases or guidelines to refer to. At a time where medico legal cases are on the increase, 
it is perhaps necessary to clarify the position of patient responsibility for MDTs. 
 
3.6.2 Limitations 
 
This study does not come without limitations. Firstly, the views of the participants involved may not 
represent the views of colorectal cancer MDT members elsewhere. However, I have interviewed a 
breadth of expert clinicians, with the sample taken from three different hospitals; a district general 
hospital, a tertiary referral hospital, and a university teaching hospital. Secondly, with interviews, 
important issues may be missed in the data collection phase. To avoid this, I ensured all interviews 
were recorded and transcribed, and proceeded to review all transcripts to ensure completeness. 
Furthermore, extraction of themes may be subjective and open to bias – therefore, I had a subset of 
the interviews analysed by a second reviewer which showed good agreement. 
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3.7 Conclusion 
This study has provided a detailed analysis of individual colorectal cancer MDTM members’ views 
on assessment of their MDTMs. My findings suggest that whilst individuals are clear of their roles, 
they agree that there are very few mechanisms to assess how they are performing their roles. They 
have gone on to identify a series of measures that may be used for assessment, which I will look at in 
subsequent chapters. The next chapter takes a detailed look at a single colorectal cancer MDT, and 
provides information about the costs of running a multidisciplinary team. 
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CHAPTER 4: COLORECTAL CANCER MULTIDISCIPLINARY 
TEAMS: WHAT ARE THE COSTS INVOLVED? 
 
 
 
 
 
4.1 Chapter overview 
While previous chapters identified key areas useful for the assessment of colorectal cancer 
multidisciplinary teams, with information from previous studies as well as practicing core clinical 
members of the multidisciplinary team. Before going into more detail about assessment methods, this 
chapter looks at the overall costs of running a multidisciplinary team at a single hospital trust, made 
up of two district general hospitals. 
 
4.2 Introduction 
Multidisciplinary teams have become an integral part of the overall cancer care pathway. Whilst there is 
evidence of that, and they have improved clinical outcomes as outlined in Chapter 2, there is little 
evidence to show at what cost this improvement has come. 
 
Colorectal cancer MDTs require large amounts of long term investment in facilities, infrastructure, 
as well as significant organisation and management in the short to medium term. For the meeting to 
run effectively, it is imperative that the appropriate core members are present, relevant patient details 
are readily available and that those attending the meeting have had ample opportunity to prepare for 
the cases to be discussed (97). All the above require significant investment of time and resources, 
both of which cost money. Estimates suggest that the National Health Service spends nearly £100 
million annually on cancer MDT related services, though there is limited data available to provide a 
more reliable estimate (98). 
 
I have therefore conducted an analysis of the costs associated with running a colorectal cancer 
multidisciplinary team meeting, and report the findings of this in the current chapter. 
 
4.3 Aims 
The specific objectives of this study are: 
1. Identify the personnel and resources that were essential for the running of a colorectal cancer 
multidisciplinary team; 
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2. Quantify the time spent preparing for and attending MDT meetings; 
3. Calculate the costs associated with running a colorectal cancer MDT. 
 
 
4.4 Methods 
I received expert guidance from a Health Economist (Hauck) in survey development, relevant 
financial information, derivation of specific measures and data analysis. 
 
4.4.1 Survey development 
In order to collect information regarding time spent on preparing for and attending the colorectal 
cancer MDT, I developed a structured survey based upon one of the study aims. This survey was 
piloted in iterative phases and the final version (Appendix 4) consisted of specific questions 
regarding the amount of time individuals spent carrying out MDT related activities. A hard copy of 
this survey was distributed to all the core members of the relevant MDTs. 
 
 
4.4.2 Participants 
Surveys were given to all the core members of two multidisciplinary teams from one NHS Trust. The 
Trust is split between two hospital sites in North London, and has an overall catchment area of 
approximately half a million people. At the time of the study, the Trust provided colorectal cancer 
services at both sites, with a fully functioning MDT at each site. The MDTs each met on a weekly 
basis. I gathered information regarding mandatory core member attendance from the Lead Clinicians 
for Colorectal Cancer at either site, and verified this with the MDT co-ordinator (single co-ordinator 
for both sites). Data were collected from all core members of the two MDTs in early 2013, and 
participants asked to base their answers on their experiences in the year 2012. 
 
4.4.3 Procedure 
I conducted this study in multiple phases. In Phase 1, I compiled a complete list of all participants, 
and then hand delivered surveys to them. Once completed, I collected these surveys personally. 
Verbal consent was obtained, and anonymity ensured. I tabulated the collected data and combined 
this with additional data regarding staff salaries received from the Trust’s Finance Department. In 
Phase 2, I compiled derived data on the running costs and overhead costs from the Finance 
Department. Phase 3 combined all this data together with observed data at one MDT over a period of 
24 meetings as well as data on cancer patient numbers, and calculated estimates for annual MDT 
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costs, costs per meeting, costs per cancer patient and costs per patient discussion. 
 
 
Utilising the observational data from 24 meetings, we calculated the mean length of time spent at a 
weekly meeting. This data was collected in real time, and is described in more detail in Chapters 6 
and 7. For the purpose of this study, only the overall length of the meeting was utilised. We added on 
the amount of time, as per the results of the survey, that core members spent preparing for the MDT, 
completing work after the MDT, and attending training related to MDTs. Using these mean figures 
we calculated the estimated time spent by core members on MDTs over the year. 
 
I collated a list of potential overhead costs, which included the following: 
1. Cost of running the room – including utilities; 
2. Equipment costs, including initial installation costs and ongoing servicing costs for: 
videoconferencing equipment, a microscope, a desktop computer with access to the 
hospitals Electronic Patient Record (EPR) and Picture Archiving and Communication 
System (PACS) and a projector; 
3. Weekly consumables – Printing of MDT patient lists. 
 
 
In order to quantify the costs of these items, I reviewed the previous year’s financial records. 
However, it was not possible to calculate an exact figure for the above items, and following 
discussion with the Finance departments at the Trust, I used a figure of 15% of direct costs. We 
arrived at this figure jointly based on previous years’ accounts. Previous calculations on the 
Colorectal Cancer service had used this same figure. Whilst similar data was lacking, a 2013 study 
by Chinai and colleagues used a different method and used a figure of 11.2% to represent overhead 
costs. Due to the lack of further available data on this subject, it was not possible to corroborate this 
value with pre-existing studies, and in the current study a figure of 15% was therefore utilised. 
 
4.4.4 Data analysis 
All the quantitative information was collated in a Microsoft Excel database, which was then used for 
further data analysis. 
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4.5 Results 
 
4.5.1 Members of the MDT 
 
The Colorectal Cancer MDT that I based my calculations on is made up of the following core 
members: Colorectal Surgeon, Oncologist, Radiologist, Histopathologist, Clinical Nurse Specialist 
and MDT co-ordinator. Figure 4.2 below shows the total number of these core member groups 
present at the Trust (across both sites). I collected completed surveys for all but one of the core 
members, who chose not to participate (n=19). 
 
 
Figure 4.2: Total number of core MDT members 
 
 
 
NB: There was overlap between the Pathologists, one of whom covered for both sites, and the MDT co- 
ordinator, who covered both sites (Total number of Pathologists = 3, MDT Co-ordinator = 1) 
 
4.5.2 Total time spent on MDTs 
 
The results of overall time spent by core members carrying out MDT related activities is summarised 
in Table 4.1 on the next page 
 
4.5.3 Direct costs of the MDT 
 
These were calculated using the overall times in the previous section, and the average salaries of the 
members involved. The results of this are also shown in Table 4.1 on the next page. 
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Table 4.1: Staff costs per MDT 
 
 
 
Time spent at 
Preparation 
Training 
MDT
1 time - pre  
time
2 
and post
2
 
Total time per 
Mean number Total time 
individual 
of individuals  per 
per meeting
1 
specialty 
Total time       Weekly       
Cost per 
per specialty  average cost   
MDT (£) 
(in WTE) 
3         
of WTE
3 
(£) 
Colorectal surgeon 63 120 17.39 200.39 2.67 535.04 0.2229 2367 527.68 
Radiologist 63 120 30.43 213.43 2.5 533.58 0.2223 2306 512.68 
Pathologist 63 120 13.04 196.04 1.04 203.88 0.0849 2219 188.51 
Oncologist 
Clinical Nurse 
Specialist 
63 60 21.74 
 
63 420 21.74 
144.74 0.75 108.56 
 
504.74 0.83 418.93 
0.0452 2409 108.96 
 
0.1746 1072 187.12 
MDT co-ordinator 63 240 13.04 316.04 1 316.04 0.1317 495 65.18 
Total 
   
£1590.13 
 
1. Data for time spent at MDT and mean number of individuals per meeting taken from observational data. 
 
2. Data from results of survey 
 
3. WTE = Whole Time Equivalent i.e. if your are full time and your hours are 40 and the full time hours for your grade of staff are also 40, then your 
WTE is 40/40 = 1.00. This is a standard measure throughout the NHS. 
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4.5.4 Additional costs 
As described in the previous section, I used a figure of 15% of direct costs to calculate additional costs. I 
therefore calculated average weekly additional costs as follows: 
 
£1590.14 * 0.15 = £238.52 
 
 
4.5.5 Total costs 
 
The average weekly cost of the MDT was calculated as follows: 
 
 
£1590.14 + £238.52 = £1828.66 
 
 
Based on this figure, I calculated the average annual cost of the MDT using the number of meetings during 
the year (50): 
 
£1828.66 * 50 = £91,433 
 
 
4.5.6 Average costs per case discussion 
 
Between 1
st 
January 2012 and 31
st 
December 2012, 50 colorectal cancer multidisciplinary team 
meetings were held. A total of 897 cases were discussed at these meetings. The average MDT cost of 
each patient case discussion was calculated as follows: 
 
£ 91,433 / 897 = £101.93 
 
 
4.5.7 Average costs per cancer patient 
 
Between 1
st 
January 2012 and 31
st 
December 2012, a total of 86 new cancer cases were diagnosed. The 
average MDT cost of each cancer patient was calculated as follows: 
 
£91,433 / 86 = £1,063.17 
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4.6 Discussion 
 
4.6.1 Summary of findings 
 
This study set out to quantify the actual costs associated with running a multidisciplinary team. 
Furthermore, I have attempted to calculate the average cost per patient case discussion and per 
cancer patient. The results of this study show that there is a large financial investment similar to 
that quoted by the National Institute for Clinical Excellence (99, 100) for various cancers. 
However, it must be noted that these quoted reference costs do not take into account the costs of 
additional preparation time required by specialists. They do include costs for non-core members of 
the MDT, as well as junior medical staff. These two factors may explain why we have reached 
similar figures as they are likely to balance each other. 
 
These results provide the minimal cost for running of a colorectal cancer MDT over one year. In 
reality, the costs may be higher, as meetings are often attended by non-core members as well as 
junior medical staff (I have not included any additional staff members in my analysis). 
 
By defining the cost per patient case discussion, this study highlights that there is an almost ten-fold 
increase in cost when comparing with cost per cancer patient. Whilst this is partly due to the fact 
that there may be some cases discussed that do not turn out to be cancers, as well as the fact that 
patient case discussions are carried out at various stages in management (including recurrent cases 
and surveillance cases, which would not be reflected in the number of new cancer patients), this 
figure suggests that there may be instances where patients are discussed more than once, possibly 
due to a lack of a definitive decision. Putting an individual cost to each discussion perhaps 
magnifies the importance of avoiding so called unnecessary repeat discussions, and emphasises the 
need for definitive, first time decision-making. This relies heavily on the presence of the 
appropriate team members as well as comprehensive information regarding the patient and any 
investigations that they may have already had. 
 
The costs per patient case discussion calculated in this study reflect the overall cost of a patient’s 
care and treatment planning by a group of experts from different specialist backgrounds. Chapter 2 
has provided evidence for improvements in clinical outcomes as a result of the introduction of such 
specialist teams, and this chapter provides data on the costs of this. When compared with costs for 
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alternatives (101), such as multiple individual outpatients appointments with different specialties, 
these figures are favourable, or at best, equivalent. 
 
4.6.2 Limitations 
 
These findings are subject to certain limitations. Firstly, these relate to calculation of staff costs. 
I utilised a staff average for consultants involved, and used average numbers of core members 
present at the meeting. This may have altered the results slightly as different consultants had 
different salaries based on their seniority. However, it was not feasible to acquire individual data 
on salaries for all the individuals, and so I followed this method. Furthermore, to be as specific 
as possible, I used the average salary of the specific members from each specialty group, rather 
than use a national or trust average. I only included those staff members that were designated 
core members of the MDT. This is likely to have led to an underestimation of cost as there are 
additional staff members who attend these meetings. However, I chose to only include the 
core members as these were considered essential to the running of the meeting. 
 
Another source of possible error is in the preparation and training times, which were self-
reported retrospectively. I tried to limit the error from this by asking all the members to 
quantify their preparation and training times, and then calculating averages for each specialty 
group. 
 
The estimation of indirect costs as 15% of direct costs meant that I did not have an exact figure 
for these costs. However, it was not feasible to accurately collect this data, and based on previous 
years’ experiences this figure was utilised. This was a similar figure to that used by the trust in 
calculating their ongoing costs and reference costs and therefore is likely to be as accurate as 
possible. 
 
Whilst a more detailed analysis is possible, with more precise figures, the objective was to gain an 
idea of the costs associated, so as to highlight the financial implications of multidisciplinary teams. A 
more detailed analysis was beyond the scope of this thesis, and would have diverted attention from 
the primary aims of the thesis.  
 
Finally, it is important to note that the results of this study are based on a single MDT, at a 
single hospital. NBOCAP figures from 2012/13 confirm that the number of cancer patients at this 
hospital lies close to the national average (102). With regards to the MDT members, 
anecdotal reports suggest that the composition of this MDT is largely representative of a 
standard District General Hospital Colorectal Cancer MDT. Despite this, it is important to bear in 
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mind that the results of this study may not be easily transferable to other hospitals, and any similar 
studies may have to be altered for local practice. This may affect the overall costings calculated. 
 
4.7 Conclusion 
 
With increasingly stringent financial measures present in the National Health Service, it is 
pertinent to ask whether Multidisciplinary teams are worth the expense. As previously described, 
these teams ‘snuck in under the radar’ with little evidence for their cost effectiveness. 
 
Chapter 2 provided evidence of improvement in clinical outcomes following the introduction 
of multidisciplinary teams in colorectal cancer, there is limited data on the cost of this. This 
study provides detailed data on costs of MDTs, and shows that there is a significant cost for each 
cancer patient as well as each patient case discussion. We should bear these costs in mind when 
discussing patients repeatedly. 
 
The financial cost of these meetings, highlighted in this chapter, identifies the need to ensure 
that meetings are run as efficiently as possible, and with a focus on quality improvement. 
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4.8 Section Two Summary 
 
The results of the previous chapters provide compelling reasons for the introduction of 
mechanisms to evaluate colorectal cancer MDTs. There is evidence of variations in practice, 
both within the United Kingdom, as well as globally. In addition to this, these meetings come at 
a significant cost, and whilst there is sufficient evidence for their ongoing implementation, the 
increasingly stringent financial measures present in the National Health Service, it is pertinent to 
ensure that these teams are run efficiently. The first step in these processes is the introduction of 
a robust assessment tool, which takes into account the different elements highlighted in the 
previous chapters. There are certain areas that are evaluated by the Peer Review Process but these 
largely relate to the running and implementation of the colorectal cancer MDT meeting. 
 
I have already identified a series of potential measures, which can be utilised in the assessment 
of Colorectal Cancer MDTs. These can be split into process and outcome measures, and Figure 
4.3 below proposes a model for viewing colorectal cancer MDTs, based upon the ‘Systems 
Approach’, popular in patient safety research (103). The Systems Approach proposes an Input-
Process-Output model to the colorectal MDT and recognizes a range of inputs to the MDT, which 
can impact on the effectiveness of the case discussion, which in turn determines the MDT 
outputs. Taken together, these factors can affect colorectal cancer patient outcomes. Whilst some of 
the  
performance measures identified in the previous chapters echo those in non-colorectal studies 
(94, 104-106) there are particular aspects of the MDT that are unique to colorectal cancer – 
which are reflected in the contents of the model. It is clear that there is no single measure of how 
well the colorectal cancer MDT works. What I propose, based on the contents of the previous 
chapters, is that a number of different aspects can be easily measured in the short term (particularly 
process measures, including team working), and that longer term patient outcomes, many of which 
are already collected routinely, can be used as a measure of the overall patients’ cancer 
pathway, of which the MDT forms an integral part.
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Figure 4.3: The "Systems Approach" to Colorectal Cancer MDTs 
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With this in mind, further chapters will develop an assessment tool to evaluate the functioning of the 
Colorectal Cancer multidisciplinary team. From the model, I have specifically chosen those areas 
where there is limited or no previous work. These include an assessment of how decisions are made 
in meetings – looking at the availability of relevant clinical information as well as the specific 
elements of team behaviours – individual members’ contributions to patient case discussions. 
Additionally I have chosen to incorporate information on whether or not clinical decisions are made 
and implemented. I have not chosen to use clinical outcomes at this stage, as they reflect the longer 
term, and are more a measure of the overall cancer care pathway. 
 
Within other healthcare settings, tools have been developed for assessing the performance of teams 
in a quantitative manner (107-109). Much of this work has borrowed heavily from experiences in 
other fields such as aviation. These studies suggest that team-performance can be measured using a 
reliable and validated approach. Moreover, they have highlighted the importance of communication, 
decision-making and leadership to both patient and clinical outcomes. Within cancer care, there were 
no such tools to assess and develop MDTs until the recent development of a tool to assess urology 
MDTs (termed ‘Multidisciplinary Team Metric for Observation of Decision-Making’, MDT-MODe) 
(96, 110). No such work has been carried out in colorectal cancer settings, and the aim of the next 
chapters is to develop and validate such a tool. 
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CHAPTER 5: DECISION MAKING IN COLORECTAL CANCER 
MULTIDISCIPLINARY TEAMS: DEVELOPMENT AND 
EVALUATION OF COLORECTAL MDT-MODE – AN 
OBSERVATIONAL ASSESSMENT TOOL 
 
 
 
 
 
5.1 Chapter overview 
 
The previous section reviewed the current evidence on colorectal cancer MDTs and gathered the 
views of current clinical members of the colorectal cancer MDT on proposed assessments. In 
addition to highlighting the improvements in outcomes associated with MDTs, it showed that there 
is a cost associated with these, and that the aim of future work should be to maximize efficiency 
and improve service quality. 
 
In this chapter I describe the development and validation of an objective observational tool used to 
evaluate teamwork and team performance in Colorectal Cancer MDTs. 
 
5.2 Introduction 
 
Whilst the importance of multidisciplinary care in colorectal cancer is clear, the optimal manner in 
which these teams should run is unclear. In order to run efficiently, they are reliant on the presence 
of all team members, the availability of patient clinical information and investigation results. In 
addition, the opportunity to engage in an open management discussion involving all the team 
members is crucial to their functioning. Studies suggest however, that such constructive discussions 
do not always take place, leading to a decision not being reached and subsequently the case 
postponed for a further meeting. This is costly, in terms of the time required by members to attend 
the meeting, and can lead to delays in care. Reasons underlying an expert teams’ failure to reach 
consensus regarding further management are complex, but contributory factors may include poor 
team cohesion (111), sub-optimal case information (112) or a misunderstanding of patient views and 
expectations (94). 
 
Moreover, in an area where there is such potential variation in practice, there are no standardized 
models for operation or assessment of MDT meetings. This is despite the presence of national 
guidelines advocating their use around the world. In the United Kingdom, where multidisciplinary 
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team-working in cancer care is mandatory, the only formal process of evaluation of multidisciplinary 
services is the National Cancer Peer Review program (26) – however this focuses mainly on the 
organisational aspects of cancer care delivery, with limited emphasis on team-working and 
information presentation within multidisciplinary team meetings. 
 
Within other healthcare settings, tools have been developed for assessing the performance of teams 
in a quantitative manner (92, 107). These studies suggest that team-performance can be measured 
using a reliable and validated approach. Moreover, they have highlighted the importance of 
communication, decision-making and leadership to both patient and clinical outcomes. Within cancer 
care, there were no such tools to assess and develop MDTs until the recent development of a tool to 
assess urology MDTs (termed ‘Multidisciplinary Team Metric for Observation of Decision-Making’, 
MDT-MODe) (96). No such work has been carried out in colorectal cancer settings, despite the fact 
that it is the 4th most common cause of cancer mortality globally, and in many healthcare settings its 
management is guided by a MDT. 
 
5.3 Aims 
 
The aim of this current study was to develop a reliable, valid and feasible tool to assess team 
performance in colorectal cancer multidisciplinary team meetings. Specific objectives were to: 
1. construct a robust tool for the systematic assessment of colorectal cancer MDT performance; 
2. define which aspects of MDT performance can be validly and reliably assessed by observers; 
3. assess the usability and feasibility of the tool. 
 
 
5.4 Methods 
5.4.1 Phase 1 – Tool development and validation 
The tool developed in this study was based on the recently developed MDT-MODe tool, designed for 
use in the assessment of urology MDT meetings. The specific content of the new tool was 
informed by literature review (Chapter 2) and the opinion of end-users from 3 UK hospitals on the 
important characteristics of colorectal cancer MDT performance and proposed methods of 
assessment (Chapter 3). 
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5.4.1.1 Content Validation 
 
The colorectal MDT-MODe tool based on the original urology framework and developed from the 
review and interviews above, together with a validation questionnaire (see Appendix 4), was 
presented to 27 experts in colorectal cancer – all at Consultant or senior nurse specialist level. There 
were 8 colorectal surgeons, 7 radiologists, 4 pathologists, 3 oncologists, 3 colorectal cancer nurse 
specialists and 2 MDT coordinators. Each person was asked to rate the importance of the various 
elements of MDT performance contained within the tool and descriptors on a 1-5 Likert scale (with 5 
= very important), as well as to provide free text comments. 
 
 
The results of the three steps described above were used to develop a preliminary version of 
Colorectal MDT-MODe for use in Phase 2 (Figure 5.1 below). This tool provided performance 
indicators of two key areas of a colorectal cancer MDT meeting: 
 
1. The quality of the information presented – including case history, patient co-morbidity, 
psychosocial issues, patient views, radiological information and pathological information. Each of 
these factors is rated on a scale of 1 to 5 in real-time by an observer with 1 indicating poor quality 
and 5 indicating high quality. A Global Information score was also calculated – this was the sum of 
the each individual factor – totalling 30. Finally a percentage Global Information score was 
calculated. 
 
2. The quality of contributions to team decision-making of the participants within the meeting: the 
surgeons, oncologists, radiologists, pathologists, colorectal cancer nurse specialists and meeting 
coordinators. Each of these specialists’ contribution is rated on a scale of 1 – 5 in real-time by an 
observer with 1 indicating no contribution and 5 indicating articulate and precise contribution aiding 
patient management. A Global Contribution score was also calculated – this was the sum of the each 
individual factor – totalling 35. Finally a percentage Global Contribution score was calculated. 
 Figure 5.1: Colorectal MDT MODe (CMDT-MODe) 
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5.4.2 Phase 2 – Psychometric testing – feasibility and reliability 
Real-time testing of the Colorectal MDT-MODe was conducted by two independent and trained 
observers with a background in surgery and training in quantitative observational methods (myself 
and Addison). Both observers used the tool to rate the live performance of 8 colorectal cancer MDT 
meetings at a single London hospital. Each case discussed by the MDT was scored using all elements 
of the tool on a scale of 1 to 5 with 5 representing the highest score/excellent performance. Informed 
consent was obtained from all participants. The study protocol and materials were submitted to the 
hospital R&D t e a m  for approval prior to data collection and the study was approved as a 
‘service evaluation’. At the end of the observation period, data were collated for statistical analyses. 
 
 
5.4.3 Data analysis 
Statistical analyses were performed using SPSS version 20.0 and significance was taken at the 0.05 
level. Regarding phase 1, Content validation scores were formally assessed by computing a ‘content 
validity index’ (CVI) for each category and each set of descriptors, as well as an overall value for the 
Colorectal MDT-MODe tool. This was done by calculating the proportion of experts with a rating of 
4 or higher (on the 5-point scale). The CVI is a way to statistically express the level of agreement 
between experts that an item is of relevance to the area that is measured. The higher the value of a 
content validity index the higher the inter-reviewer agreement and hence the higher the content 
validity (113). 
 
Regarding Phase 2, the inter-observer reliability was assessed statistically using intra-class 
correlation coefficients, ICCs (114). Mean and standard deviation are reported for all individual 
ratings. All categories within the tool were also assessed against each other using an Analysis of 
Variance (ANOVA). Finally, to assess improvement in tool utilisation over time, observed cases 
were grouped into cohorts of 10 and ICC calculated for each cohort. Improving ICCs would 
demonstrate learning curves in tool usage by the observers. 13 cohorts of real-time MDT 
observations (corresponding to 130 cases) were analysed for most categories – except for the 
contribution of the oncologist and cancer nurse where there were 12 cohorts due to absence during 
one meeting. Regarding the assessment of pathological information and contribution of the 
histopathologist, there were only 5 cohorts as all cases did not require pathological input. 
 
In this chapter, Global Scores and Global Percentage Scores were not utilised for any of the analysis, 
and are therefore not reported. They are reported in the Chapter 6 
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5.5 Results 
 
5.5.1 Phase 1 – Tool development and validation 
 
The results of the systematic review are presented in Chapter 2. A key finding was that there were no 
specific methods or tools to evaluate the MDT in colorectal cancer. However my literature search did 
identify a tool to measure performance in urology multidisciplinary team meetings termed MDT 
Metric for Observation of Decision-making (MDT-MODe) (96). I utilised this extensively validated 
urology MDT-MODe tool as a template to guide the development of the tool to assess Colorectal 
MDTs. Regarding the interviews, described in Chapter 3, no participant was aware of any tool or 
method which formally assessed the quality of MDT meetings (reinforcing the lack of such tools in 
practice) although informal feedback by a peer was cited as useful. Proposed measures of assessment 
included an assessment of team working, specific measures of individual performance, quality of the 
information presented on which to base the decision, attendance levels and outcome measures of 
relevance. 
 
 
5.5.1.1 Content Validation 
 
The results of the content validation are summarized in Table 5.1. The values were high, both for the 
categories of MDT assessment (median CVI=0.85, range 0.74 to 0.96), and for the specific 
descriptors used in Colorectal MDT-MODe (median CVI=0.81, range 0.63 to 0.85). 
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Table 5.1: Content validation indices for Colorectal MDT MODe 
 
 
Category CVI – Category CVI – Descriptors 
 
 
 
Case history information 0.96 0.85 
Radiological information 0.96 0.74 
Pathological information 0.96 0.81 
Psychosocial issues 0.74 0.70 
Patient co-morbidity 0.89 0.89 
Patient views 0.74 0.67 
Contribution of MDT Chair 0.89 0.85 
Contribution of Surgeon 0.85 0.85 
Contribution of Oncologist 0.85 0.81 
Contribution of Radiologist 0.85 0.81 
Contribution of Histopathologist 0.81 0.81 
Contribution of Clinical Nurse Specialist 0.85 0.81 
Contribution of MDT Co-ordinator 0.89 0.74 
Point of discussion 0.74 0.63 
Final MDT decision 0.81 0.78 
Overall Content Validity Index 0.81 n/a 
 
 
 
96  
5.5.2 Phase 2 – Psychometric testing – feasibility and reliability 
 
5.5.2.1 Colorectal Cancer MDT meeting characteristics 
 
131 cases were observed and rated in real-time across 8 MDT meetings by two blinded observers. Upon 
completion of this, minor modifications were further made to the wording of the tool in light of its usage. 
Figure 5.1 earlier presents the current version of the Colorectal MDT-MODe assessment tool, following all 
modifications. An earlier version of the tool is contained in Appendix 3. 
 
Descriptive information about the meetings is summarized in Table 5.2. On average, we found that the 
teams consisted of 13 to 20 cancer specialists and discussed an average 16 patients in just over 60mins – 
with each case review lasting 3.68mins. 
 
5.5.2.2 Inter-rater reliability 
Table 5.3 summarizes the observers’ intraclass correlations (ICCs). The ICCs were high (>0.70) for all but 
one of the assessed categories - contribution of the MDT Chair (0.69). This suggests that the two observers 
were consistent in their observational scores and had good inter-rater agreement. 
 
5.5.2.3 Performance of Colorectal Cancer MDT meetings: 
Quality of Information and Team Contributions 
 
Table 5.3 also highlights the observer’s ratings (mean and SD) of each element that was assessed using 
Colorectal MDT-MODe. Regarding the quality of presented information to the team, case history 
information was rated highest (observers’ mean= 4.57), followed by pathological information (observers’ 
mean=  4.49)   and   radiological   information   (observers’   mean=  4.46).   Regarding   each   team-
member’s contribution to discussion, surgeons were scored highest (observers’ mean=4.35), followed by 
radiologists (observers’ mean=4.14) and MDT coordinators lowest (observers’ mean=1.33). 
  
Table 5.2: Characteristics of meetings 
 
 
 
 
 
 
 
 
 
Characteristics 
 
 
 
 
 
 
Attendance 
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 Meeting  
 1 2 3 4 5 6 7 8 Total Mean 
Number of cases 19 14 17 21 10 19 11 20 131 16.38 
Length of meeting 65 49 60 79 41 56 53 79 482 60.25 
Average time per case 3.42 3.50 3.53 3.76 4.10 2.95 4.82 3.95 3.68 3.68 
Surgeon 3 3 2 3 2 1 2 3 19  
Oncologist 1 1 1 1 0 1 1 1 7  
Radiologist 1 4 2 3 2 3 3 2 20  
Pathologist 1 2 1 1 1 1 1 1 9  
Cancer nurse 1 1 1 1 0 1 0 1 6  
MDT Coordinator 1 1 1 1 1 1 1 1 8  
Other 
Total 
8 
16 
12 
24 
7 
15 
6 
16 
7 
13 
12 
20 
9 
17 
11 
20 
72 
141 
 
 
 Table 5.3: Inter-observer reliability and descriptive ratings of Colorectal MDT performance 
 
 
 
 
 
Category  
Number of 
observations 
Intraclass 
correlation (95% 
CI) 
 
p-values 
Mean S.D. 
Case history 131 0.87 (0.82-0.91) <0.05 4.57 0.69 
Radiological 131 0.96 (0.94-0.97) <0.05 4.47 1.15 
Information 
Pathological 51 0.81 (0.66-0.89) <0.05 4.49 0.75 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contribution 
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Psychosocial issues 131 0.86 (0.80-0.90) <0.05 2.18 1.39 
Patient co-morbidity 131 0.82 (0.74-0.87) <0.05 2.82 1.44 
Patient views 131 0.82 (0.74-0.87) <0.05 2.24 1.38 
MDT Chair 131 0.69 (0.56-0.78) <0.05 4.12 0.91 
Surgeon 131 0.89 (0.84-0.92) <0.05 4.34 0.85 
Oncologist 121 0.83 (0.76-0.88) <0.05 3.72 1.65 
Radiologist 131 0.93 (0.90-0.95) <0.05 4.13 1.35 
Histopathologist 51 0.74 (0.54-0.85) <0.05 3.71 1.32 
CNS 121 0.80 (0.71-0.86) <0.05 3.9 1.46 
MDT Co-ordinator 131 0.92 (0.88-0.94) <0.05 1.33 0.79 
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In order to compare the mean ratings of the different categories an analysis of variance (ANOVA) to 
evaluate statistically significant differences between ratings was performed, followed by 
Bonferroni’s post-hoc pairwise comparisons. 
 
These analyses demonstrate whether certain aspects of clinical information are systematically better 
presented at the MDT, and whether certain cancer specialists are likely to have more contribution to 
the case review during the meeting. The overall results revealed a statistically significant difference 
between the different scoring categories: F(12,3033) = 187.37, P<0.05. 
 
Analysis of the post-hoc Bonferroni procedure revealed systematic differences in quality of 
information presentation – with case history, radiological and pathological information significantly 
better presented at the meeting compared to co-morbidities, psychosocial elements, and patients’ 
views (all Ps<0.05). Regarding team-members’ contributions, surgeons and oncologists scored 
significantly higher than other team-members, whereas in contrast the MDT coordinators scored 
lowest (all Ps<0.05) – these findings are discussed in more detail in the Discussion. 
 
 
5.5.2.4 Observer learning curves 
Figures 5.2 and 5.3 display ICCs for cohorts of 10 cases in each category of observation. The plots 
are annotated with a horizontal line at ICC= 0.70. The ICCs can range from 0.00 to 1.00, with a 
higher value indicating higher agreement. Whilst there are no specific cut-offs described for 
“adequate” ICCs, we have used the broadly acceptable as a reliability standard for research purposes 
value of 0.70 (176). Reliability coefficients above the line (>0.70) indicate adequate agreement 
between observers; observations below the line (<0.70) indicate some but not adequate agreement – 
generally, the lower the value the lower the level of agreement. 
 
Overall, these learning curves between the blinded observers show that there was a general 
improvement in ICCs between the first cohort and the last cohort over time in the assessment of case 
history information, radiological information, psychosocial issues, patient co-morbidity, patient 
views, contribution of MDT chair, contribution of the surgeon, the oncologist, the radiologist, the 
histopathologist, the CNS and the MDT co-ordinator. These are positive findings, in that they 
demonstrate that surgeon observers can feasibly evaluate the quality of these meetings. A 
problematic finding emerged in relation to the evaluation of the quality of pathological information – 
where no learning curve was obtained.  Although the overall ICC for this category was 0.81 
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(indicating overall good reliability between observers), this finding was not expected. This suggests 
that it is somewhat more difficult for surgeon observers to rate the quality of pathological 
information. 
 
Further analysis of these learning curves revealed systematic drops in agreement in the 10
th 
cohort in 
all the categories, and also in the 9
th 
cohort for the assessment of contribution of the oncologist and 
the CNS. Review of field notes from the associated meetings identified a high number of people 
attending the MDT, as well as a high number of interruptions during the course of the meeting. This 
suggests that external influences such as these may affect the observers’ ability to evaluate a cancer 
MDT. I return to this in the Discussion. 
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Figure 5.2: Learning curves: ICC – Information scores 
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Figure 5.3: Learning curves: ICC – Contribution scores 
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5.6 Discussion 
5.6.2 Summary of findings 
 
This study goes some way to addressing the issue of a lack of a standardized mode of operation for 
colorectal cancer MDT, by developing a tool to allow objective assessment of how colorectal cancer 
MDTs are performing. It combines the assessment of the quality of the information presented to the 
MDT and the quality of the contributions of various team members. The results show that 
observational metrics can be derived and provide an objective measure of performance, which is 
acceptable to colorectal specialists from a range of disciplines – including surgery, oncology, 
radiology and nursing. Furthermore, these metrics can be used reliably by surgeon observers to 
assess the different aspects of MDT performance. There was good agreement between the two 
observers in nearly all the categories assessed, and there was improvement in this agreement over a 
period of time in eight out of the thirteen categories assessed. 
 
This study borrowed some key elements from previous work from looking at urology MDTs (96, 
110). The results of my study show that the broad categories of team evaluation across urology and 
colorectal cancer teams are similar – but also that specific aspects of colorectal cancer assessment 
and management should be used. These have been incorporated into Colorectal MDT-MODe. 
 
Whilst previous studies assessing team work and performance have demonstrated good reliability 
between medical and non-medical observers, the higher ICCs in this study suggest that medical 
observers may be better suited for such assessments, as they are often able to interpret clinical 
specificities better, and translate these to the observational tools. As an example, Lamb et al (96) 
suggested that non-medical observers may find it difficult to interpret the presentation of specific 
information if not presented by the relevant individual – this is less likely to be an issue with a 
medical observer who would be able to identify the information, irrespective of its source. 
 
 
5.6.3 Limitations 
 
The results of this study, though encouraging, are subject to limitations. My results come from a 
single London hospital – and therefore may not be representative of MDTs across England, or the 
rest of world for that matter. Further work is required in a variety of settings to fully evaluate the 
functionality of this tool. This will also aid in identifying practical issues in the tool’s usage in a 
clinical setting, which may require further improvements to the tool. 
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Two issues with scoring MDT-MODe became apparent during the study. The first one was that in 
meetings attended by a large number of experts and where distractions were prevalent the observers 
found it difficult to score – which was reflected in the drop in their agreement around cohort 10. This 
is a recognized limitation of observational assessments, and suggests that the clinical environment 
may impact on the quality of an assessment. 
 
Furthermore the lower scores given to the MDT coordinators may not accurately reflect the role of 
this key individual – which is relatively new in the UK and continues to evolve (80). A lot of the 
work carried out by the coordinator takes place before and after the meetings – a view highlighted in 
one of the comments in the content validity questionnaire. During meetings, their role is often 
limited to recording data, and as such is much less visible. The true extent of their contribution is 
thus difficult to capture in this sort of an observational tool, and may require other forms of 
assessment. Further studies are required to investigate these scoring issues. 
 
Finally, correlational studies are required to evaluate the construct validity of these assessments – in 
other words, do teams which score higher on MDT-MODe objectively manage their patients better? 
These are questions for further prospective research. 
 
 
5.7   Conclusion 
 
Overall, this study reinforces the view that performance of colorectal cancer MDTs can be assessed 
objectively and reliably, with adequate attention to the specifics of different specialties. The 
observational tool developed has been shown to have face and content validity, and is feasible to use 
by different users. The use of the tool in evaluating Colorectal Cancer MDTs may be the first step to 
a regular process of quality assessment and improvement. It has particular use in providing a structure 
to a “team debrief” – giving the observer a platform for identifying strengths and areas of 
development for individual teams. 
 
In the next chapter I make further use of Colorectal Cancer MDT MODe to evaluate an MDT, and 
analyse whether the scores provided with the tool are able to predict the team’s ability to reach a 
clinical decision. 
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CHAPTER 6: WHAT FACTORS AFFECT MDT DECISION 
MAKING AND MEETING OUTCOMES? 
 
 
 
 
6.1 Chapter overview 
 
The previous chapter described the development of Colorectal MDT MODe, and provides evidence 
of its validity, reliability and feasibility. Previous chapters have highlighted the use of a team’s 
ability to reach a decision, as well as a review of whether these decisions are implemented as a 
measure of the MDT’s performance. In this chapter, I combine the two measures, to see if the results 
of colorectal MDT MODe do indeed predict a team’s ability to reach a decision, as well as whether 
this decision is implemented. In addition to this, I explore some of the other factors described in 
Chapter 5 to see if they impact on a team’s ability to make and to implement a clinical decision. 
 
6.2 Introduction 
 
Evaluating the performance of a colorectal cancer multidisciplinary is, as has been discussed in 
earlier chapters, a difficult undertaking. The previous chapter presents a novel method of evaluating 
team performance, but does not take into account whether this method correlates with outcomes. 
Figure 4.3 in Chapter 4 describes both meeting outcomes and clinical outcomes. Clinical outcomes 
such as recurrence rates and overall survival are regarded by many as the ideal method of evaluating 
cancer treatment. However, as discussed earlier, they may not be entirely appropriate when solely 
evaluating the multidisciplinary team, as they are more a reflection of the entire cancer care pathway. 
Therefore, a simple measure to evaluate the efficacy of a multidisciplinary team is whether or not the 
team reaches a clear clinical decision (94), and whether or not this decision is actually implemented 
at a later date. 
 
In order to further validate Colorectal Cancer MDT MODe, I conducted another observational study 
to test specific hypotheses. 
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6.3 Aims 
The aims of the study reported here are to prospectively assess the relationship between the quality of 
the presented information, contribution to discussion of team members, team size, number of cases 
per meeting and the number of distractions and the ability of a colorectal cancer MDT to reach 
clinical decisions using the MDT assessment tool developed and validated in the previous Chapter. 
Additionally, I aim to evaluate whether the other factors have an effect on the information and 
contribution scores. 
 
The following specific hypotheses were tested: 
 
 
Hypothesis 1: A higher Global Information percentage score predicts a team’s ability to reach a 
decision regarding further management 
 
Hypothesis 2: A higher Global Contribution percentage score predicts a team’s ability to reach a 
decision regarding further management 
 
Hypothesis 3: The composition and number of core members in the team predict a team’s ability to 
reach a decision regarding further management 
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6.4 Methods 
6.4.1 Cases and Study setting 
 
A prospective observational study took place between January and December 2012 at a single 
London Hospital, with a busy colorectal department. The colorectal cancer MDT discussed 897 cases 
over the course of 50 meetings in 2012. Prospective observations were carried out 24 of these 
meetings, where a total of 423 patients were discussed. Details of the meetings can be found in Table 
6.1 below. 
 
 
6.4.2 Procedure 
 
Real-time observations using Colorectal MDT-MODe were conducted by me. In addition to 
using the tool rate the live performance of 24 colorectal cancer MDT meetings, I collected data on 
meeting length, number of people present, number of core members present and details of any absent 
core members. Additionally, I noted whether a clear clinical decision had been made at the end of 
each patient case discussion. In order to evaluate whether clinical decisions were implemented, I 
reviewed patient records after 3 months to check for implementation. I chose 3 months as this allows 
sufficient leeway for patients to commence any treatment within the government stated guidelines 
(184). Where decisions were not reached or had not been implemented at 3 months I noted the 
reasons for this. Oral informed consent was obtained from all participants in the MDT. The study 
protocol and materials were submitted to the hospital R&D t e a m  for approval prior to data 
collection and the study was approved as a ‘service evaluation’. At the end of the observation period, 
data were collated for statistical analyses. 
 
6.4.3 Data collection 
Data collected on features of team decision-making in the MDT meeting was collected using 
colorectal cancer MDT-MODe, and all additional data were collected with a pre-prepared proforma. 
 
6.4.4 Data analysis 
Values for the mean, 95% confidence intervals, standard deviation, Spearman‘s correlations and 
logistic or linear regressions are reported for outcomes and meeting characteristics and results 
tabulated. All statistical analyses were performed using SPSS version 20.0 (SPSS Inc., Chicago, IL, 
USA). Significance was taken at the 0.05 level. 
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Table 6.1: Meeting characteristics 
 
 
Characteristics Attendance 
 
 Number of cases Length of meeting Average time per case Surgeon Oncologist Radiologist Pathologist CNS MDTC Other Total 
a 18 75 4.17 2 1 2 1 1 1 11 19 
b 19 65 3.42 3 1 1 1 1 1 8 16 
c 19 58 3.05 2 0 3 1 1 1 6 14 
d 25 83 3.32 1 1 1 1 1 1 7 13 
e 21 81 3.86 4 1 3 1 1 1 9 20 
f 14 49 3.50 3 1 4 2 1 1 12 24 
g 17 60 3.53 2 1 2 1 1 1 7 15 
h 10 43 4.30 3 0 2 1 1 1 13 21 
i 21 79 3.76 3 1 3 1 1 1 6 16 
j 15 44 2.93 3 1 3 1 1 1 9 19 
k 10 41 4.10 2 0 2 1 0 1 7 13 
l 13 45 3.46 4 1 2 1 0 1 8 17 
m 19 56 2.95 1 1 3 1 1 1 12 20 
n 17 60 3.53 2 0 2 1 1 1 7 14 
o 11 53 4.82 2 1 3 1 0 1 9 17 
p 20 79 3.95 3 1 2 1 1 1 11 20 
q 17 64 3.76 4 1 3 1 1 1 13 24 
r 20 79 3.95 1 1 2 1 1 1 7 14 
s 26 77 2.96 2 0 2 1 0 1 4 10 
t 19 80 4.21 3 1 3 1 1 1 6 16 
u 23 57 2.48 4 0 4 1 1 1 8 19 
v 16 59 3.69 4 1 3 1 1 1 12 23 
w 12 50 4.17 3 1 2 1 1 1 9 18 
x 21 67 3.19 3 1 3 1 1 1 7 17 
Total 423 1504 3.56 64 18 60 25 20 24 208 419 
Mean 17.63 62.67 3.56         
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 6.5     Results 
 
Prospective observations were carried out at 24 colorectal cancer MDTs at a single London hospital. 
A total of 423 patients were discussed. Details of the meetings can be found in Table 6.1 above. 
 
Table 6.2 below presents data on each domain of MDT meeting assessment (information and 
professional contribution) as well as information score, contribution score and decision score for 
each MDT meeting. Overall, a clinical decision could be reached in 347 of 423 cases (82%) of the 
cases discussed. In the 76 cases where decision could not be reached, reasons included insufficient 
radiological information, inadequate pathological information, lack of patient information, 
unavailable clinical notes, and non- attendance of team members. Furthermore, of the 347 cases 
where a decision was reached, this decision was implemented in 317 of these cases (91.4%). In the 
30 cases where decisions were not implemented, reasons included change in patient’s clinical 
condition (including requiring emergency admission), patient co-morbidity, patient choice and 
availability of additional clinical information. 
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Table 6.2: CMDT MODe Results by meeting 
 
 
 
Information Contribution Decision 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Meeting 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Hist 
ory 
 
 
Radiolo 
gical 
 
 
Patholog 
ical 
Psyschos 
ocial 
Co- 
morbid 
ity 
Patie 
nt 
views 
Glob 
al % 
MDT 
Chair 
 
 
Surg 
eon 
 
 
Oncol 
ogist 
 
 
Radiolo 
gist 
 
 
Patholo 
gist 
 
 
CN 
S 
M 
D 
T 
C 
 
 
Global 
%r 
Made  Imple 
mented 
A 4.17 4.44 4.38 2.11 2.89 2.00 64.07 4.06 4.06 3.44 4.11 4.00 4.06 2.22 73.57 0.94 0.94 
B 4.10 4.63 4.50 2.00 2.74 1.79 62.60 4.18 4.18 3.00 4.16 3.83 4.00 1.63 70.73 0.89 0.88 
C 3.84 4.21 2.67 2.68 2.53 1.79 59.90 4.11 3.74 - 3.32 4.00 3.47 2.63 57.97 0.79 0.93 
D 3.84 3.64 3.56 2.72 2.96 2.56 62.96 3.32 4.12 3.92 3.84 3.67 4.16 2.04 71.70 0.80 0.90 
E 3.43 4.24 3.88 2.71 2.86 2.43 63.21 4.10 3.86 3.76 3.90 4.00 3.86 2.57 73.79 0.86 0.83 
F 4.86 4.64 4.43 2.07 2.50 1.93 66.24 3.50 4.64 3.93 4.71 4.00 3.36 1.00 71.36 0.93 1.00 
G 4.53 4.47 4.17 2.24 2.65 2.35 66.27 4.00 4.18 4.00 4.35 4.00 3.23 1.00 70.03 0.82 0.93 
H 3.60 4.10 4.50 2.00 2.90 1.70 58.67 4.20 4.80 - 4.20 4.00 3.30 2.90 65.10 0.80 0.88 
I 4.19 4.33 4.00 2.52 2.90 2.05 64.88 4.00 4.14 3.67 4.29 4.33 4.48 2.19 76.17 0.95 0.95 
J 4.00 4.07 4.71 2.33 3.67 2.40 67.82 3.80 3.93 3.67 3.53 3.57 4.07 2.40 71.56 0.87 0.92 
K 4.50 5.00 4.00 1.26 2.70 1.00 59.93 4.00 4.60 - 5.00 4.00 - 1.00 50.38 0.60 0.83 
L 3.77 3.92 3.86 2.38 2.15 1.85 58.26 3.62 3.54 3.69 3.92 4.00 - 2.38 58.79 0.85 0.82 
M 4.58 4.26 4.29 1.63 3.00 1.74 62.63 4.11 4.26 4.42 3.79 3.86 4.11 1.21 73.43 0.89 0.88 
N 4.47 4.18 3.89 2.29 2.12 2.53 63.64 4.00 3.53 - 4.06 4.56 3.94 3.24 64.57 0.88 0.93 
O 4.73 4.27 4.29 1.64 2.45 3.09 67.58 4.00 4.45 4.55 4.09 3.60 - 1.00 60.87 0.91 0.80 
P 4.80 4.00 3.89 2.05 2.90 2.50 66.80 4.35 4.25 4.75 3.80 3.88 5.00 1.00 77.31 0.95 0.89 
Q 4.35 3.94 4.80 2.00 2.82 2.53 64.27 4.29 4.06 4.35 3.65 3.88 4.76 2.00 77.34 0.88 0.93 
R 3.95 4.00 4.00 2.55 3.40 2.65 66.50 4.00 3.40 3.05 3.10 3.08 3.80 2.65 66.38 0.80 0.88 
S 3.62 4.27 3.46 2.23 3.35 2.19 65.21 4.00 3.69 - 4.46 4.28 - 2.50 52.55 0.81 0.90 
T 3.84 4.53 4.28 2.00 3.11 2.05 64.39 3.89 3.58 3.53 3.89 3.92 3.68 2.42 70.50 0.95 1.00 
U 3.87 4.22 4.20 2.48 2.78 1.87 61.80 3.87 3.39 - 4.26 3.80 4.09 2.39 60.52 0.83 0.95 
V 3.75 3.44 3.43 3.25 2.88 2.81 64.46 3.25 3.88 3.81 3.50 3.29 4.06 1.81 67.71 0.81 0.85 
W 
X 
3.75 
3.71 
3.42 
4.00 
3.83 
4.18 
2.83 
2.38 
3.17 
3.10 
3.08 
2.52 
66.83 
64.54 
3.42 
3.67 
4.00 
3.86 
3.92 
3.62 
3.25 
3.62 
3.33 
3.54 
3.75 
3.62 
1.83 
1.95 
68.29 
68.00 
0.92 0.82 
0.86       0.84                
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6.5.1 Correlations between domains and outcome measure 
6.5.1.1 Individual components of CMDT-MODe and 
outcome measures 
 
Correlational analysis was conducted in order to determine the relation between individual 
components of MODe and global contribution, global information (both calculated as a percentage), 
decision made and decision implemented. The results are displayed in Table 6.3 on the next page. 
 
 
  
Table 6.3: Correlations between different components of CMDT MODe 
 
 
 
 
Category 
Global Information 
% 
Global 
Contribution % 
Decision made
 
Decision 
implemented 
Case history 0.29** 0.18** 0.10* 0.10 
Radiological 0.31** 0.11* 0.08 0.06 
Pathological 0.23** 0.17* 0.09 0.21** 
Information Psychosocial issues 0.47** 0.06 -0.03 0.14 
Patient co-morbidity 0.58**  0.04 0.04 -0.05 
Patient views 0.54** 0.14** 0.05 -0.11* 
 
 
 
 
 
 
 
Note: N = 
 
 
 
 
 
 
 
 
 
 
Contribution 
 
 
 
 
 
 
 
 
 
 
Global information % 
 
MDT Chair 
- 
 
-0.01 
0.21** 
 
0.37** 
0.08 
 
0.17** 
0.03 
 
0.02 
number. 
Analysis 
conducted by 
     case (N = 423). * 
Surgeon 0.09 0.41** 0.13** 0.04 p < 0.05, ** p < 
0.001 
Oncologist 0.07 0.42** 0.11 0.12*  
Radiologist 0.04 0.28** 0.12* 0.19** 
 
Histopathologist 0.18* 0.36** 0.26** 0.16* 
 
CNS 0.18** 0.43** 0.05 0.1 
 
MDT Co-ordinator 0.02 0.20** 0.07 -0.04  
Global contribution % 0.21** - 0.26** 0.15** 
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6.5.1.2 Predictors of decision made 
 
Logistic regression was performed on the CMDT-MODe items that correlated significantly with the decision 
made. Specifically, case history, chair, surgeon, radiologists, histopathologists and Global Contribution % 
variables were entered as predictors and decision made as the predicted variable. 
 
All the variables were retained in the model as they were the significant predictors, accounting for overall 
30% of the variance in the decision made and having an overall prediction accuracy of 87%. 
 
 
Table 6.4: Logistic regression predicting decision made 
 
 
Predictors B SE B Wald df Sig 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note. Decision made was represented as 0 signifying no decision made, and 1 signifying decision made 
Odds 95% CI 95% CI 
      ratio Lower Upper 
Step 4         
Constant -5.47 1.77       
Contribution % 0.09 0.03 9.71 1 0.01 1.09 1.03 1.15 
Chair 0.56 0.22 6.66 1 0.01 1.74 1.14 2.66 
Histopathologist 0.54 0.24 5.19 1 0.02 1.71 1.08 2.71 
Surgeon -0.57 0.25 5.08 1 0.02 0.57 0.34 0.93 
Model X2 34.71 
  4 0.01    
R2 
0.30        
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6.5.1.3 Predictors of decision implemented 
 
Logistic regression was performed on the CMDT-MODe items that correlated significantly with the decision 
implemented. Specifically, pathological information, patient views, oncologists, radiologists, 
histopathologists and Global Contribution % variables were entered as predictors and decision implemented 
as the predicted variable. 
 
Only patient views, radiological information and Global Contribution % were retained in the model as they 
were the significant predictors, accounting for overall 14% of the variance in the decision implemented and 
having an overall prediction accuracy of 91%. 
 
 
Table 6.5: Logistic regression predicting decision implemented 
 
 
Predictors B SE B Wald df Sig 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note. Decision implemented was represented as 0 signifying no decision implemented, and 1 
signifying decision implemented. 
Odds 95% CI 95% CI 
      ratio Lower Upper 
Step 3         
Constant         
Radiologist 0.42 0.15 8.16 1 0.01 1.52 1.14 2.02 
Patient views -0.35 0.14 6.33 1 0.01 0.71 0.54 0.93 
Contribution % 0.04 0.02 5.20 1 0.02 1.04 1.01 1.08 
Model X2 24.34 
  3  0.00   
R2 
0.14        
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6.5.2 Core members and decision making 
 
6.5.2.1 The effect of absent members on CMDT-MODe 
components 
 
Scores were non-normally distributed, thus a nonparametric method was employed. Kruskal-Wallis 
test was used to explore the difference on MODe scores between groups with various core members 
absent, namely, when nobody was absent, when oncologist only was absent, when CNS only was 
absent and when both, CNS and oncologist were absent. 
 
There was a significant effect of absent members on the patient comorbidity (H(3)=11.7, p<0.01), 
patient views (H(3)=8.02, p<0.05), radiologist’s contribution (H(3)= 14.27, p<0.01), coordinator’s 
contribution (H(3)=24.39, p<0.001), and the Global Contribution % (H(3)=131.01, p<0.001). Mann- 
Whitney U tests were used to follow up this finding using significance level of 0.003 (corrected for 
multiple comparisons), however, only comparisons on patient comorbidity, patient views and Global 
Contribution % were explored due to their clinical relevance. 
 
The group where nobody was absent had significantly higher Global Contribution % in comparison 
to the group where the CNS was absent (U= 1321, z= -5.10, p<0.001), and where oncologist was 
absent (U=4556.5, z=-7.13, p<0.001), and where both (CNS and oncologist) are absent (U=551.5, 
z= -8.78, p<0.001). The contribution % was significantly lower when both (CNS and oncologist) 
were absent than when the CNS alone was absent (U= 178.5, z= -3.84, p<0.001), and when the 
oncologist alone was absent (U= 474, z=-5.2, p<0.001). However, no statistical difference was 
detected in Global Contribution % when either CNS or oncologist were absent (U= 773, z=-0.49, 
p=0.63). 
6.5.2.2 The effect of absent named clinician on CMDT- 
MODe components 
The Mann-Whitney test was performed to explore the variability in on CMDT-MODe components 
when the patient’s named clinician was absent and when present. The significance level was adjusted 
for multiple comparisons with a significance level being 0.001. The Global Contribution % was 
significantly higher when named clinician was present than absent (U=8108, z=-3.18, p<0.001). 
116  
6.5.2.3 Predictors of decision made and decision 
implemented – presence of team members 
 
Logistic regression was performed on the items related to the core members’ absence that correlated 
significantly with the decision made and decision implemented. After initial analysis, only the 
absence of the Named clinician was retained in the model for both decision made and decision 
implemented as it was the only significant predictor for both outcome variables. It accounted for 
overall 19% of the variance in the decision made having an overall prediction accuracy of 86%, 
while it accounts for 17% of the variance in decision implemented with an overall prediction 
accuracy of 90%. 
 
 
Table 6.6: Logistic regression predicting decision made – presence of 
team members 
 
Predictors B SE B Wald df Sig 
 
Step 1 
Constant 2.37 0.19 
Odds 
ratio 
95% CI 
Lower 
95% CI 
Upper 
Named clinician -2.24 0.32 48.98 1 0.01 0.11 0.6 0.20 
Model X2 47.07 1 0.01 
R2 0.19 
Named clinician was represented as a dummy variable with 0 signifying their absence, and 
1 signifying their presence. 
 
Table 6.7: Logistic regression predicting decision implemented – 
presence of team members 
 
Predictors B SE B Wald df Sig 
 
Step 1 
Constant 2.69 0.23 
Odds 
ratio 
95% CI 
Lower 
95% CI 
Upper 
Named clinician -2.44 0.42 33.59 1 0.01 0.09 0.6 0.20 
Model X2 30 1 0.01 
R2 0.17 
Named clinician was represented as a dummy variable with 0 signifying their absence, and 1 
signifying their presence. 
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6.5.2.4 Predictors of decision made – number of core 
members 
Additionally, in order to explore the effect of core members further, linear regression was 
conducted with the number of core members present as a predictor variable and decision 
made as a predicted variable. The number of core members present variable was retained in 
the model as it was a significant predictor, accounting for overall 49% of the variance in the 
decision made. 
 
 
Table 6.8: Linear regression predicting decision made from 
number of core members present 
 
 
 
Predictors B SE B t Sig β 
 
Step 1 
Constant 0.68 0.07 
No. of core 
95% CI 
Lower 
95% CI 
Upper 
members 
Note. R2= 0.49. 
0.02 0.01 2.49 0.02 0.47 0.00 0.04 
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6.6 Discussion 
6.6.1 Summary of results 
 
The aim of this study was to prospectively assess the relationship between the quality of the 
presented information, contribution to discussion of team members, team size and composition and 
the ability of a colorectal cancer MDT to reach clinical decisions using the MDT assessment tool 
developed and validated in the previous Chapter. In describing the results, I will consider these 
individually, based on the hypotheses generated at the beginning of the chapter: 
 
Hypothesis 1: A higher Global Information percentage score predicts a team’s ability to reach 
a decision regarding further management 
 
There was no significant correlation between the global information percentage score and the 
decision made, and so no further predictive analysis was carried out. The case history information 
correlated with the decision made, however it was not a significant predictor. With regards to 
whether or not decisions were implemented, I found that once more, the Global Information 
percentage score was not a predictor, however both information on patient views and radiological 
information were. 
 
Interestingly, information on patients views was a negative predictor of whether or not a decision 
was implemented – i.e. a lower score in this category predicted that a decision would be 
implemented – this was the opposite of what I anticipated – I felt that low patient view scores – 
which would reflect a lack of knowledge about what the patient wanted - would mean a higher rate 
of decisions not being followed, as patients may not be agreeable to the decisions based on their own 
opinions. However, the results suggest that this is not the case, and may be explained by the fact that 
those patients with low scores for patient views may in fact be those patients that did not wish to 
express any particular views – leaving decisions to the doctors, and therefore were less likely to 
challenge the decision made and result in non-implementation. 
 
Hypothesis 2: A higher Global Contribution percentage score predicts a team’s ability to reach 
a decision regarding further management 
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I found this to be true – the Global Contribution percentage was a significant predictor of whether or 
not a decision was made by the team. Furthermore, the individual contribution scores of the Chair, 
surgeon, radiologist and histopathologist all predicted whether or not a decision was made. 
Finally, the Global Contribution percentage was also a significant predictor of whether or not a 
decision was implemented. 
 
Hypothesis 3: The composition and number of core members in the team predict a team’s 
ability to reach a decision regarding further management 
Within this category, I found that the presence of the patient’s named clinician was a significant 
predictor of whether or not a decision was made as well as whether or not this decision was 
implemented.  Of the other parameters, only the number of core members present predicted whether 
a decision was made – i.e. the greater the number of members, the more likely the team was to make 
a decision. 
 
6.6.2 Limitations 
 
This study takes the results of the previous chapter and builds on them. By nature it is a similar 
observational study, and therefore has similar limitations – observational studies are open to some 
bias, and the clinical environment may impact on the results. Additionally, in this instance, I was the 
only observer. Whilst the previous chapter showed that CMDT-MODe can be reliably used by 
different users, I collected additional data for this study, and therefore there is a risk that there may 
have been data missed or included. However, the majority of additional items were quite objective 
and could be quantified easily – not requiring interpretation to produce a score. Finally, the results 
showing correlational relationships between different factors do not necessarily suggest causality, 
and the therefore we proceeded to carry out further regression analysis to evaluate the predictive 
value of the different components of CMDT-MODe. 
 
Once again, the results come from a single London hospital – and therefore may not be 
representative of MDTs across England, or the rest of world for that matter. Further work is required 
in a variety of settings to add strength to the predictors identified in this study. Whilst the overall 
number of cases was high, certain characteristics were analysed on a meeting basis, and therefore the 
overall number of meetings was not sufficient to draw wide-reaching conclusions. Ongoing studies 
will build on this data and aim to produce suitably powered results fully evaluating the functionality 
of this tool. 
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6.7   Conclusion 
 
In this chapter, I described a study that takes CMDT-MODe and evaluates how the different 
components are related as well as looking at its use as a predictive tool for decision making and 
decision implementation. The results are promising, and highlight the fact that t he  global 
contribution percentage score (as well as the individual contributions of various individuals) is 
important in predicting whether or not decisions are made and implemented. It reinforces the view 
introduced in the previous chapter that CMDT-MODe can be used in the development of a 
process of quality assessment and improvement. The performance of colorectal cancer MDTs can 
be assessed objectively and reliably and the tool can then be used to facilitate improvements for the 
wider team. The structure that the tool provides makes it useful in identifying particular areas of the 
team and the service that perform well and those that can be developed and improved further. 
 
 
In the next chapter I make use of Colorectal Cancer MDT MODe in live and video recorded settings 
to establish whether it is feasible to use the tool to evaluate MDTs whilst the observer is not 
physically present at the meeting – either by video conferencing facilities or at a later date and time 
following video recording. 
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CHAPTER 7: ASSESSMENT AND EVALUATION OF 
PERFORMANCE – A VIDEO OBSERVATIONAL STUDY – HOW 
WELL DO WE CORRELATE? 
 
 
 
7.1 Chapter overview 
 
Chapters 5 and 6 described the process of developing and initial evaluation of an evidence based tool 
for the observational assessment of team decision-making at Colorectal MDT meetings. I have 
demonstrated that the tool can be used reliably, and that it can be used to predict whether or not a 
Colorectal Cancer multidisciplinary team is able to come to a clear clinical decision. In this Chapter I 
evaluate the feasibility of utilising Colorectal Cancer MDT MODe to assess video recordings of 
meetings. 
 
7.2 Introduction 
 
In this Chapter, I report a study to evaluate whether it is feasible to use colorectal MDT MODe to 
assess video recordings of MDT meetings. As I have shown in Chapter 3, MDT meetings cost 
money, and the additional cost of having a designated observer – either internal or external – may 
detract teams from using this tool. Previous studies in other healthcare settings (115, 116) have 
showed good reliability between live and video observers. However, these have often utilised 
expensive video recording systems. After exploring the feasibility of using the video conferencing 
facilities, it was clear that the added cost of adding a video recorder to these cameras would be high. 
Therefore, I chose to record the MDTs through a digital handycam, which is readily available, and 
reviewed unedited videos on my computer. 
 
7.3 Aims 
 
The aims of this Chapter are to: 
1. assess intra-rater reliability of utilising Colorectal Cancer MDT MODe for live observations 
and video observations 
2. assess  inter-rater  reliability  of  utilising  Colorectal  Cancer  MDT  MODe  with  video 
observations 
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7.4 Methods 
7.4.1 Cases and study setting 
 
I conducted real-time observations and video recording using Colorectal MDT-MODe at 10 
colorectal cancer MDT meetings at a two London hospitals (5 meetings at each). Each case discussed 
by the MDT was scored using all elements of the tool on a scale of 1 to 5 with 5 representing the 
highest score/excellent performance. Following initial live scoring, I proceeded to review the videos 
following an interval of 6 weeks and scored the cases once more using all elements of CMDT-MODe 
tool. A sample of one meeting was observed by a second observer (Matharoo) and both live and 
video scores were recorded in the same manner. I encountered problems with the video recorder at 
one meeting, and therefore the results of this meeting were not included in the analysis (this was not 
one of the 10 meetings included above). The assessment process was similar to that described in 
Chapter 5. 
 
Informed consent was obtained from all participants. The study protocol and materials were 
submitted to the hospital R&D t eam  for approval prior to data collection and the study was 
approved as a ‘service evaluation’. At the end of the observation period, data were collated for 
statistical analyses. 
 
7.4.2 Video recording 
 
MDTs were recorded using a readily available digital handycam (Figure 7.1). As the layout of the 
meetings and the positions of core members varied slightly, the handycam was placed on a tripod at a 
point where maximal coverage was guaranteed. Digital recordings were reviewed at the end of the 
meeting and files transferred to a secure disk drive for further review and analysis at a later time. 
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Figure 7.1: Sony Digital Handycam 
 
 
 
7.4.3 Data analysis 
 
Statistical analyses were performed using SPSS version 20.0 and significance was taken at the 0.05 
level. The intra-observer and inter-observer reliability was assessed statistically using intra-class 
correlation coefficients, ICCs (114). Mean and standard deviation are reported for all ratings. 
Furthermore, to assess improvement in tool utilisation with the videos over time, observed cases 
were grouped into cohorts of 10 and ICC calculated for each cohort. Improving ICCs would 
demonstrate learning curves in tool usage with the videos by the observer. 16 cohorts of real-time 
MDT observations (corresponding to 160 cases) were analysed for most categories – except for the 
contribution of the oncologist and cancer nurse where there were 14 and 15 cohorts respectively due 
to absences during meetings. Regarding the assessment of pathological information and contribution 
of the histopathologist, there were only 8 cohorts as at one site the histopathologist left the meeting 
after all the cases requiring pathological input were discussed. 
 
7.5 Results 
 
7.5.1 Meeting characteristics 
 
164 cases were observed and rated in real-time across 10 MDT meetings by myself, and the videos 
rated again 6 weeks after the meeting. In addition, one meeting was attended by a second observer 
(Matharoo) who carried out live observations using CMDT-MODe, and followed this up 6 weeks 
later with an assessment of the video of this meeting using CMDT-MODe. 
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Descriptive information about the meetings is summarized in Table 7.1. On average, we found that 
the teams consisted of 13 to 24 cancer specialists and discussed an average 16 patients in just under 
64 minutes – with each case review lasting 3.90mins. This table also summarizes the observers’ 
ratings. Regarding the quality of presented information to the team, radiological information was 
rated highest (observers’ mean=4.48), followed by case history information (observers’ mean=4.41). 
Regarding each team-member’s contribution to discussion, surgeons were scored highest (observers’ 
mean=4.44), followed closely by radiologists (observers’ mean=4.43) and MDT coordinators lowest 
(observers’ mean=1.97). 
  
Table 7.1: Characteristics of meetings 
 
 
 
 
 
Meeting 
 
 
 
 
 
 
Characteristics 
 
 
 
 
 
 
Attendance 
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 1 2 3 4 5 6 7 8 9 10 Total Mean 
Number of cases 19 14 17 21 10 19 11 20 17 16 164 16.40 
Length of meeting 65 49 60 79 41 56 53 79 82 75 639 63.90 
Average time per case 3.42 3.50 3.53 3.76 4.10 2.95 4.82 3.95 4.82 4.69 3.68 3.90 
Surgeon 3 3 2 3 2 1 2 3 2 4 25  
Oncologist 1 1 1 1 0 1 1 1 0 1 8  
Radiologist 1 4 2 3 2 3 3 2 3 2 25  
Pathologist 1 2 1 1 1 1 1 1 2 1 12  
Cancer nurse 1 1 1 1 0 1 0 1 1 1 8  
MDT Coordinator 1 1 1 1 1 1 1 1 1 1 10  
Other 
Total 
8 
16 
12 
24 
7 
15 
6 
16 
7 
13 
12 
20 
9 
17 
11 
20 
7 
16 
9 
19 
88 
176 
 
 
126 
 
7.5.2 Inter-observer reliability 
 
The results of the inter-observer reliability were based on one meeting where 21 patients were 
discussed. The mean intraclass correlation coefficient for live inter-observer reliability was 0.83 
(0.75-0.89), whilst the mean ICC for video inter-observer reliability was 0.72 (0.64-0.80). Further 
analysis on this group was not carried out due to the small number of cases. 
 
 
7.5.3 Intra-observer reliability 
 
Table 7.2 summarizes the intraclass correlations (ICCs) between the live and video observations 
carried out by myself. The ICCs were high (>0.70) in only four of the 13 categories assessed. The 
remainder ranged from 0.44 (information on patient views) to 0.69 (contribution of the radiologist). 
The ICCs can range from 0.00 to 1.00, with a higher value indicating higher agreement. Whilst there 
are no specific cut-offs described for “adequate” ICCs, we have used the broadly acceptable as a 
reliability standard for research purposes value of 0.70 (190). Reliability coefficients above the line 
(>0.70) indicate adequate agreement between live and video observations; coefficients below the line 
(<0.70) indicate some but not adequate agreement – generally, the lower the value the lower the level 
of agreement. This suggests that there was limited agreement between the live and video 
observations carried out. 
 
I proceeded to analyse this further and reviewed cohorts of ICCs to see if there was an overall 
improvement, suggesting ongoing learning. Figures 7.2 and 7.3 display ICCs for cohorts of 10 cases 
in the overall categories of observation (Global Information Percentage and Global Contribution 
Percentage scores). The plots are annotated with a horizontal line at ICC= 0.70. Overall, these 
learning curves show that there was a general, if gradual, improvement in ICCs between the first 
cohort and the last cohort over time. Despite the fact that the overall ICCs are low, these are positive 
findings, as they suggest that it may be feasible to utilise video based assessments to evaluate MDTs, 
but that the learning curve may be over a greater period of time. 
 
 
 
 
 
 
 
 
 
 
 Table 7.2: Intra-observer reliability (live vs video) and descriptive ratings of Colorectal MDT performance 
 
 
 
 
 
Category  
Number of 
observations 
Intraclass 
correlation (95% 
CI) 
p-values 
Mean S.D. 
Case history 164 0.76 (0.72-0.82) <0.05 4.57 0.69 
Radiological 164 0.56 (0.54-0.57) <0.05 4.47 1.15 
Information 
Pathological 67 0.51 (0.51-0.59) <0.05 4.49 0.75 
 Psychosocial issues 164 0.68 (0.64-0.70) <0.05 2.18 1.39  
Patient co-morbidity 164 0.82 (0.74-0.87) <0.05 2.82 1.44 
 
Patient views 164 0.44 (0.41-0.49) <0.05 2.24 1.38 
 
MDT Chair 164 0.69 (0.56-0.78) <0.05 4.12 0.91 
 
Surgeon 164 0.89 (0.84-0.92) <0.05 4.34 0.85 
 
Oncologist 143 0.63 (0.56-0.68) <0.05 3.72 1.65 
 
Contribution Radiologist 164 0.69 (0.66-0.72) <0.05 4.13 1.35 
 
 
Histopathologist 67 0.64 (0.54-0.75) <0.05 3.71 1.32 
 
 
CNS 149 0.80 (0.71-0.86) <0.05 3.9 1.46 
 
 
MDT Co-ordinator 164 0.62 (0.58-0.64) <0.05 1.33 0.79 
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Figure 7.2: Intra-observer reliability Learning curves: ICC, Global 
Information scores 
 
 
 
 
Figure 7.3: Intra-observer reliability Learning curves: ICC, Global 
Contribution scores 
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7.6 Discussion 
 
7.6.1 Summary of findings 
 
In this study I set out to explore whether it was feasible to use CMDT-MODe to evaluate colorectal 
cancer multidisciplinary teams by video. I have utilised the tool developed in previous chapters and 
assessed its suitability for a different mode of assessment. Whilst the results do not show excellent 
reliability, they are encouraging as they appear to show that there is a trend towards improvement. 
The results show that the observational metrics can be derived using Colorectal Cancer MDT-MODe 
are not simply for use in real time – there may be a role in video based assessments. 
 
The implications of this are significant as, without the need to have somebody observing in person, 
MDTs can take advantage of the benefits afforded by CMDT-MODe for quality assessment and 
improvement by recording meetings and sending them to a suitably qualified observer. Furthermore, 
this may limit the time and man-power resources – and the associated costs. Alternatively, pairs 
of multidisciplinary teams could utilise video conferencing facilities for a similar purpose. 
 
 
7.6.2 Limitations 
 
The results of this study, though encouraging, are subject to limitations. My results come from a 
small sample (10 MDT meetings) from two London hospitals – and therefore may not be 
representative of MDTs across England. Additional observations are required to see if the improving 
trends in the learning curve continue to improve. Furthermore there is an element of bias as I 
reviewed both the live observations as well as the videos, although I allowed a 6 week gap between 
these evaluations. Further work may be required using a separate observer for the videos to see if the 
interobserver reliability between one live observer and another video observer is sufficiently high to 
utilise this concept further. 
 
The use of the videos produces some challenges in itself. Whilst every effort was made in this study 
to ensure maximal coverage, there is inherent difficulty in ensuring that videos capture all that is 
going on during meetings. There may be aspects of communication – particularly non-verbal 
communication that may be missed. Additionally, those being assessed are more aware of this in the 
presence of a video camera, and this may affect results. 
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7.7 Conclusion 
 
Overall, this study reinforces the view that performance of colorectal cancer MDTs can be assessed 
objectively and reliably, with adequate attention to the specifics of different specialties. Furthermore, 
the observational tool developed in previous chapters has been shown to be feasible when used to 
assess MDTs on video. Whilst its reliability is lower than for paired live observations, there is 
sufficient evidence to suggest with a longer learning period this may improve. 
 
In the final chapter of this thesis I review the findings in view of the aims of this thesis, discuss the 
specific results and their implications as well as set out ideas for future work in this area. 
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CHAPTER 8: GENERAL DISCUSSION 
 
 
 
 
This final chapter begins with a summary of the key findings from each of the chapters. I proceed to 
examine each of the individual aims set out, with specific links to relevant literature. Next, I consider 
the methodological strengths and limitations, practical implications and areas for ongoing and future 
research. I complete the section with concluding remarks. 
8.1 Summary of thesis findings 
This thesis has presented a series of studies exploring the role of multidisciplinary teams in the 
management of colorectal cancer. Chapter 1 highlighted specific aspects of colorectal cancer 
management that make the multidisciplinary team approach a vital part of clinical care. In Chapter 2 
I performed a systematic review and meta-analysis of the available literature on colorectal cancer 
multidisciplinary teams. This highlighted the high prevalence of the use of multidisciplinary teams to 
guide decision making, with improved clinical outcomes as a result of their introduction. However, 
the studies reviewed did not identify any specific methods of measuring how well colorectal cancer 
MDTs work. I proceeded to explore some of the issues raised in Chapter 2 further in Chapter 3, by 
conducting an interview study – targeting the core members of the colorectal cancer MDT. This 
study reiterated the finding that few methods existed to assess how well colorectal cancer MDTs 
work, or how well individual members were performing their specified roles. Importantly, the study 
identified specific measures that core members of the colorectal cancer MDT felt would be suitable 
for assessment. 
 
In chapter 4, I presented a study reporting financial data on the cost of colorectal cancer 
multidisciplinary teams. This data showed that there is significant cost associated with each MDT 
discussion – both overall costs per cancer patient, as well as costs per patient case discussion. This 
provides compelling financial reasons to ensure that these meetings run efficiently. 
 
I introduced the idea of a “Systems Approach” to Colorectal Cancer MDTs and proceeded to focus 
on specific process measures and meeting outputs. In Chapter 5 I utilise the findings from previous 
chapters and described the development of an observational assessment tool – Colorectal Cancer 
MDT-MODe. I proceeded to demonstrate validity and feasibility of use by different users. In Chapter 
6, I utilised the validated tool to assess Colorectal Cancer MDTs, and demonstrated there are 
relationships between the different components of the assessment tool. Furthermore, I was able to 
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identify specific components and global scores which predicted whether or not care decisions were 
made and implemented. Finally, in Chapter 7, I showed that it is feasible to utilise Colorectal Cancer 
MDT-MODe to assess pre-recorded videos of Colorectal Cancer MDTs, with sufficient reliability 
with paired live observations. 
 
8.2 Thesis findings by aim 
 
In this section I will now explore each individual thesis aim in more detail. 
 
8.2.1 Aim 1: To review the evidence base on Colorectal Cancer 
MDTs 
 
At the time of starting this period of research, Colorectal Cancer multidisciplinary teams were 
embedded in clinical practice in the UK, and across a large part of Europe. Outside of these areas, 
the presence and extent of multidisciplinary care was variable. From the outset, I set out to review 
the literature related to multidisciplinary team management in colorectal cancer. Whilst there use is 
widespread, there was little conclusive evidence to support their use and the positive impact they had 
on patient care, primarily due to the concurrent advances in patient management. 
 
The systematic review and meta-analysis of the literature highlighted that there were few reliable, 
empirical studies on Colorectal Cancer MDTs. There was significant variation in the types of study 
and the data presented, making further data analysis challenging. Indeed, despite the 
recommendations made by Fleissig and colleagues nearly ten years ago, there have been few studies 
that have addressed the issues raised. Whilst the body of evidence suggests a general acceptance of 
their use and benefit, there remain significant variations in the make-up, implementation and running 
of Colorectal Cancer multidisciplinary teams. One of the major issues identified has been variable 
attendance levels from core members - an issue raised in serial reports of national data. The work of 
National Cancer Action Team in producing key guidelines and mandatory auditing of data has gone 
a long way to improving this. 
 
The review proceeded to separate studies and identify those that reported changes to pre-treatment 
decisions and clinical outcomes. Overall, the findings support the hypothesis that the introduction of 
Multidisciplinary teams in the management of Colorectal cancer have resulted in more appropriate 
pre-treatment decisions being made – with better adherence to “gold standard guidelines”, as well as 
improvements in clinical outcomes. 
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A key conclusion from the review of the literature was that there were no standardised tools for 
assessment of how well multidisciplinary teams were performing. 
 
8.2.2 Aim 2: To identify key aspects that could be utilised in 
evaluating Colorectal Cancer MDTs 
The results from the systematic review identified a number of potential areas that could be used for 
the assessment of Colorectal cancer multidisciplinary teams – different standards and benchmarks 
had been used in a number of different studies. In addition to this, the then mandatory NCAT reports 
and the submission of specific data to NBOCAP provided a wide range of potential sets of 
information to use. The interview study reported in Chapter 3 identified a number of similar areas, 
with a broad split between process measures and outcome measures. I proceeded to introduce a 
“Systems approach” to assessment of Colorectal Cancer Multidisciplinary teams which included 
areas highlighted by the previous studies – broadly split into inputs, processes, outputs and clinical 
outcomes. This has been shown previously (Figure 4.3) and is highlighted again below in Figure 8.1. 
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Figure 8.1: The “ Systems Approach” to Colorectal Cancer MDTs 
 
 
 
 
Whilst the majority of clinicians preferred utilising clinical outcomes to assess colorectal cancer 
multidisciplinary teams, the disadvantage of using these was that there were a number of factors – 
clinician, hospital and patient based that would affect these. Therefore I focussed on the other aspects 
identified – a viewpoint shared by other studies assessing teams in healthcare. I chose to proceed 
with assessments of information presented, team member contributions and whether or not a decision 
was made and implemented. The latter two areas are easily objectively measured. The challenge was 
developing a tool that could reliably assess quality of information presented and team member 
contributions. 
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8.2.3 Aim 3: To develop an objective evaluation tool for 
Colorectal Cancer MDTs, which can be used in different 
formats 
In Chapters 5 and 6 I developed and assessed the inter-rater reliability of a tool to assess the quality 
of teamwork and decision-making in colorectal cancer MDT meetings (cMDT-MODe), followed by 
a period of use of the tool for assessment. Development was based on a recently designed tool which 
underwent a process of revision based on the findings of Chapters 2 and 3, followed by a rigorous 
process of content validation utilising 27 experts in colorectal cancer. A period of observations using 
this tool followed. The studies demonstrated that this observational assessment tool can reliably be 
used by different observers to assess the quality of information presentation to the team, and the 
contributions to team decision-making of the core members of the MDT. Reliability between 
observers was good, with only one area falling below the accepted level for an adequate score (0.7). 
This was in the assessment of the contribution of the MDT chair. Overall learning curves showed 
that there was a general improvement between raters from the first to the last cohort of patient 
discussions. 
 
 
In Chapter 7 I utilised the same tool to assess Colorectal cancer Multidisciplinary team meetings that 
I recorded using a video recorder. I then assessed the reliability of real time observations against 
those from the video recordings of the meetings. The results here are less reliable then live 
observations between 2 different individuals. However, there was a definite trend to improvement 
with the learning curves – albeit a slower improvement. The results suggest that with adequate 
support and time, video based assessments may be useful adjunct in assessing Colorectal Cancer 
Multidisciplinary team utilising CMDT-MODe. 
 
 
8.2.4 Aim 4:  To identify key elements that predict decision 
making in Colorectal Cancer MDTs 
In Chapter 6 CMDT-MODe I analysed the relationships between different components of CMDT- 
MODe, as well as between the components and the team’s ability to come to a definitive clinical 
decision and latterly, whether this decision was implemented. The results suggest that the Global 
Contribution percentage score was able to predict the ability of an MDT to reach a clinical decision, 
as well as the actual implementation of said decision. Finally, the presence of a patient’s named 
clinician was a significant predictor of the MDT’s ability to reach a clinical decision. 
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8.3 Thesis Limitations 
 
8.3.1 Subject area 
 
Chapter 1 highlighted the specific reasons for choosing Colorectal Cancer multidisciplinary teams as 
the focus for this thesis. It is these same reasons that, to an extent, limit the data presented. Managing 
patients with colorectal cancer is challenging, given the number of cases, the different presentations 
and the various options for treatment modalities. There remain a number of areas where there is 
equipoise with regards to optimal management – related to pre-operative investigations, neoadjuvant 
therapies – type and duration, and operative techniques and strategies (51, 53, 57, 117, 118). 
Furthermore, there are numerous stages to the management process, involving a wide range of 
healthcare workers. Therefore clinical outcomes in patients with colorectal cancer are affected by 
numerous factors - the quality and efficiency of care provision as well as variations in patient. It is 
therefore not accurate to utilise clinical outcomes as a marker for assessing colorectal cancer 
Multidisciplinary teams, as they are a more accurate marker of the overall cancer pathway, taking 
into account the factors listed earlier. Furthermore, it is not possible to attribute improvements in 
clinical outcomes solely to the introduction of multidisciplinary team working as there have been 
technological and pharmacological advances in the assessment and management of patients with 
Colorectal cancer. 
 
8.3.2 Studies on the subject 
 
There are several limitations in the evidence base identified for Colorectal Cancer MDTs working. 
The systematic review and meta-analysis presented in Chapter 2 identified a relatively a small 
number of studies on multidisciplinary teams in colorectal cancer – an interesting finding given how 
large the evidence base is on colorectal cancer alone, and the fact that multidisciplinary teams in 
cancer care are mandatory in the UK and large parts of Europe. Furthermore, there was significant 
variation in the study types and results presented, making further analysis difficult. A simplified 
quality assessment tool, to assess study suitability for meta-analysis identified only a small number 
of studies suitable for inclusion. Importantly, there were no randomised controlled trials comparing 
interventions to improve the processes of the multidisciplinary team or the effect of multidisciplinary 
team working on clinical outcomes. The majority of comparative studies were retrospective studies, 
with a longitudinal assessment of pre-MDT and post-MDT outcomes. This in itself limits their value 
as the retrospective nature introduces bias, and the longitudinal nature of these studies means that 
advances in clinical care cannot be accounted for and eliminated. 
The gold standard scenario of carrying out a prospective, randomised controlled trial with strict 
inclusion criteria to evaluate the impact of colorectal cancer MDTs on clinical outcomes is not an 
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option in the UK setting given that MDTs are now mandatory and there is no allowance for clinical 
care in cancer patients without the involvement of a multidisciplinary team. 
 
The next step was to identify studies that presented data on MDT running and implementation. Again 
there was significant variation in practice and reporting, and one could argue that the published 
papers represented a sample of MDTs that were focussed on quality improvement, and therefore 
providing a biased sample of the better end of the spectrum. 
 
8.3.3 Choice of assessment methods 
 
The first 2 sections of this thesis identified the key challenge of identifying specific assessment tools, 
given the variation in methods previously used. The development of the “Systems Approach” to 
assessment of Colorectal cancer Multidisciplinary teams, described at the end of Section 2, allowed 
me to identify different areas, and distil my thoughts to identify key measures to focus on, that would 
reflect accurately the workings of these multidisciplinary teams. These measures focus on inputs, 
processes and outputs and this thesis has shown that they can be reliably assessed. 
 
One of the overarching aims of any healthcare research is to improve outcomes for patients. It is 
therefore the focus of results presented in clinical journals, and is often more easily understood then 
the measures described in this thesis. Similar difficulties arise in related healthcare disciplines, where 
process measures have been shown to be components of reliable assessment tools. However, a 
significant challenge, and one that this thesis has not addressed, is linking these measures of process 
to clinical outcomes to see if there is significant improvement in these “hard” clinical outcomes, 
which remain the standard when assessing the effectiveness of clinical care. 
 
8.3.4 Study methodology 
 
I chose observation as the method of assessment of teamwork and team decision-making in 
colorectal cancer MDT meetings. Whilst this methodology has clear advantages, the limitations 
mentioned in other experiences of observational studies in healthcare settings applied to my studies. 
 
Firstly, the colorectal cancer MDTs being assessed are generally busy meetings, with a number of 
people attending. Case discussions were often rapid and discussions moved on to the next patient 
very quickly. As a result, it was sometimes difficult to capture all the information required to 
complete the rating tool and record this accurately. This problem was more of an issue when 
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evaluating the videos of the MDTs for data analysis in Chapter 7, as the presence of a single, static 
camera meant that some aspects were missed entirely. This is likely to be a significant reason for the 
lower levels of intra-observer reliability found in this study. Additionally, the often disorganised 
presentation of information and contribution to team discussion that I observed made data capture 
difficult. Information on pathology or radiology was often presented within the case history, not by 
the expected or appropriate professional (i.e. the Histopathologist or the Radiologist), which at the 
start was difficult to keep up with for both observers. However, learning curves were apparent across 
the course of the study, which implies that observers can eventually learn to separate the information 
from the contribution. 
 
8.4 Implications of thesis findings and areas for further research 
The research presented in this thesis was carried out with the overarching aim of improving patients’ 
outcomes and safety. With the different methodologies employed, I have presented a series of studies 
that have significant implications for clinical practice, whilst at the same time identifying related 
areas for further research. 
 
8.4.1 Multidisciplinary teams are here to stay 
The value of multidisciplinary teams in colorectal cancer care has been scrutinised in numerous 
studies. However as they form the basis of a number of cancer care systems globally, they are likely 
to continue in their current form. What is apparent from the data presented in this thesis is that there 
is significant variation in practice. Despite national guidance there are shortcomings when it comes 
to effective and efficient use of Multidisciplinary teams in Colorectal Cancer. This thesis aims to 
address this with the development of an objective assessment tool to assess and improve 
Multidisciplinary teams in Colorectal Cancer. The tool has been validated and has been used in 
multiple formats. 
 
Future work should aim to build on this by utilising the tool further, in different hospital settings to 
build up a large set of data for analysis. This will have the additional benefit of refining and 
developing further versions of the tool to ensure it remains up to date with current clinical practice. 
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8.4.2 Decision making and implementation ability 
In this thesis I have used a multidisciplinary team’s ability to reach a clinical decision, as well as 
whether this decision is implemented as a marker for the effectiveness of decision making. This is a 
novel way of approaching the problem, and provides a clear endpoint for assessment. Studies 
presented in the systematic review have also identified concordance with individual clinicians’ 
decisions (made blindly) and adherence to guidelines as study endpoints. However I strongly believe 
that using decision making and implementation ability will lead to largely unbiased data, as at that 
point there is no argument as to whether this was a right or wrong decision (which could be argued 
when using the other two methods), but simply whether a decision was reached. I believe that at this 
stage all studies should present this data which will allow for useful data collection and analysis of 
larger data sets. 
It is important to note that whilst I have referred to MDT decisions in this thesis, the views and 
treatment options presented to a patient following a MDT discussion are in truth recommendations for 
management and the final decision lies with the patient – following a careful consideration of the 
options, facilitated by appropriately informed healthcare professionals. Patient autonomy is a 
fundamental principle of healthcare today, and whilst the specialist members of the MDT are able to 
make decisions based on the information available, the final decision to consent to treatments lies with 
the patient. It may be prudent therefore to refer to MDT recommendations in further work in this area. 
 
8.4.3 Clinical outcomes 
 
I have outlined my rationale for using decision making and implementation as a measure of 
effectiveness. As explained above, this does not answer the question of whether this is the ‘right’ 
clinical decision for the patient. As a larger data set is developed, the next step should be to examine 
whether implemented decisions are ‘good decisions’ that do indeed lead to patient health benefits;  
a proposed method would be to assess if there is a relationship between CMDT-MODe scores, 
decision implementation and clinical outcomes – in colorectal cancer these could include, but are 
not limited to, R0 resection rate, disease free survival and 30 day morbidity and mortality. 
 
8.4.4 Quality improvement 
 
One of the proven advantages of objective scoring systems is that repeated scoring and feedback 
carried out in the right manner will result in gradual improvements over time. Whilst there is an 
argument that some of the effect seen is as a result of the Hawthorne effect, this in itself is not 
necessarily a bad thing as it does drive improvement. The results of this thesis showed a gradual 
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improvement in the scores for the teams assessed over time. What I have not explored is the role of 
effective de-briefing following a period of observation. There is evidence to support the fact that 
an effective de-briefing is just as important as objective assessment in driving improvements in 
individuals and teams, and this is an area for future work. 
 
Additionally, the tools used in this thesis may be a useful adjunct to the National Peer Review 
Programme, which is in itself a formal Quality assurance and improvement process. This is not an 
area I addressed in detail, and one may argue that going forward, aligning the work in this thesis with 
the Programme increases the chances of successfully incorporating cMDT MODe in regular practice. 
 
8.4.5 Resource implications 
 
One of the things that my research has shown is that Colorectal Cancer MDTs cost money. Whilst it 
is difficult to compare this with patient management without these teams, it is clear that any potential 
savings of time and money should be looked at in more detail. The colorectal cancer MDT provides a 
unique area where it is worth considering whether all patients need to be discussed equally. Given 
that there are often established departmental, local, regional, national or international guidelines in 
place for some of the disease stages, it is an area that needs further research to establish whether 
savings can be made without compromising patient care. 
 
Anecdotally, there has also been an increase in the number of colorectal cancer cases managed in the 
private sector. Whilst there is limited information in this area, such cases are often brought to the 
clinicians’ local MDTs for discussion. If there are significant increases in these numbers, there may be 
certain cost implications for those involved, and the data in this thesis may provide a framework for 
calculating this. 
  
    8.4.6    Teaching and training 
The MDT provides a relatively underused method for training of junior doctors. There is a large 
amount of clinical knowledge that is discussed and it is a brilliant opportunity for keeping up to date 
with management options and engaging in critical discussion with like-minded colleagues. 
Additionally, the video based assessments described in this thesis can prove to be an invaluable 
resource in training of junior doctors, as well as whole MDTs. It may be of particular use in training 
MDT co-ordinators – as the only non-clinical members of the team, the videos may be useful in 
ensuring they are familiar with terminology and maximize their engagement and impact in meetings.  
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8.5 Concluding remarks 
 
I started this thesis at a time when there was a little in the way of research in the area in question. My 
period of research has proved to be an exciting time in the field, with a number of new contributors 
to this area from different backgrounds. 
 
The research presented in this thesis has shown that whilst there is variation in practice, it is possible 
to objectively assess Colorectal Cancer Multidisciplinary teams with the aim of improving their 
practice. Given the current climate in the healthcare setting, there is a need for ensuring that clinical 
practice continues to provide safe healthcare for patients with good clinical outcomes, whilst 
maximising the efficiency of the processes involved. 
 
Multidisciplinary teams in colorectal cancer are an area where this is especially true, and this thesis 
sets the foundation for an ongoing process of objective quality improvement. There is a need for 
further research in this area, and I hope that the work presented in this thesis provides the foundation 
for this. 
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APPENDIX 2 -Interview Schedule 
Interview Schedule: User defined opinions of outcome measures for Colorectal 
cancer MDTs 
 
Objectives for this interview: 
:.- To explore individuals perceptions of their roles in MDTs and their insight into their 
performance 
,.  To investigate awareness of any assessment tools, both for individuals as well as 
for the MDT as a whole 
:.- To  understand what  outcome  measures  may  be suitable for  assessing Colorectal 
cancer MDTs 
,_ To identify groups that may represent an expert consensus on outcome measures 
for Colorectal cancer MDTs 
Key: 
-+ = prompts 
 
 
 
INTRODUCTION 
• Establish ID of who I'm speaking to - name,job title 
• Introduce myself 
• Introduce project - State aim of the interview:To identify outcomes that can be used 
to evaluate ColorectalCancer MDTs. 
• Ask permission to tape interview, assure anonymity 
• Confirm that the information provided will be treated confidentially 
RESPONSIBILITIES 
1. Can you please describe your role in the ColorectalCancer MDT? 
What strengths do you bring to the MDT 
Do you think your role is limited to the meeting? 
Do you have time to prepare for the MDT beforehand? How much time is typically 
required? 
Is there anything that limits your ability to perform your role? If yes,what is it? 
2.  How do you know that you are performing your role satisfactorily? 
Do you ever self-evaluate your contribution? 
How is your performance measured and reviewed? 
Have you received any detailed feedback (verbal or written)? 
Are such performance assessments I reviews regular I formal or ad hoc? 
CURRENT METHODS OFASSESSING COLORECTAL CANCER MDTs 
3.   Do you know of any tools or methods available to assess how well Colorectal Cancer 
MDTs work? 
Do these assess individualmembers? 
Do these assess the overall process of the MDT? 
Do these assess the outcomes from MDTs? 
If there are such tools, how are they applied (ie how frequent ly, in what form?) 
4.  Do you think these tools are suitable? 
How could they be improved? 
YOUR OPINIONS 
5. W hat measures of performance would you recommend for assess ing how well Colorectal 
Cancer MDTs work? 
What aspect of the MDT would these measures assess? 
Rather than focusing on the process,are there measures that could assess the outcome? 
If you were designing a tool,what outcome measures would you include? - Do you think 
these assess the MDT decision individually,or do they assess the whole process,from initial 
referral to final treatment? 
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EXPERT OPINION  
6. Who would you consider to be experts who could provide a consensus on outcome 
measures for Colorectal Cancer MDTs? 
-+ Do you think that these should be specialty specific , or that an overall consensus for all 
MDTs would be suitable? 
-+ Are there any particular organisations? 
-+ What do you think is the best way to collect this consensus - ie are there particular groups 
I conferences that could be contacted to facilitate this? 
RESPONSIBILITY  
7.   In the event of any complaints I proceedings, who do you think is responsible for the 
recommendations of multidisciplinary team meetings? 
-+ Do individual clinicians have responsibility / liability, even if they have not been actively 
involved in the discussion? 
-+What would you do in the event that you did not agree with the final recommendation given 
by the MDT? 
 
Do you have any questions? Is there anything else that you would like to add? 
 
Additional notes: 
 
Interviewee 
 
 
 
 
 
 
 
 
 
 
 
Location I Settings 
 
 
 
 
 
 
 
 
 
 
 
Any new avenues 
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APPENDIX 3 – Sample Interview Transcript 
 
Interviewer: Good morning, it’s 13th July.  It’s Sujay Shah, I’m one of the Research Fellows at Imperial 
College and Barnet. Thank you for taking the time to complete this interview.  Can I just ask 
you, for the purpose of the interview, just to introduce yourself, your role within the hospital 
and within the MDT? 
 
Respondent: So my name is Pawan Mathur, I’m a Consultant Colorectal General and Laparoscopic 
Surgeon at Barnet. I am the lead for lower GI cancer in the Trust, and I was MDT lead at 
Barnet but am no longer, so I’m a core member of the MDT. 
 
Interviewer: Okay. The purpose of this interview is to explore individuals’ perceptions of their roles within 
their MDT, in, insight into their performance and awareness of any assessment tools. And 
also to understand if there are any specific outcome measures that they’re, they may feel are 
suitable for assessing colorectal cancer, MDT specifically. So just, in the first instance, can 
you briefly describe your role within the MDT? I know you’ve mentioned what you do but 
what does that involve? 
 
Respondent: Well, as a (coughs) core member, it, it, it involves attending the MDT every week, being 
knowledgeable of your patients and playing an active part in the MDT. I often step in for the 
MDT lead and chair the MDT and, and that. And I’ve, and I’ve done that before for about 
four or five years. My role there, I very much felt, was to facilitate the meeting, make sure 
that all the information is available for each patient, to ensure that every, sort of, person 
that’s involved in a patient’s care gets a say when discussing each patient. Then to make 
sure that a, a MDT decision is recorded and decided at the end, yeah. 
 
Interviewer: Any particular strengths that you think, that you feel you bring to the MDT? 
 
Respondent: Myself? I think I’m organised, I think I can chair a meeting well, and… I think I’m fairly 
knowledgeable and fair, probably(?) (coughs). 
 
Interviewer: And do you see your role as being limited to the meetings, so the, whatever, the hour and a 
half of the meeting on a Friday morning? Or does your role extend beyond that? 
 
Respondent: No(?), because I’m lead for lower GI cancer, my overall role is to ensure that we are, you 
know, running proper MDTs if you like on both sites. We have two sites and two separate 
MDTs, and to make sure that both are, are functioning in a appropriate manner. 
 
Interviewer: Fine. Do you have specific time set aside for MDT preparation before the, before the MDT 
meeting itself? 
 
Respondent: When I was leading the MDT, I would make sure I had about an hour the day before to look 
through the list and look through any problems. I mean, now, as a core member, I just 
attend on the morning so I don’t have any other time. 
 
Interviewer: Anything in particular that you think limits your ability to perform your role within the MDT? 
Respondent:  No (laughter), okay(?), no, yeah. 
Interviewer: No, okay, that’s fine.  Moving on to your perceptions of your role, how do you know that you 
are performing your role satisfactorily? 
 
Respondent: (Hums) I think, as a core member… I mean I, I don’t really know, except that I feel that at the 
end of, you know, and discussion about a particular patient, we, I feel that I’ve had my say 
and that… the other members that I may want to get advice from have also had their say. 
So we, we’ve had a very fair discussion and so I, you know, the decision of the MDT that’s 
recorded, I feel is a, you know, a good outcome for that patient. What else did you ask? 
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Interviewer: How do you know whether you’re performing your roles, kind of, satisfactorily, so? 
 
Respondent: Yeah, as, in terms of performing my role, I, there, there’s nothing to measure that. There 
was nothing to measure when I was chairing the meeting, there was nothing to measure that 
to say, aside from people, you know, verbally feeding back that the MDT’s great and it works 
well, we get through the patients and nothing is missed really. But we’re not measuring it per 
say. 
 
Interviewer: So kind of informal feedback? 
Respondent:  Yeah, yeah. 
Interviewer: Okay. Anything that, even within your overall remit as, as consultant surgeon, in the way of 
formal, either self evaluation or formal external assessment, that specifically focuses on the 
MDT, so? 
 
Respondent: No, I mean, a, years back when PELICAN ran the, sort of, national MDT programmes, they 
sent out people to every MDT who looked at our MDT, and they, sort of, I don’t know if they 
scored it but they, they said our MDT was doing well. Obviously there’s peer review that 
looks at certain aspects of the MDT and, and scores us on those outcomes. But there’s, 
there’s nothing else really, out there, to, to really ascertain whether the, you know, one’s 
MDT is functioning properly. 
 
Interviewer: Okay. Do you, and do you know of any other tools or any other methods that, that may be of 
use? Not that, that are not in use at the moment but anything that you, you could use to 
assess how the MDT functions, how the teams work, overall efficiency(?)? 
 
Respondent: No, I mean, aside from, you know, the things we’ve been discussing, I don’t know of an 
actual tool or a score that measures MDT function. We have tried doing some work in the 
past to use CRM positivity as a, as a surrogate marker for the functioning of an MDT for 
rectal cancer. But, and there’s a few papers around that, but I don’t know of any other 
scores, tools. 
 
Interviewer: Okay.  In your opinion, what sort of things would be useful to measure?  So breaking down 
the MDT into the actual process of the MDT and, and, sort of, process measures that you 
could use, things like whether everybody’s there. So that’s, kind of, the first sort of things. 
And then the second thing is kind of the outcomes, so you mentioned, for example, using the 
CRM positivity radar as a surrogate marker. Is there any other, you know, any other things 
like that that you could, that you feel would be useful in, in measuring and assessing an 
MDT? 
 
Respondent: I think in, in terms of the process, I mean, when I was chairing the meetings, I had very 
strong feelings about, if you like, what the, you know, if, if people are attending the MDT and 
they’re a core member, of what they should actually do, i.e., switch off their mobile phones or 
put them on silent and really focus on the MDT. And that, there, there was, you know, I was 
quite strict about there being just one meeting and not little meetings in the, in the audience 
where people are discussing things so you have a… you know. So some kind of tool to, in, 
in a way, measure things that disrupt an MDT rather than, you know, I, I think we all know of 
things that can make it run smoothly, that, you know. So, in the process, thing, things that 
disrupt or… you know, perhaps results aren’t there and it’s a recurrent problem, that, that 
sort of thing in the process.  In terms of, you know, clinical outcome, I do think rectal cancer 
is the group of patients where the, a successful MDT could be measured, if you like. For the 
reasons we’ve discussed in that, you know, there’s a lot, the, the, there’s no real clear 
consensus about how, you know, which patient’s getting the urgent therapy, what kind are 
the urgent therapy, what is classified as a CRM positive, you know, are lymph nodes at 
this(?), you know.   So there’s a lot of uncertainty, and, so that, you’re kind of begging to 
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develop a consensus across the board in that field, so, for, for rectal cancer.  Yeah, because 
I think that the colonic cancer’s fairly straightforward most of the time and, you know, lower 
rectal cancer and rectal cancer, that, that’s the group we really need to focus on. 
 
Interviewer: With that group specifically then, are, are there any particular, as you said, it’s difficult to get 
consensus nationally, or, or internationally. But are there any particular guidelines that you 
as an MDT follow, or whether it be international guidelines, or do you have local guidelines 
for your MDT? 
 
Respondent: We don’t have local (laughter), strict local guidelines, no. We’re very much, it’s almost like 
every patient is individually assessed. But you, you, you know, if you examined things over a 
few weeks you’ll probably find some trends in, you know, T3N1s or whatever. But a lot of the 
time I feel that we, we, we make the decision based on each patient rather than the. 
 
Interviewer: And are you aware of any guidelines that… within the UK or sort of nationally that you could 
use? 
 
Respondent:  No, I’m not, I’m not, nothing’s been published really, or. 
 
Interviewer: Okay. Moving on to kind of specialty groups or, or national, national organisations that 
would, that may be involved in development of guidelines. What sort of groups would you, 
as a consultant surgeon, would you see developing these sort of guidelines or? 
 
Respondent: Well I think it’s, it’s a sort of collaboration between the surgeons, oncologists, I mean, yeah, 
the, the core members basically, you know, surgeons, radiologists, oncologists and 
pathologists probably, do need to get together and come up with some kind of guidelines. 
 
Interviewer: And are there a, are there kind of an existing group of, of core members, so you mentioned 
the PELICAN group earlier on. Is, is there a, a, an organisation that involves core group, 
core group members  within the MDT? Because obviously  there are specialty  specific 
organisations but is, is there one that involves the whole MDT? 
 
Respondent:  Not really, not that I know of, no. 
 
Interviewer: Okay. And finally, moving on to the, the, the actual decisions made, and, and how they 
are… how they’re, they’re implemented. There are occasions when there is not full 
agreement within the MDT. What’s your view on discussions in the MDT that don’t have full 
agreement from the group, so? 
 
Respondent: I mean, I have to say, in our MDT, that’s, that’s pretty rare actually. At the end of the day, 
the, the, the, the doctor who’s seen the patient, obviously it’s their responsibility as to the 
decision that’s made. And they’ll be, often seen the patient so they know what they look like 
and comorbidities, etc. I mean, I, I seriously cannot remember a time when, you know, the 
MDT has advised one thing and the surgeon thought something different. At the end of the 
day, we, we usually go with what the physician, you know, the responsible physician wants. 
But we’ll always discuss all the other options. But, you know, I don’t think there’s been a 
time when there’s been any kind of argument about the, the outcome. 
 
Interviewer: In a situation where you had a difference of opinion with what everybody else was saying, 
would you voice it, as a, kind of a minority in a group, would you, would you? 
 
Respondent: No, I’d definitely voice it. I mean, again, one of the strengths of our MDT is that I, I feel 
completely safe in doing so, no matter how crazy maybe my ideas may be, I do voice them 
and see what people think.  And I have no fear that people will ridicule it or contest it really. 
 
Interviewer:   And in, in the, in the event that there is a problem or, or there are some complications related 
to treatment, and, and, for example, there are any proceedings against, against the trust as 
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such. Do you see individual responsibility per clinician, per lead clinician, or collective 
responsibility for the MDT decision?  Any kind of thoughts(?) about that? 
 
Respondent: Yeah, I mean, both. I would, I, you know, I would support any of my colleagues in, if there 
were such proceedings, I would support them from the point of view of our MDT. I do think 
it’s our collective responsibility for whatever decisions we’ve made. 
 
Interviewer: Okay, fine. Anything else related to what we’ve talked about that you want to add on to, 
we’re essentially at an end to the interview? 
 
Respondent: No, I think it’s a very interesting, you know, area to, to look into, because there isn’t any kind 
of consensus about MDTs. MDTs are sort of central to our functioning and becoming more 
and more important so I think it would be very helpful to come up with some scores, 
guidelines on how we do. 
 
Interviewer: Any questions that you have regarding any of this? 
Respondent:  No, good luck. 
Interviewer: Thank you very much, that’s the end of the interview, thank you. 
[End of Transcript] 
161   
APPENDIX 4 – The Cost of an MDT – Survey 
 
 
Thank you for agreeing to take part in this survey. Please complete all the responses as accurately as possible, 
relating to your activities in 2012. Survey results will be anonymised. 
 
1. What is your current specialty? 
 
2. How many years have you been a consultant in this specialty? 
 
3. Are you a core member of this MDT? 
 
4. What was your gross annual salary in the year January to December 2012? 
 
5. Did this include any awards / performance bonuses? If so, to what amount? 
 
6. In an average week, how long do you spend at the Colorectal Cancer MDT? 
a) Under 1 hour 
b) Between 1 and 1.5 hours 
c) Between 1.5 and 2 hours 
d) Over 2 hours 
 
7. In an average week, how long do you spend preparing for the Colorectal Cancer MDT? 
a) Under 1 hour 
b) Between 1 and 2 hours 
c) Between 2 and 3 hours 
d) Between 3 and 4 hours 
e) Over 4 hours 
 
8. On average, over the year, how many MDT meetings did you miss? 
 
9. On average, how many hours / days in a year do you spend on training related to MDTs? 
 
10. What types of training does this include? Do you have to pay for this? 
 
 
From your experience, 
 
11. On average, how many patients are discussed per MDT? 
 
12. How long, on average, do you spend discussing one patient? 
 
13. How often do you discuss the same patient again in the next MDT? 
 
14. Have you changed your treatment decision because of the MDT? 
a) often 
b) occasionally 
c) rarely 
d) never 
 
 
15. Does it happen that treatment of patients gets deferred because of non-attendance of team members? 
a) often 
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b) occasionally 
c) rarely 
d) never 
 
16. The MDTs lead to better patient outcomes: 
a) agree strongly 
b) agree 
c) not sure 
d) disagree 
e) strongly disagree 
 
 
Thank you for completing this survey. 
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APPENDIX 5 – Validation Questionnaire 
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 Not at all  --->  Very much Additional Comments 
 
Overall, is this tool suitable for 
use in assessing Colorectal 
Cancer MDT meetings? 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
I am a (please circle): Surgeon/Nurse/Radiologist/Oncologist/Pathologist/Co-ordinator/Chair 
 
 
 
 
3 
 
 
 
 
I 
Leaders.hip neither enhancing nor impeding 
infonuation I presentation I discus.sion / 
decision making 
Leadership iu1peding infonuation 
presentation / discussion / decision making 
 
 
Contribution of 
Surgeon 
 
 
1   2    3    4 5 
5 
 
 
3 
 
I 
At1iculate and precise specialty related 
contribution 
Contribution ina11iculate or vague 
Nil I i1npedes contribution of others 
 
 
1   2    3   4    5 
 
 
Contribution of 
Oncologist 
 
 
1   2    3    4 5 
5 
 
 
3 
At1iculate and precise specia lty related 
contribution 
 
Contribution ina11iculate or vague 
 
 
1   2    3   4    5 
I 
 
 
Contribution of 
Radiologist 
5 At1iculate and precise specialty related 
contribution 
 
 
1   2    3   4    5 
3 Contribution ituu1iculate or vague 
I 
 
 
Contribution of 
Histopathologist 
5 At1iculate and precise specia lty related 
contribution 
 
 
1   2    3   4    5 
3 
 
I 
Contribution ina11iculate orvague 
 
Nil I impedescontribution of other; 
 
Contribution of 
Cliuirnl Nurs(' 
Specialist 
 
 
1   2     3    4 5 
5 
 
 
3 
 
I 
At1iculate and precise specialty related 
contribution 
 
Contribution iua11iculate I vague 
 
Nil I impedes contribution of other; 
 
 
1   2    3    4    5 
 
 
Point of 
discussion 
 
 
 
1   2    3    4 5 
p 
r 
e 
p 
0 
s 
R 
Pre.treatment 
 
 
 
Post-treatment 
 
 
 
Recull'ence I surveillance 
 
 
 
1   2    3    4    5 
 
 
Final MDT 
d('cision 
 
 
1   2     3    4 5 
y 
 
 
D 
 
N 
Clear deci;ion about treatment(s) to be 
offered 
 
Decision to defer to next MDT 
No decision I decision tmclear 
 
 
1   2    3    4    5 
5 Leaderhip enhancing i11f011uation / 
presentation I discussion / decision making 
Contribution of 
:vIDT Chair 
1   2 3 4 5 1   2    3    4    5 
Nil I i1npedes contribution of others 
1   2 3 4 5 
Nil I impedescontribution of other; 
1   2 3 4 5 
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APPENDIX 6 – Participant Information Presentation (Observational Study) 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
Systematic review - results 
• Final list of 26 articles from 8 countries 
– 3116 articles retrieved by specific search criteria. 
– Application of the inclusion criteria excluded 3092 articles. 
– 6 further articles were identified from hand-searching, and of these 2 fitted 
the inclusion criteria. 
– A final list of 26 included articles from 8 countries was completed, published in 
peer reviewed journals between 2003 and 2012 inclusive. 
– ..\Studies\Systematic review\Thematic analysis of included studies -  
metanalysis data.xlsx 
 
• Reported data: 
– Not all hospitals had weekly MDTs 
– 62% had problems with organization – absence of MDT co-ordinator a key 
factor 
– Attendance of core members variable 
– Clinicians found working within MDTs useful, and was a source of improved 
job satisfaction 
– European studies – not all patients discussed at MDTs 
– Discussion at MDTs positively affected pre-treatment decisions 
– Some improvement in clinical outcomes 
Systematic review – materials and 
methods 
• Search strategy and Selection Criteria 
– Systematic literature searches of Embase, Medline, PsycINFO (using Ovid SP) and the Cochrane 
Library. ..\Studies\Systematic review\Screenshots OVID search 120312.docx 
– Free text search terms used were “colorectal”, “cancer”, “multidisciplinary” and relevant 
derivatives. MeSH terms were identified for each database separately and incorporated into 
the search. 
– Results limited to humans, English Language and dates from 1980 to 12th March 2012. 
– Additionally, reference lists of all articles that fitted the inclusion criteria were hand searched. 
– Articles were included in the review by a staged process of exclusion, by 2 reviewers, with any 
discordant decisions arbitrated by a third reviewer. S:\Studies\Systematic review\Flow chart   
v3 0409.docx 
– 26 articles were finally included in the review. 
– Meta-analysis – in line with PRISMA recommendations; random effects model used 
• Data extraction 
– Country in which the study was undertaken 
– Population size 
– Patient characteristics 
– Health care professional characteristics 
– Setting of the MDT 
– Study design, objectives and findings. 
– The studies were divided into three groups – the first included studies that presented data on 
MDT running and implementation, the second on the impact of MDT on pre-treatment 
decisions, and the third on the impact of MDT on patient outcomes. 
Progress to date – an overview 
 
Aims and objectives 
• Aims 
– To evaluate and assess the functioning of Colorectal MDTs and their 
decision making. 
– To develop methods of assessing outcomes which reflect the 
appropriateness of MDT recommendations. 
– To implement a series of measures aimed at improving functioning, 
appropriate decision making and continuous self appraisal of MDTs. 
 
• Objectives: 
– To systematically review the current literature on colorectal cancer MDT 
decision making 
– To validate a pre-existing tool for MDT evaluation for use in colorectal 
MDTs 
– To correlate decisions made in MDTs with outcomes 
– To derive surrogate markers of outcomes for MDTs from expert colorectal 
cancer MDT members 
– To implement a cycle of feedback into the colorectal cancer MDT and 
evaluate whether this improves MDT functioning and outcomes. 
 
Introduction 
• Colorectal cancer is the 3rd most common cancer in 
the United Kingdom 
• “Recent” changes to multidisciplinary care 
– Rationale: involvement of all key clinical groups in decision 
making 
• Multidisciplinary team defined as “group of people of 
different healthcare disciplines, which meets together 
at a given time to discuss a given patient and who are 
each able to contribute independently to the 
diagnostic and treatment decisions about the patient”. 
• Widespread use in UK, variable in rest of world 
• Limited data on functioning, impact on outcomes 
 
 
 
 
 
An evaluation of the functioning and quality of decision- 
making in Colorectal Cancer Multi-disciplinary Meetings – 
how can we improve the process? 
 
 
 
Primary researcher: Sujay Shah 
 
Co-supervisors: Nick Sevdalis, Sonal Arora, Rob 
Glynne-Jones, Pawan Mathur 
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Impact of MDTs on the use of MRI/TRUS for 
staging in rectal cancer 
 
 
 
 
 
 
• MRI/TRUS is the gold standard for evaluation of 
patients with rectal cancer 
• The introduction of MDTs has seen the use of 
MRI/TRUS increase – OR 7.62 (2.07, 28.02) 
 
Impact of MDTs on occurrence of positive 
resection margins 
 
 
 
 
 
 
• Reduction of positive resection margins is one of the 
primary outcomes when measuring effectiveness of 
treatments 
• The introduction of MDTs has seen occurrence of positive 
resection margins decrease – OR 0.33 (0.17, 0.67) 
 
Impact of MDTs on 3 year overall survival 
 
 
 
 
 
 
• 3 year overall survival is one of the primary 
outcomes when measuring effectiveness of 
treatments 
• The introduction of MDTs has seen overall 3 year 
survival increase – OR 1.81 (1.13, 2.91) 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
Prospective validation study – 
materials and methods 
• Materials: 
– Current version of tool for use in urological cancer MDTs - MDT 
MODe tool ..\Studies\Validation study\MDT MODe tool.pdf 
– Content validation questionnaire 
• Methods: 
– MDT MODe tool and content validation questionnaire (1-5 
scoring scale and free text section) given to a sample of core 
colorectal cancer MDT members for completion 
..\Studies\Validation study\Validation questionnaire - MDT 
MODe Final.pdf 
– Results utilised to develop a modified version of MDT MODe for 
use in Colorectal Cancer. 
– The modified MDT MODe was then used to record observations 
at a single Colorectal Cancer MDT, over a number of meetings. 
 
Interview study - results 
• 20 interviews with core colorectal cancer MDT 
members (6 Surgeons, 5 Radiologists, 3 
Oncologists, 3 Pathologists, 3 CNSs). 
• Emergent themes included: 
– Individuals were able to clearly define their roles 
– Limitations included time constraints and insufficient 
information regarding the patient 
– No formal MDT specific assessments are currently in 
use in colorectal cancer MDTs in the UK 
– Measures of MDT working can be divided into process 
measures, overall outcome measures and measures of 
individual performance 
Interview study – materials and 
methods 
• Semi-structured individual interviews with a purposive 
sample of expert MDT members 
• Interview protocol developed and piloted in phases 
• Distilled into a topic guide, consisting of key questions 
which explored participants’ opinions on the following 
issues related to Colorectal cancer MDTMs: 
– Individual roles and responsibility 
– Evaluation of performance 
– Current methods of assessment 
– Potential measures of assessment 
– Expert consensus 
– ..\Studies\Interview study\Interview V6 - FINAL.pdf 
• Emergent theme analysis undertaken 
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Questions / comments 
References 
• Cancer Research UK website: http://info.cancerresearchuk.org/cancerstats/ 
• A Policy Framework for Commissioning Cancer Services: A Report by the Expert Advisory Group on Cancer to the 
Chief Medical Officers of England and Wales (1995). Available from: http://www.doh.gov.uk/cancer/pdfs/calman- 
hine.pdf 
• The NHS Cancer plan: a plan for investment, a plan for reform. The Department of Health. (2000):    
http://www.thh.nhs.uk/documents/_Departments/Cancer/NHSCancerPlan.pdf 
• Manual for Cancer Services (2004). Department of Health 
• Taylor C, Munro AJ, et al. Multidisciplinary team working in cancer: what is the evidence? BMJ 2010; 340: c951 
• Augestad K, Lindstemo R, et al. International Preoperative Rectal Cancer Management: Staging, Neoadjuvant 
Treatment, and Impact of Multidisciplinary Teams. World J Surg 2010; 34: 2689-2700 
• Fleissig A, Jenkins V, et al. Multidisciplinary teams in cancer care: are they effective in the UK? Lancet Oncology 
2006; 7: 935-443 
• Salerno G, Daniels I, et al. Management and imaging of low rectal carcinoma. Surg Onc 2004; 13(2-3): 55-61 
• Kelly M, Lloyd, T, et al. A snapshot of MDT working and patient mapping in the UK colorectal cancer centres in 
2002. Colorectal Disease 2003; 5: 577-581 
• Lamb BW, Brown KF, et al. Quality of care management decisions by multidisciplinary cancer teams: a systematic 
review. Ann Surg Oncol 2011;18(8): 2116-25 
• Pelican Cancer Foundation website:  
http://www.pelicancancer.org/index.php?option=com_content&view=article&id=217:lorec&catid=96:bowel- 
cancer&Itemid=308 
• Low Rectal Cancer Development Programme website: http://www.lorec.nhs.uk/system/content.asp?pkey=1 
• NHS National Cancer Action Team. Multidisciplinary team members views about MDT working: Results from a 
survey commissioned by the National Cancer Action Team. London: NHS National Cancer Action Team; 2009. 
 
What next for this MDT? 
• No change to current practice 
• Period of self assessment (in real time) 
• Period of video recording 
– Initial trial / pilot 
– Further 4 weeks 
– All videos will be edited to anonymise patient 
specific data 
 
Future studies 
• A comparison between self-assessment, observer assessment and 
video assessment in Colorectal Cancer MDTs 
– Study design: Prospective observational study 
– Research question: Are different methods of assessment of MDTs 
comparable? 
• Intervention for performance evaluation and feedback in Colorectal 
MDTs – what methods can be used? 
– Study design: Development and piloting of intervention 
– Research question: Can interventions be developed that allow 
evaluation and feedback of Colorectal MDTs’ functioning and 
performance? 
• Which intervention is best? – a study testing different interventions 
for evaluation and feedback in Colorectal Cancer MDTs 
– Study design: Prospective evaluation of intervention 
– Research question: Which intervention is best for use to evaluate and 
provide feedback to Colorectal MDTs? 
 
Prospective validation study – results 
 
• The content validity index for MDT-MODE was excellent at 0.82, 
with each individual item having high content and face validity 
• 267 patient cases were assessed in 840 minutes of observations 
across 11 MDT meetings. 
• Inter-rater reliability was high (ICC = 0.79). 
• Regarding quality of information presented: 
– radiological (mean 4.2, SD. 1.58) and pathological information (mean 
3.8, SD 0.92) was significantly above average (p<0.01). 
– Presentation of patient views (mean 2.1, SD 1.28) and psychosocial 
history (mean 1.8, SD 1.44) was significantly below average (p<0.01). 
– Contributions of the surgeon (mean 4.8, SD 0.54), the oncologist 
(mean 3.8, SD 1.60), the radiologist (mean 4.4, SD 1.54 and the 
pathologist (mean 3.4, SD. 0.54) to the decision-making process was 
rated as above average (all ps<0.01). 
• A decision was reached in 258 /267 cases. In cases where a treatment 
decision was not reached, absence of a key member of the MDT was 
noted. 
